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Cerebral small vessel disease 
On brain MRI of the elderly, various age-related changes are frequently found, 
including global cortical atrophy, widened perivascular spaces and vascular changes. 
Vascular lesions consist of large vessel disease, such as cortical lobar infarcts or 
lobar hemorrhages, and small vessel disease (SVD). The most important MRI 
expressions of cerebral small vessel disease are white matter hyperintensities 
(WMH), lacunes and microbleeds (figure 1).1-3
Figure 1 
MRI expressions of small vessel disease. Axial Fluid Attenuated Inversion Recovery (FLAIR)-images of a 
subject with periventricular and deep white matter hyperintensities (A); a subject with two lacunar infarcts in 
the right hemisphere and deep white matter hyperintensities (B). A T2*-gradient echo image of a subject 
with multiple cortical-subcortical microbleeds (C). 
WMH are highly prevalent in the general population and their severity increases with 
age. Only 5% of subjects older than 60 years is free of any WMH.1 So in almost all 
subjects, WMH can be found to some degree. Besides aging, hypertension, diabetes, 
female gender, previous stroke, and smoking, have been identified as risk factors for 
WMH.4 WMH are commonly defined on T2-weighted MRI scans, such as FLAIR 
images, and may present as periventricular lesions/ hyperintensities (PVL), adjacent 
to the lateral ventricles as caps and bands, and as deep WMH (DWMH), located in 
the deep white matter. The extent of deep WMH is generally rated as mild, moderate 
and severe: in mild WMH, small separate and ‘punctate’ hyperintensities are seen; in 
moderate WMH, individual hyperintensities are larger and are ‘beginning confluent’ 
with grouping of the lesions; and in severe WMH, hyperintensities are widespread and 
‘confluent’ (see figure 2).5
White matter Lacunes Microbleeds
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Figure 2 
WMH severity as graded by Fazekas’ scale. Axial Fluid Attenuated Inversion Recovery (FLAIR)-images of a 
subject with mild punctate (A), moderate beginning confluent (B) and severe confluent white matter 
hyperintensities (C).  
Lacunar infarcts are identified on MRI as small cavities with a diameter of 3mm to 1 - 
2cm and signal intensities comparable to cerebrospinal fluid on all MRI sequences. 
They may have a surrounding hyperintense halo and are typically located in the areas 
supplied by the deep thalamoperforant, lenticulostriate, or pontine paramedian 
arterioles, i.e. subcortical white matter (WM), deep gray matter and pons.6, 7 One or 
more lacunes are present in one-fourth of the elderly  population of which the majority 
did not experience stroke-like symptoms.2
Microbleeds are small round hypointense foci on gradient echo T2*-weighted MRI, in 
the cortical-subcortical area, basal ganglia or infratentorial region. The prevalence of 
microbleeds was found to be 5% in healthy adults, 34% in subjects with ischemic 
stroke, and 60% in people with non-traumatic intracerebral hemorrhage.8, 9
The clinical problem of cerebral SVD 
SVD is even more prevalent in patients with Alzheimer’s Disease (AD) than in the 
non-demented elderly population.10 The contribution of cerebrovascular pathology to 
the course of cognitive decline in AD patients remains to be established, as some 
studies found an interactive effect of WMH on cognitive decline in AD patients, 
whereas other studies did not find a role for WMH in AD.11-13 In some patients, 
extensive small vessel disease may even lead to subcortical vascular dementia.14
In non-demented subjects with SVD, studies showed that the occurrence of clinical 
symptoms is highly variable and clinical-radiological associations were weak and 
Mild WMH Moderate WMH Severe WMH 
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inconsistent. Some studies found that WMH were associated with subtle cognitive 
dysfunction, especially mental slowing and executive dysfunction.15, 16 WMH have 
further been weakly associated with gait disturbances, depression and urinary 
incontinence.17-19 Some studies suggest that only PVL, in contrast to DWMH, are 
associated with cognitive disturbances,20, 21 whereas others claimed that there is no 
difference in clinical impact.22 Lacunes may cause typical lacunar syndromes, but a 
large part is not accompanied with stroke-like symptoms. These ‘silent’ lacunes have 
been found to be associated with subtle cognitive dysfunction and a higher risk of 
future stroke.23, 24 The clinical role of cerebral microbleeds has not been elucidated 
yet. An effect on cognitive dysfunction and associations with future lacunar infarction 
or intracerebral hemorrhage have been suggested.25-28
Overall, clinical MRI studies have reported that SVD have clinical implications. 
However, findings across studies are inconsistent and associations between clinical 
findings and MRI expressions of SVD are only weak.25, 29-31 On an individual basis, it 
remains unknown why SVD in some of the patients leads to clinical symptoms, 
whereas it remains clinically silent in others. As 1) age-related cerebral SVD in 
demented and non-demented elderly is highly prevalent, 2) SVD may lead to a range 
of potentially disabling symptoms and 3) is potentially treatable or preventable, 
improvement in understanding of SVD is of the utmost importance.  
Aims and outline of this thesis 
The general objective of this thesis was to explore possible ways to improve the weak 
clinical-radiological associations of SVD, in order to increase understanding of SVD. 
When features of SVD can be determined with more specificity, it will eventually be 
possible to predict the clinical impact of SVD in an elderly individual. The following 
three chapters will investigate several aspects of SVD in cross-sectional MRI studies 
(part 1), longitudinal MRI studies (part 2) and postmortem MRI – pathology correlation 
studies (part 3). 
Part 1: Clinical impact of SVD in cross-sectional MRI studies. 
The weak clinical-radiological associations of SVD may be explained in the methods 
used to rate or quantify SVD on MRI. It is possible that the various visual rating scales 
and volumetric methods, used to measure the severity of WMH, are not specific 
enough and leads to inconsistencies between studies.32, 33 More elaborate or 
volumetric assessment may increase specificity of WMH, improving the clinical-
radiological associations. Furthermore, the clinical significance of SVD may differ 
between brain regions. We hypothesize that the consideration of possible strategic 
locations for SVD also increases specificity.   
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Part 2: Longitudinal studies and pathogenetic mechanisms of SVD. 
Although cross-sectional MRI studies attempt to specify WMH on T2-weighted images 
in relation to clinical symptoms, they do not provide information on temporal 
relationships and causality. In longitudinal studies, the development of SVD can be 
evaluated over time and risk factors for progression or occurrence of SVD can be 
characterized. These temporal relationships are suggested to provide more insight in 
the pathogenetic mechanisms underlying SVD.  
Part 3: Heterogeneity in underlying pathology of SVD. 
Longitudinal MRI studies are informative for investigating the course of SVD over 
time, but MRI remains an indirect reflection of the true underlying pathological tissue 
changes. It is conceivable that the high signal intensity on T2-based images (e.g. 
FLAIR) in WMH actually reflects a spectrum of tissue changes with varying severity. 
Heterogeneity in the underlying neuropathological substrates of SVD may explain the 
inconsistent and weak clinical-radiological associations. Furthermore, the contribution 
of SVD features that are not readily detected by conventional MRI, i.e. cortical 
microinfarcts and tissue changes in the normal appearing white matter (NAWM), to 
cognitive decline have recently been reported.34, 35 The only way to investigate the 
exact underlying pathological changes in SVD is by postmortem MRI scanning and 
matching of the MRI changes to pathological stainings.36, 37 Studies that correlate 
postmortem MRI findings with pathology bridge the discrepancy between MRI and 
clinical findings and may help to better understand the pathology and pathogenetic 
mechanisms of SVD. Moreover, attempts are being made to improve specificity of in 
vivo MRI scanning by novel quantitative MRI techniques.38, 39 However, their 
pathological correlates are still unknown. 
Outline of this thesis 
Chapters 2 and 3 are clinical MRI studies, based on baseline and follow-up data of 
the LADIS-study, that will be introduced in the chapter 1.2. In chapter 2, possible 
ways to increase specificity in cross-sectional MRI studies are investigated (part 1). In 
chapter 2.1, we compare a simple visual rating scale, a detailed rating scale and 
volumetric assessment of WMH with respect to their associations with measures of 
gait and cognition. Chapter 2.2 describes whether the location of lacunes in distinct 
subcortical structures has an independent influence on cognitive performances. 
Chapter 3 focuses on longitudinal observations of SVD (part 2). We first determined 
the most reliable and sensitive method for measuring progression of WMH over time 
(three conventional visual rating scales, two visual progression scales with semi-
quantitative volumetry) in chapter 3.1. We then describe WMH progression and the 
occurrence of new lacunes over a three-year period and we investigate their baseline 
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predictors in chapter 3.2. In chapter 3.3, we compared the occurrence of lacunes 
between brain regions, with respect to their relationship with WMH and risk factor 
profiles, in order provide more insight in their pathogenesis. Chapter 4 explores the 
pathological substrates underlying SVD using postmortem MRI (part 3). In chapter 
4.1, we review postmortem MRI studies that used postmortem MRI scanning and 
histopathological correlates in order to elucidate the pathological substrates of distinct 
features of SVD. In the study of chapter 4.2, we investigate whether postmortem 
quantitative MRI and pathological measures show differences between WMH of AD 
patients and of non-demented controls and reflects underlying pathological substrates 
of WMH. Finally, in Chapter 5, we summarize and discuss the main findings of this 
thesis and conclude with suggestions for future research.  
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A large part of this thesis is based on cross-sectional and longitudinal data of the 
multi-center, multinational Leukoaraiosis and Disability (LADIS)-study, which is a 
collaboration of eleven European centers (see figure 1 and the list of participating 
centers and personnel at the end of this chapter). The general aim of the LADIS-study 
is to investigate the role of WMH as an independent predictor of the transition to 
disability in initially non-disabled elderly. This chapter gives a brief overview of the 
LADIS-study design, rationale and main results, which have been described in detail 
by Pantoni et al.1
Figure 1 
The eleven European centers participating in the LADIS-study. 
Rationale
In proportion with the progressive aging of the world population, the number of 
disabled and/or demented patients will grow exponentially. These developments have 
major consequences, not only for the patients, but also for their caregivers and our 
health care system. It is important to elucidate the determinants of disability to find 
ways to delay conversion to disability as long as possible.  
The prevalence of WMH, also called ‘leukoaraiosis’, is expected to increase along 
with the aging population, as age is the most important risk factor of WMH.2 Cross-
sectional studies showed that the occurrence of functional and clinical abnormalities 
in patients with WMH is variable, ranging from normal functioning to severe physical 
or cognitive disability.3 Global or selective cognitive deficits, depression, motor 
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abnormalities and urinary dysfunction have been weakly associated in several 
studies.4-7 As clinical associations are only weak and inconsistently found across 
studies, the contribution of WMH to the transition to disability in the elderly remains to 
be elucidated. Furthermore, it is of interest to explore the relationships between 
severity and progression of WMH and subjects’ clinical/ functional natural history. 
These questions led to the design of the longitudinal LADIS-project. 
Objectives
The LADIS-study aims to: 1) establish whether WMH and their progression over time 
play a role as an independent determinant of the transition from functional autonomy 
to disability in elderly subjects; 2) confirm whether WMH and their progression 
independently predict death from any cause or specific causes, dementia, 
cardiovascular events, and depression; 3) examine whether progression of WMH 
parallels the deterioration of selective motor and cognitive performances; and 4) 
evaluate whether WMH have an impact on quality of life.  
Study design 
At baseline, 639 elderly subjects who had no or only mild disability in their 
instrumental activities of daily living (IADL) were enrolled in a hospital based setting. 
Among the reasons for presentation were mild memory losses, minor motor 
disturbances, minor focal cerebrovascular events, depressive symptoms or non-
specific reasons for undergoing a cranial neuroimaging study (WMH as incidental 
finding). To be included, subjects had to have: an age between 65 and 84; WMH on 
MRI of any degree;8 no or only mild disability as determined by the Instrumental 
Activities of Daily Living Scale (no impairment at all or only 1 item compromised);9
presence of a regularly contactable informant; agreement to sign an informed 
consent. Exclusion criteria were: likelihood of dropping out because of the presence of 
severe illnesses e.g. cardiac, hepatic or renal failure, cancer or other relevant 
systemic diseases; severe unrelated neurological diseases; leukoencephalopathy of 
nonvascular origin (immunologic, demyelinating, metabolic, toxic, infectious, other); 
severe psychiatric disorders; inability to give an informed consent; inability or refusal 
to undergo cerebral MRI. Subjects were selected and stratified for WMH severity - 
according to the categorization into three severity classes of the modified Fazekas 
scale.8 All subjects were assessed using an extensive standardized set of global 
functioning, psychiatric and quality of life tests and physical/ neurological, laboratory 
and neuropsychological examination. Subjects underwent yearly clinical follow-up 
evaluations for three years. Cerebral MRI scanning was performed at baseline and 
repeated after 3 years, using the same protocol. Baseline patients’ characteristics are 
listed in Table 1. 
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Table 1. Baseline patients’ characteristics in the total sample and by WMH severity. 
 WMH   
 Mild Moderate Severe Total p-value 
Number 285 (45%) 196 (31%) 158 (25%) 639  
Gender (% male) ‡ 44.6 % 39.3 % 53.2 % 45.1 0.162 
Age (years) † 73.3 ± 5.0 74.5 ± 5.2 75.1 ± 4.8 74.1 ± 5.0  0.001 
Education (years) † 9.8 ± 3.6 9.6 ± 3.9 9.2 ± 3.9 9.6 ± 3.8 0.266 
‡ Ȥ2 for trend, † ANOVA.  
One-year follow-up results 
The main results of the LADIS concern the role of WMH as an independent 
determinant of the transition from functional autonomy to disability in elderly subjects. 
The final analyses of three year follow-up data are still ongoing, but data on global 
functional decline after one-year follow-up have already been reported.10 In this paper, 
the transition to disability, defined as transition to 2 IADL activities limited, at 1-year 
follow-up is described in the target LADIS population (0 or 1 IADL activity limited) and 
in a subset of patients who were fully independent at baseline (0 activities limited). 
Of the 639 patients enrolled, 619 (96.9%, age = 74.1±5.1 years, 45.1% male) were 
available for analyses at 1-year follow-up. In this selection, baseline WMH severity 
was mild in 44%, moderate in 31% and severe in 25%. At baseline, 506 of these 
patients were independent in every IADL activity and 113 were impaired in just 1 
activity. After one-year follow-up, the proportion of subjects that converted to disability 
increased with severity of baseline WMH: 9% in the mild, 15% in the moderate, and 
26% in the severe WMH group (for the target LADIS population). Among the subset of 
patients who were fully independent at baseline, the proportions of subjects that 
converted to disability were lower but were also related to baseline WMH severity 
(5%, 9%, and 15%, for mild, moderate and severe WMH, respectively). (Figure 2).  
In a logistic regression model, adjusted for other possible predictors (including patient 
demographics, risk factors, physical disturbances), the risk of transition to disability 
was more than two-fold higher for the presence of severe WMH, compared to mild 
WMH, for the target LADIS study group. For patients who were fully independent at  
baseline, the risk was three-fold higher (Table 2). After controlling for acute events 
occurring during the 1 year of follow-up (such as falls, incidental stroke, myocardial 
infarction, heart failure or hospitalization), the effect of WMH severity in predicting 
functional decline remained significant (OR [95%CI] = 2.71 [1.37 - 5.34]; severe 
versus mild WMH).  
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Figure 2 
Transition in disability at 1 year across the three WMH severity groups. 
In conclusion, the one-year follow-up data of the LADIS-study show that non-disabled 
elderly individuals with severe WMH on brain MRI are at high risk of decline in global 
functioning. 
Table 2. Independent predictors for 1-year transition in IADL status. 
WMH severity Target LADIS-study group Subgroup (0 IADL-items limited at BSL)  
 N = 619 N = 506 
Mild 1.00 1.00 
Moderate 1.26 (0.67-2.37) 1.87 (0.83-4.21) 
Severe 2.38 (1.29-4.38) * 3.02 (1.34-6.78) * 
Values are Odds’ Ratios (95%-confidence intervals), analyzed using multiple logistic regression, stepwise 
forward method. WMH = white matter hyperintensities. *  p<0.05. 
The LADIS-study in this thesis  
The LADIS-study, aimed to investigate the role of WMH as an independent predictor 
of the transition to disability in initially non-disabled elderly, provides the opportunity to 
focus on MRI expressions of SVD. The selection of a large patient group with a wide 
range of WMH provides statistical power to assess subtle associations with clinical 
symptoms. Furthermore, the longitudinal design with yearly clinical follow-up 
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evaluations and repeated MRI scans at baseline and after three years enables us to 
study the natural course of SVD on MRI.  
We first used the baseline MRI data of the LADIS to investigate clinical correlates of 
WMH and lacunes with respect to WMH assessment method and strategical locations 
(chapter 2). Furthermore, we investigated the natural course of WMH and lacunes 
over time using the longitudinal MRI data. Baseline predictors of both WMH 
progression and occurrence of new lacunes were established and the occurrence of 
lacunes between brain regions was compared (chapter 3) 
.
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Abstract
Background: White matter hyperintensities (WMH) on MRI are associated with 
disorders of gait and balance and with cognitive impairment. The most suitable 
method to assess WMH in relation to the clinical evaluation of disturbances in these 
areas has not been established yet. We compared a simple visual rating scale, a 
detailed visual rating scale and volumetric assessment of WMH with respect to their 
associations with clinical measures of physical performance and cognition. 
Methods: Data were drawn from the multicentre, multinational LADIS study. Data of 
574 subjects were available. MRI analysis included assessment of WMH using the 
simple Fazekas scale, the more complex Scheltens scale and a semi-automated 
volumetric method. Disturbances of gait and balance and general cognitive function 
were assessed using the Short Physical Performance Battery (SPPB) and the Mini 
Mental State Examination (MMSE), respectively.   
Results: Irrespective of the method of measuring WMH, subjects with disturbances of 
gait and balance (SPPB  10) had more WMH than subjects with normal physical 
performance. Subjects with mild cognitive deficits (MMSE  25) had more WMH than 
subjects with normal cognition. Correlations between clinical measures and WMH 
were equal across methods of WMH measurement (SPPB: Spearman r = -0.22, -
0.25, -0.26, all p < 0.001; MMSE: Spearman r = -0.11, -0.10, -0.09, all p < 0.05, for 
Fazekas scale, Scheltens scale and volumetry, respectively). These associations 
remained significant and comparable after correcting for age, gender and education in 
multivariate linear regression analyses. 
Conclusion: Simple and complex measures of WMH yield comparable associations 
with measures of physical performance and cognition. This suggests that a simple 
visual rating scale may be sufficient, when analyzing relationships between clinical 
parameters and WMH in a clinical setting. 
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Background 
Brain MRI in elderly persons frequently shows white matter hyperintensities (WMH).1
These lesions are known to be associated with gait disorders, impaired balance,2, 3
and cognitive disturbances.4-6 Visual rating scales and volumetric methods have been 
used to measure the severity of WMH. Visual rating scales offer a relatively quick and 
easy method to measure WMH. Moreover, they can be applied to scans of different 
quality.7 On the other hand, quantitative techniques to measure WMH volume are 
more precise. However, as sufficient scan quality is necessary,8 volumetric methods 
may be more difficult to perform in multi-center studies. Moreover, it has been 
reported that visual rating scales are not optimal because of poorly defined criteria 
and because of their non-linearity.8 In addition, discrepancies between the various 
scales may lead to inconsistent findings.9 Thus, the most suitable method of 
measuring WMH for associations with clinical parameters has not been established 
yet.
In the present study, we compared a simple rating scale, a detailed rating scale and a 
volumetric assessment of WMH with respect to their associations with measures of 
gait and cognition that are widely used in clinical practice in a group of non-disabled 
elderly subjects. 
Methods
Patients
Data were drawn from the multi-center, multinational Leukoaraiosis and Disability 
(LADIS) study. The LADIS project studies the role of WMH as an independent 
predictor of the transition to disability in initially non-disabled elderly. The rationale 
and design of the LADIS study have been described elsewhere.10 In short, 639 elderly 
subjects who had no or only mild disability in their instrumental activities of daily living 
(IADL), and were stratified for grade of WMH severity, were enrolled. Subjects 
presented with complaints including mild memory loss, minor motor disturbances, 
minor focal cerebrovascular events or non-specific reasons for undergoing a cranial 
neuroimaging study (WMH as incidental finding). To be included, subjects had to 
have: (a) an age between 65 and 84, (b) WMH on MRI of any degree, according to 
the categorization into the three severity classes of the Fazekas scale, (c) no or only 
mild disability as determined by the IADL scale, (d) presence of a regularly 
contactable informant, (e) agreement to sign an informed consent. Exclusion criteria 
were: (a) likely drop out because of the presence of severe illnesses (cardiac, hepatic, 
or renal failure, cancer or other relevant systemic diseases), (b) severe unrelated 
neurological diseases, (c) leukoencephalopathy of non-vascular origin (immunologic-
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demyelinating, metabolic, toxic, infectious, other), (d) severe psychiatric disorders, (e) 
inability to give an informed consent, (f) inability or refusal to undergo cerebral MRI. 
Subjects were selected and stratified for grade of WMH severity - according to the 
categorization into three severity classes of the modified Fazekas scale 11 - to balance 
subject groups with mild, moderate and severe WMH. 
All subjects were assessed using an extensive set of clinical and functional tests 
including global functioning, cognitive, motor, psychiatric and quality of life measures. 
For the present study, general cognitive function was assessed according to the Mini 
Mental State Examination (MMSE).12 Disturbances of gait and balance were 
evaluated with the Short Physical Performance Battery (SPPB).13 The SPPB ranges 
from 0 – 12 and consists of three parts containing simple clinical tests of gait and 
balance: (1) side-by-side, semi-tandem and tandem stand, (2) time to walk three 
meters and (3) time to rise from a chair five times. For one subject, MMSE was not 
available and SPPB was not available in 43 subjects. Volumetric WMH measurement 
was not possible due to insufficient scan quality in 21 subjects. Therefore, 574 
subjects were included in the present study. 
It is conceivable that more specific measures of cognition and physical performance 
yield stronger correlations with WMH. Therefore, cognitive function and physical 
performance were additionally assessed with the trail making task B (TMT B) and the 
single leg stance time, respectively. The TMT B is the complex condition of the trail 
making task, which is a test of executive function.14 As an additional measure of 
physical performance, the single leg stance time - which is the maximal time that a 
subject is able to stand on one leg with two attempts per leg and a maximum time of 
30 seconds – was taken.2
MRI studies 
Each MRI study included fluid attenuated inversion recovery (FLAIR) images (TE 100 
- 140 ms, TR 6000 - 10000 ms, TI 2000 - 2400 ms, slice thickness 5 mm, interslice 
gap 0.5 mm, FOV 250 mm, matrix size 256 x 256), on which all WMH measurements 
were performed. Scans were made on a 0.5 T (one center) or 1.5 T scanner (ten 
centers). All scans were transferred to the Image Analysis Center (IAC) in 
Amsterdam, the Netherlands, for central data storage and post-processing.  
All MRI analyses were performed by a single rater (ECWvS). We applied the simple 
modified Fazekas rating scale11 and the more complex Scheltens rating scale15 for the 
visual WMH assessment on FLAIR images. The modified Fazekas scale ranges from 
mild to severe. Mild WMH is defined by punctate lesions in the deep white matter with 
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a maximum diameter of a single lesion of 9 mm and of grouped lesions of 20 mm. In 
moderate WMH early confluent lesions are present with single lesions between 10 – 
20 mm, grouped lesions more than 20 mm in any diameter and no more than 
connecting bridges between individual lesions. Severe WMH are single lesions or 
confluent areas of hyperintensity of 20 mm or more in any diameter. The Scheltens 
rating scale ranges from 0 to 84. For 3 periventricular regions (frontal and occipital 
caps and bands) scores 0 – 2 can be given. Score 1 is given for a smooth halo which 
extends not more than 5 mm and score 2 is given for confluent lesions larger than 5 
mm. Scores 0 – 6 can be given in 4 subcortical regions (frontal, parietal, occipital and 
temporal lobes), 5 basal ganglia regions (caudate nucleus, putamen, globus pallidus, 
thalamus and internal capsule) and 4 infratentorial regions (cerebellum, 
mesencephalon, pons and medulla). If the largest lesion in a region is smaller than 4 
mm, score 1 is given when there are not more than 5 lesions or a score 2 when there 
are more than 5 lesions. If the largest lesion is between 4 and 10 mm, score 3 is given 
when there are not more than 5 lesions, while score 4 is given when there are more 
than 5 lesions. Score 5 represents the presence of the largest lesion that is 10 mm or 
more. Score 6 accounts for confluent lesions.  
Volumetric analysis of WMH was performed on a Sparc 5 workstation (SUN, Palo 
Alto, Calif.).16 Lesions were marked using a “seed”, and local thresholding was 
performed using home-developed software (Show_Images, version 3.6.1 using a 
Canay-filter) on each slice. When necessary, borders could be adjusted by the 
operator by changing thresholds for upper and lower intensity values. If all lesions are 
delineated, the program calculates the total surface of the outlined area. By 
multiplying with the interslice distance, total volume of WMH is established.  
Intra-observer reliability of the visual scales and the volumetric measurement was 
assessed by rating 18 scans with equal distribution across the Fazekas categories 
twice. The weighted Kappa of the Fazekas scale was 0.84. For the Scheltens scale, 
the intra-class correlation coefficient (ICC) was 0.92. The ICC of the volumetric 
measurement was 0.99. Consistency between measures was established by 
Spearman correlation (for n = 574: Fazekas scale – Scheltens scale: r = 0.81; 
Fazekas scale – volumetry: r = 0.86; Scheltens scale – volumetry: r = 0.88, all p < 
0.001).
Statistical analysis  
Chi-square tests and Mann-Whitney U-tests were used to test differences between 
groups (mild cognitive deficits: MMSE d 25, disturbances of physical performance: 
SPPB d 10). Spearman correlations were used to assess associations between WMH  
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methods and clinical measures. In addition, we performed multivariate linear 
regression analyses with age, sex and education as covariates. As eleven different 
centers participate in the LADIS project, it is conceivable that center of origin acts as a 
confounder in the association between WMH and SPPB and MMSE. Therefore, 
center of origin was additionally corrected for. 
Results
A description of the study sample with patient and MRI characteristics is given in table 
1.
Table 1. Characteristics of study sample.  
Characteristic 
 Total N = 574 
Age (years)  74 (5) 
Sex (women)  314 (55%) 
Education (years)  10 (4) 
MMSE   27 (2) 
SPPB  10 (2) 
WMH (Fazekas scale) Mild 261 (46%) 
 Moderate 174 (30%) 
 Severe  139 (24%) 
Lacunes 0 299 (52%) 
 1-3 198 (35%) 
t 4 77  (13%) 
Infarcts # Absent 522 (91%) 
 Present 51 (9%) 
MTA * Absent 380 (71%) 
 Present 158 (29%)  
Values are mean (SD) or numbers (percentage). MTA = medial temporal lobe atrophy, according to a 5-
point visual rating scale 26. A score of 0/1 is congruent with no MTA, a score of 2 or more reflects MTA.  
* available for n = 538. # available for n = 573. 
Table 2 shows the WMH load as measured by the visual and volumetric methods 
compared between patient groups. Subjects with disturbances of gait and balance 
had a significant higher WMH load as measured by Fazekas score, Scheltens score 
and volumetry. Also, WMH load in subjects with cognitive disturbance was 
significantly higher than in subjects with normal cognition, irrespective of method of 
measuring WMH. 
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Correlations between clinical measures and WMH were comparable across methods 
of WMH measurement (SPPB: Spearman r = -0.22, -0.25, -0.26, all p < 0.001; MMSE: 
Spearman r = -0.11, -0.10, -0.09, all p < 0.05, for Fazekas scale, Scheltens scale and 
volumetry, respectively). Associations between clinical measures and each method of 
WMH are visualized in the figure. In multivariate linear regression analyses, age, 
gender and education were entered as covariates. Table 3 shows that after correction 
for these variables, associations remained significant for all methods of measuring 
WMH. The standardized regression coefficients are comparable, indicating that all 
WMH measurements give comparable associations with motor performance and 
cognitive function. Results did not change after correction for center of origin. 
Table 3. Multivariate linear regression analyses of WMH measurements and clinical 
parameters.
Gait (SPPB) Cognition (MMSE) 
WMH
Standardized ȕ p-value Standardized ȕ p-value 
Fazekas scale  -0.19  <0.001 -0.13  0.001 
Scheltens scale  -0.21  <0.001 -0.13  0.001 
Volumetry  -0.22  <0.001 -0.10  0.010 
Multivariate regression analyses were performed for each measure of WMH separately. SPPB and MMSE 
were the dependent variables. Age, sex and education were included as covariates. Standardized ȕs
represent increase in test score with an increase of one standard deviation in WMH.  
In an additional analysis, associations between WMH measures and TMT B (available 
for n = 543) and single leg stance time (available for n = 553) as more specific tests of 
executive function and physical performance were assessed. Across methods, 
correlations between clinical test and WMH were comparable (TMT B: Spearman r = 
0.22, 0.24, 0.24, all p < 0.001; Single leg stance time: Spearman r = -0.18, -0.19, -
0.18, all p < 0.001; for Fazekas scale, Scheltens scale and volumetry, respectively). 
After correction for age, gender and education in multivariate linear regression 
analyses, correlations for all methods remained significant and standardized 
regression coefficients remained comparable (data not shown).  
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Assessment of white matter hyperintensities by Fazekas scale, Scheltens scale and quantitative 
measurement gives comparable associations with measures of motor performance (Short Physical 
Performance Battery) and cognitive function (Mini Mental State Examination). 
Figure
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Discussion 
We demonstrated in a large group of non-disabled elderly that simple and complex 
methods of WMH assessment yield comparable associations with disturbances of gait 
and balance and cognitive disturbances. Our results suggest that the three 
investigated methods have equal validity with respect to these clinical parameters.  
It has been shown consistently that presence and severity of WMH are related to 
disturbances of gait and balance.2, 3 Typical features of the gait pattern associated 
with WMH are slight widening of the base, slowing and shortening of stride length and 
turning en bloc.17 Furthermore, WMH have also been associated with cognitive 
impairment in elderly subjects.5, 6 Especially speed of cognitive processes and frontal 
skills may be impaired in subjects with WMH.4 In this study of non-disabled elderly 
subjects, we confirmed these earlier findings, as we observed significant associations 
of WMH with disturbances of gait and balance and cognitive disturbances. Visual 
inspection of the figure depicting the Fazekas scale suggests severe WMH account 
for the association between clinical measures and WMH. This has been suggested 
earlier.18 However, associations are only modest, and it is still conceivable that WMH 
and clinical measures are associated in a dose-effect related manner. 
Several studies have dealt with reliability of WMH assessment. Good interrater 
agreement of several visual scales, including Fazekas and Scheltens scales, and high 
correlation between visual scales and volumetry have been described.19, 20 We extend 
on these findings, as in the present study we show comparable associations between 
WMH and clinical parameters irrespective of method of measuring WMH. Earlier, 
Sachdev established the validity of two visual rating scales and a quantitative WMH 
measure using neuropsychological data from schizophrenic patients as a clinical 
parameter. In analogy with the present study, similar associations across methods 
with the neuropsychological data were found.21 Our data suggest that in clinical 
practice, the gain of more sensitive volumetric methods over a simple rating scale for 
WMH is limited. However, as volumetric methods are more precise than rating scales, 
it is conceivable that these methods remain desirable for research settings. 
Furthermore, in contrast to time-consuming semi-automated methods that still require 
operator-interference as most studies have used, fully automated techniques have 
recently been developed that are fast and accurate 22 and even claim to be suitable 
for use in large and longitudinal studies.23 These methods are a major gain in 
research settings. However, in contrast to simple visual rating scales, they will not be 
widely available in the near future.  
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Strengths of the current study are the large group of subjects and the broad range of 
WMH that is represented, enabling us to find subtle associations with clinical 
parameters. Former studies have suffered from the left-sided distribution of WMH, 
with many subjects having none at all. The present study sample was selected to 
represent the full range of severity of WMH. While stratification by WMH may hamper 
the generalizability of the results to the general population, the reasons for referral 
were those commonly leading to discover WMH in elderly persons, so that the LADIS 
sample likely reflects the assorted patient population with WMH encountered in the 
everyday clinical practice. 
As subjects were selected to be non-disabled, we were not able to evaluate the full 
spectrum of physical and cognitive impairment. Subjects were allowed to have only 
minor problems such as minor motor disturbances or mild memory loss. 
Consequently, we may even have underestimated the strength of the associations of 
WMH with physical performance and cognitive function. However, the magnitudes of 
the current correlations are comparable with large population-based studies.4, 5
Nevertheless, the observed modest correlations stress the need of assessing not only 
WMH, but also other MR changes such as medial temporal atrophy and general 
cortical atrophy in relation to functional decline.24
Although our results suggest that a simple visual rating scale may suffice in cross-
sectional settings, it is conceivable that a visual rating scale will not be suitable for 
measuring WMH progression. Prins et al reported the reliability of visual scales 
compared to volumetry for measuring progression of WMH.25 Agreement between 
conventional scales and volumetry was unsatisfying, whereas reliability of scales 
especially made for measuring progression of WMH was fairly good. Further 
evaluation of methods for WMH assessment needs to be performed for determining 
the most suitable method of establishing associations between WMH progression and 
clinical measures. 
In conclusion, we demonstrated that volumetric measurement of WMH, the detailed 
Scheltens scale and the simple Fazekas scale show comparable associations with 
widely used clinical measures of gait and balance and cognition. Our data suggest 
that visual scoring may be sufficient when analyzing WMH in a clinical setting in 
relation to disturbances in these areas. 
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Abstract
Objectives: In cerebral small vessel disease, white-matter hyperintensities (WMH) and 
lacunes are both related to cognition. Still, their respective contribution in the elderly 
remains unclear. The purpose of this study is to assess the topographic distribution of 
lacunes and determine whether it has an impact on cognitive functions in a sample of 
non-disabled patients with age-related white matter changes.  
Methods: Data were drawn from the baseline evaluation of the LADIS (Leukoaraioisis 
and Disability study) cohort of non-disabled subjects beyond 65 years-old. The 
neuropsychological evaluation was based on MMSE, a modified Alzheimer Diseases 
Assessment Scale for global cognitive functions, and compound Z scores for memory, 
executive functions, speed and motor control. WMH were rated according to the 
Fazekas scale; the number of lacunes was assessed in the following areas: lobar 
white matter, putamen/pallidum, thalamus, caudate nucleus, internal/external capsule, 
infratentorial areas. Analysis of covariance was performed after adjustment for 
possible confounders.  
Results: Among 633 subjects, 47% had at least one lacune (31% at least one within 
basal ganglia). The presence of lacunes in the thalamus was associated with lower 
scores of MMSE (E = -0.61; p = 0.043), and worse compound scores for speed and 
motor control (E = -0.25; p = 0.006), executive functions (E = -0.19; p = 0.022) 
independently of the cognitive impact of WMH. There was also a significant negative 
association between the presence of lacunes in putamen/pallidum and the memory 
compound Z score (E = -0.13, p = 0.038). By contrast, no significant negative 
association was found between cognitive parameters and the presence of lacunes in 
internal capsule, lobar white matter and caudate nucleus.  
Conclusion: In non-disabled elderly subjects with leukoaraisosis, the location of 
lacunes within subcortical grey matter is a determinant of cognitive impairment, 
independently of the extent of WMH.  
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Background 
Ischemic cerebral small vessel disease is characterized by two main types of lesions 
on brain MRI, white matter hyperintensities (WMH) and lacunar infarcts.1 This entity is 
frequent in elderly people and has been related to cognitive impairment in demented 
patients, as well as in non-disabled elderly.2 Still, the relative contribution of WMH and 
lacunar infarcts to cognitive dysfunction, particularly in these populations, has not 
been clarified. Most previous clinico-radiological studies indicated a significant 
association between the extent of WMH and both cognitive impairment and decline in 
the elderly.3-6 However, the potential influence of associated lacunar infarcts was 
rarely investigated. In addition, some results cast doubts on an independent impact of 
lacunar infarcts on cognition in the elderly population.7 Finally, the main determinants 
of the cognitive impact of cerebral lacunar infarcts, particularly, the exact role of their 
number and/or location, remain poorly studied in large populations of elderly subjects.  
The LADIS (Leukoaraiosis and Disability) study is a prospective multinational 
European study investigating the impact of WMH in the transition to disability of a 
cohort of non-disabled elderly subjects with varying degrees of small vessel disease.8
Using data obtained at baseline, we previously reported that lacunar infarcts and 
WMH were independently associated with global cognitive performances in this 
population.9 In the present study, we investigated whether the location of lacunes in 
different subcortical structures has a significant and independent influence on 
cognitive performances in the same sample. Particularly, the location of lacunar 
infarcts in various subcortical structures was analyzed since some of these structures, 
such as the thalamus, have been reported as locations for strategic infarcts in 
vascular dementia10 and are involved in cognition.11,12
Methods
Patients
Data were drawn from the multicenter, multinational Leukoaraiosis and Disability 
(LADIS) study. In short, 639 elderly subjects, who had no or only mild disability in their 
Instrumental Activities of Daily Living (IADL) and showed WMH were enrolled. 
Subjects presented for evaluation in the following settings: stroke units or stroke 
departments, cerebrovascular disease clinics, memory or dementia clinics, neurologic 
or geriatric wards/clinics, population studies on aging, and controls in other studies. 
Among the reasons for presentation were, mild memory loss, minor motor 
disturbances, minor focal cerebrovascular events or non-specific reasons for 
undergoing a cranial neuroimaging study (WMH as incidental finding). To be included, 
subjects had to have (1) age between 65 and 84 years; (2) WMH on MRI of any 
degree, according to the classification into the 3 severity classes of the Fazekas 
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scale,13 (3) no or only mild disability as determined by the IADL scale,14 (4) presence 
of a regularly contactable informant and (5) agreement to sign an informed consent. 
Exclusion criteria were (1) likely drop out because of the presence of severe illnesses 
(cardiac, hepatic or renal failure, cancer or other relevant systemic diseases), (2) 
severe unrelated neurological diseases, (3) leukoencephalopathy of non vascular 
origin (immunologic-demyelinating, metabolic, toxic, infectious, other), (4) severe 
psychiatric disorders, (5) inability to give informed consent, and (6) inability or refusal 
to undergo cerebral MRI. Subjects have been followed up for 3 years with repeated 
clinical and MRI studies. The present study is based on the baseline data of the 
LADIS project. 
Neuropsychological evaluation 
The neuropsychological battery used in the LADIS study is detailed elsewhere.15
General cognitive function was measured using the Mini Mental Status Examination 
(MMSE)16 and a modified version of the Alzheimer Diseases Assessment Scale 
(ADAS Mod).17 The ADAS was slightly modified to include the item “delayed word 
recall”. A higher MMSE indicated better performances, whereas a higher ADAS Mod 
score corresponded to worse performances. Performances by cognitive domains 
were compared using Z standard scores to calculate compound measures. These 
compound measures were based on subtests of ADAS Mod and on the Stroop18,19
and Trail making test.20 Three main domains were analysed: (1) compound Z score 
for memory domain = Z-scores of ( Immediate word recall + delayed recall + word 
recognition + digit span) / 4; (2) compound Z score for executive functions domain = 
Z-scores of (Stroop test + Trail making + Symbol digit + Verbal fluency) / 4; (3) 
compound Z scores for speed and motor control domain = Z-scores of (Trail making 
part A + Mazes + Digit cancellation) / 3. Z scores of tests with higher scores 
representing worse performance were inverted (-Z) in order to calculate these 
compound measure scores. Memory, executive functions and speed and motor 
control compound Z-scores were respectively missing for one, 53 and 13 subjects. 
Therefore, for these 3 variables, the statistical analysis was performed with a different 
number of subjects. 
MRI studies
All subjects were studied by MRI following a standard protocol on the same day as 
the clinical investigation. Scans were made on a 0.5 T (one center) or 1.5 T scanner 
(10 centers) and were collected at the Image Analysis Center of the Vrije Universiteit 
Medical Center, Amsterdam. Imaging guidelines were distributed among all centers, 
specifying name convention and scan positioning. To check and maintain quality, 
dummy runs were requested before the beginning of the study and in case of 
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upgrades. Data transfer was done using CD Rom or through FTP. The MR protocol 
included the following sequences: T1-weighed 3D MPRAGE (magnetization prepared 
rapid-acquisition gradient-echo, scan parameters: coronal or sagittal plane, field of 
view (FOV) 250mm, matrix 256X256 or 512X512, slice thickness: 1mm [isotopic 
voxels], TE: 2 to 7 ms, TR: 9 to 26 ms, FA 10% to 30%), T2-weighed FSE (fast spin 
echo, scan parameters: axial plane, FOV 250mm, matrix 256X256 or 512X512, slice 
thickness: 5mm, interslice gap 0.5 mm, TE: 100 to 130 ms, TR: 4000 to 8000 ms), 
and FLAIR (Fluid Attenuated inversion recovery, scan parameters: axial plane, FOV 
250mm, matrix 256X256 or 512X512, slice thickness: 5 mm, interslice gap 0.5 mm, 
TE :100 to 160 ms, TR: 6000 to 10000 ms, TI: 2000 to 2400). 
Visual ratings of WMH and lacunes were performed by raters who were blind to 
clinical details. The degree of WMH severity was rated visually by a single rater 
(ECWvS) on axial FLAIR images using the Fazekas Scale as grade 1 (punctate), 
grade 2 (early confluent) or grade 3 (confluent). The intrarater reliability of rating WMH 
was determined on 18 randomly selected scans that were scored twice (weighted 
Cohen N = 0.84). Lacunes were defined as hypointense foci of t 3 mm on MPRAGE 
that were surrounded by white matter or subcortical gray matter and not located in 
areas of high prevalence of widened perivascular spaces (eg anterior commissure, 
vertex). The number of lacunes was recoded into none, few (1 to 3 lacunes) and 
many (4 lacunes or more). In patients with lacunes, their number was first assessed in 
the following structures on both sides: lobar white matter, basal ganglia (including 
thalamus), infratentorial areas.9 In patients with lacunes present within the basal 
ganglia, the number and the location of lacunes was assessed on both side and after 
consensus by 2 raters (SB, AP) in the following structures: putamen, pallidum, 
caudate nucleus, internal and external capsule, and thalamus. The inter-rater and 
intra-rater reliabilities of this procedure were not determined. During the evaluation of 
follow-up MRI scans, baseline MRI rating was corrected in 22 scans. This correction 
was necessary because of a mistake in the data processing. The correction proved 
not to affect the main results of the baseline analysis, but has resulted in small 
differences in some data reported in the present paper compared to those reported in 
previous publications.    
Statistical analysis 
The association between lacune location and each of the outcomes was assessed 
using Analysis of Covariance adjusted for age, sex, education, diabetes, 
hypertension, alcohol consumption, history of stroke, depression and for grades of 
WMH according to Fazekas scale. Additionally, the analyses were adjusted for the  
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center of origin, treated as a random effect in the model. For each outcome, separate  
models where first fitted for the presence of lacunes in each of the predetermined 
locations. In order to reduce the number of parameters tested in the model, we chose 
to estimate at most 4 different regression coefficients. For this purpose, we 
considered only location with coefficients greater than 20% of their standard deviation. 
Thereafter, we set identical effect for locations with nearly equal coefficients as judged 
by comparing their difference to the corresponding standard error. A differential effect 
related to the location of lacunes was then assessed by a test of heterogeneity of the 
coefficients. The association between each location and the outcome was tested only 
in presence of a significant heterogeneity. Analyses evaluating the side effect were 
carried out using a framework similar to the main analysis and a model with different 
effects according to the side of lacunes. Such analyses were restricted to locations 
and endpoints where a significant effect was shown. 
The models were fitted using restricted maximum likelihood (REML), as usually 
favored. However, comparisons of models involving different fixed effects were based 
on maximum likelihood estimates (ML), as likelihood comparison between REML fits 
with different fixed effects are not valid. The comparisons of nested models were 
carried out using likelihood ratio tests. The comparisons of non-nested models were 
based on Akaike’s information criterion (AIC). Results are expressed in terms of 
estimated regression parameter (ȕ) and standard error (se), as well as Wald test for 
the parameter. All tests were two-sided, at the 0.05 significance level. Analyses were 
performed using R 2.5.1 statistical software (The R Foundation for Statistical 
computing, Vienna, Austria). 
Results
In the LADIS cohort, 639 patients were included. Of them, 6 were excluded because 
the ADAS score was missing. Analysis was thus performed on a sample of 633 
patients. Characteristics of the participants, including socio-demographic factors, risk 
factors, cognitive scores are presented in table 1. 
Three-hundred patients (47% of the total population) presented with at least one 
cerebral lacunar infarct (114 of them had a history of stroke) and the total number of 
lacunar infarcts was 958. Among these patients, 64% had at least one lacune within 
basal ganglia; 16% in caudate nucleus, 30% in putamen and pallidum, 12% in internal 
capsule, 12% in external capsule and 25% in thalamus. The topographic distribution 
of all lacunar infarcts and their range in each area is presented in table 2.  
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Table 1 
Age, y 74 (5) 
Female gender 350 (55%) 
Education, y 10 (4) 
Hypertension 439 (70%) 
Diabetes 91 (15%) 
Alcohol consumption  
 Yes 301 (48%) 
 Yes, in the past 48 (8%) 
 No 282 (45%) 
Depressive symptoms 176 (28%) 
History of stroke 180 (29%) 
Mini Mental State Examination 27 (2) 
Alzheimer Disease Assessment Scale (ADAS)* 17 (7) 
White matter hyperintensities  
 Mild 281 (44%) 
 Moderate 196 (31%) 
 Severe 156 (25%) 
Lacunes  
 None (0) 333 (53%) 
 Few (1 to 3) 217 (34%) 
 Many (4 or more) 83 (13%) 
Cortical infarct 57 (9%) 
Values are mean (sd) or number (percentage). 
Table 2 
N (%) present Mean (range) no. of lacunes when present 
Any Location 300 (47%) 3.2 (1 to 25) 
Lobar white matter 171 (27%) 2.4 (1 to 25) 
 Frontal 129 (20%) 2.0 (1 to 19) 
 Parieto-occipital 70 (11%) 1.5 (1 to 4) 
 Temporal 32 (5%) 1.4 (1 to 5) 
Infratentorial 76 (12%) 1.5 (1 to 8) 
Basal ganglia 193 (31%) 2.2 (1 to 15) 
 Caudate nucleus 49 (8%) 1.3 (1 to 3) 
 Putamen and pallidum 107 (17%) 1.4 (1 to 4) 
 Internal capsule 35 (5%) 1.2 (1 to 2) 
 Thalamus 74 (12%) 1.4 (1 to 6) 
 External capsule 37 (6%) 1.6 (1 to 4) 
 Patient number (N) of and percentage of the total 633 patients (%). 
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The adjusted association between location and load of lacunes, WMH and general 
cognitive performances are presented in table 3. The association between the 
presence of lacunes in any location and MMSE scores was found significant after 
adjustment for potential confounders (E [se] = -0.31 [0.14], p = 0.023). When the 
regional location of lacunes was included in the analysis, a negative association with 
MMSE scores was found significant only when lacunes were located in the thalamus 
(p = 0.043). A significant differential effect related to the location of lacunes was 
detected (test of heterogeneity: p = 0.033). Particularly, the impact of the presence of 
lacunes in the thalamus on the MMSE was found three times greater than the effect of 
the presence of lacunes in the caudate and twice the effect of the presence of lacunes 
in other locations. In contrast, a trend for a positive association was detected between 
MMSE and the presence of lacunes in the internal capsule which suggests a relative 
preservation of MMSE scores in the presence of lesions in this location. Finally, the 
model with lacune locations had a better AIC than the model with the number of 
lacunes irrespective of their location, despite three more degrees of freedom (2765.2 
vs 2762.8). No side effect of lacunes in the thalamus was detected on MMSE (p = 
0.58), speed and motor compound Z score (p = 0.31); executive functions compound 
Z score (p = 0.74). Nor was a side effect detected for lesions in putamen and pallidum 
on memory compound Z score (p = 0.75). The association between the presence of 
lacunes in any location with the ADAS mod scores did not reach statistical 
significance. The only significant association detected with lacunar infarcts located in 
the caudate suggested that the corresponding performances were relatively 
preserved in the presence of lesions at this location. Finally, a significant association 
was observed between the extent of WMH and both MMSE and ADAS Mod. 
Table 3 
 MMSE ADAS 
E (se) p-value E (se) p-value 
WMH -0.32 (0.12) 0.007 1.07 (0.34) 0.002 
Lacunes     
Any location (None/Few/Many) -0.31 (0.14) 0.023 0.20 (0.39) 0.61 
Presence in each location     
 Thalamus -0.61 (0.30)1 0.043 -0.04 (0.86) 0.96 
 Caudate -0.17 (0.35)2 0.63 -2.06 (1.01) 0.042 
 Internal capsula 0.77 (0.40)3 0.051 -0.83 (1.14) 0.47 
 Putamen and pallidum -0.02 (0.26) 0.95 1.08 (0.75) 0.15 
 Lobar white matter -0.30 (0.22)4 0.17 0.47 (0.64) 0.46 
 External capsula and infratentorial -0.31 (0.25)4 0.22 0.89 (0.73) 0.23 
Heterogeneity of effect  Between 1,2,3,4 0.033 - - 
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The adjusted associations between location and load of lacunes, WMH and 
compound Z scores are presented in table 4. A significant association was found 
between the number of lacunes (none/ few/ many) and the compound Z score for 
executive functions but not with the compound Z scores for memory or for speed and 
motor control. The heterogeneity test of the different locations of lacunes was 
significant for all compound Z scores. For the memory compound Z score, a 
significant effect of the presence of lacunes in the putamen and/or pallidum was 
detected (p = 0.038). For the speed and motor control, a significant association was 
detected for the presence of lacunes in the thalamus (p = 0.006) with a lower effect of 
the presence of lacunes in the putamen, pallidum, external capsule and infratentorial 
areas (p = 0.049 and p = 0.047). Finally, for executive functions, a differential effect of 
the presence of lacunes in the thalamus (p = 0.022), in the lobar white-matter (p = 
0.048) or in the putamen and pallidum (although non-significant, p = 0.10) was 
observed. A significant association was observed between the extent of WMH and all 
the compound Z scores. 
Discussion 
The main result of this study is that, in non-disabled elderly subjects with 
leukoaraiosis, the cognitive impact of lacunar infarcts depends on their location and 
not only on their total number. According to our data, the location of lesions in three 
structures, mainly the thalamus, but also the putamen and pallidum, may be involved 
in cognitive performances. In the same cohort, we previously observed an 
independent impact of both white matter lesions and lacunar infarcts on cognition, 
after correction for multiple confounders.9 In the present study, after adjustment for 
WMH severity, we showed that the presence of lacunar infarcts within some specific 
subcortical structures is also significantly and independently associated with worse 
cognitive performances. 
These results are in line with former post-mortem data21 showing that lacunes in the 
thalamus and basal ganglia significantly predicted cognitive status and were a better 
predictor of the cognitive status than periventricular or diffuse “leukoaraïosis”.21
Conversely, although Mungas et al7 observed that the volume of lacunes in the 
thalamus was associated with several cognitive performances in elderly subjects, their 
results were no longer significant when the extent of white-matter lesions was also 
considered in their model. Besides, the results of Mungas et al were obtained in a 
widely heterogeneous sample of both demented and non-demented subjects.  In such 
a sample, the weight of hippocampal atrophy and/or diffuse brain damage may have 
blurred a more limited impact of lacunar lesions on cognitive parameters. In the 
Rotterdam study, a prospective population based cohort designed to study causes 
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and consequences of brain changes in the elderly, Vermeer et al observed that the 
presence of silent infarcts (mainly lacunar infarcts) was also associated with worse 
performances at baseline using a global cognitive compound score but they did not 
find a significant decline in MMSE score after an average follow-up of 3.6 years. 
Interestingly, they detected a significant decline in memory performances when 
lacunar infarcts were located in the thalamus at baseline and a larger decline  in 
psychomotor speed when these lesions were located elsewhere,22 suggestive of a 
differential impact of location of these lesions as observed in the present study.  
In this study, the presence of lacunes in the thalamus was associated with worse 
performances in global cognitive function as well as in both speed and motor control 
and executive functions. Noteworthily, the impact on global cognitive function was 
only observed with the MMSE, though this scale was only mildly impaired in non-
disabled subjects. By contrast, no significant association was detected with the ADAS 
Mod score except for lacunar infarcts located in the caudate nucleus suggesting that 
the corresponding performances were relatively preserved in presence of lesions at 
this location. This may be due to the fact that this scale is adapted from the ADAS 
cog, designed for detecting the progression of Alzheimer’s disease, especially at 
moderate stages,23 and is not a good tool for detecting mild cognitive changes.24
Besides, when specific cognitive domains were considered in the analysis, speed and 
motor control were affected by the presence of lacunar infarcts in the thalamus. This 
result is in line with previous data showing that 1) speed of information processing is 
frequently impaired in patients with thalamic lesions,12 and 2) age-related decrease of 
thalamic volume is associated with reduced speed processing.25 In addition, in the 
present study, the location of lacunar infarcts in the thalamus was associated with a 
lower compound Z score for executive functions in line with previous reports in 
thalamic infarctions.12 In contrast, no significant association was detected between the 
thalamic location and memory performances. In 22 cases with thalamic infarction, Van 
der Werf et al. reported that an amnestic syndrome was not necessarily related to 
lesions involving only the mamillo-thalamic tract.12 Beside, simple attention deficit was 
found to be a rather general trait of thalamic lesions and did not appear associated 
with a specific structure within the thalamus. Thus in our population, the thalamic 
lesions may not have been severe enough or properly localized to alter significantly 
memory performances. Alternatively, the use of compound scores for the assessment 
of different cognitive domains instead of single tests as well as the lack of detailed 
anatomical analysis of lacunar thalamic infarcts may also have reduced our ability to 
detect some discrete effects on memory functions. In this study, a significant effect of 
location of lesions in the putamen or pallidum was detected on memory 
performances. This is in line with persisting short term memory impairment already 
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reported after the occurrence of unilateral lenticular infarcts.26 However, in contrast 
with thalamic infarcts, no significant effect was detected on MMSE scores. Finally the 
strategic role of lesions located in the internal capsule on cognition27 was not 
observed in this study but cannot be excluded in the absence of detailed location 
analysis.   
Our study also sheds light on the relative contribution of lacunar infarcts (number and 
location) and WMH on cognition. Interestingly, the load of lacunar infarcts was found 
associated only with the compound Z score for executive functions whereas WMH 
had a significant effect on all general cognitive and compound scores. In contrast with 
the absence of impact of their number, the location of lacunar infarcts within the 
thalamus was found associated with speed and motor control. Moreover, the 
importance of location of lacunar infarcts as a determinant of cognitive impairment is 
also supported by the following results: 1) there was a significant heterogeneity effect 
of lacunes location on cognitive performances, 2) a model with separate effects for 
the presence of lacunar infarcts in the thalamus and in other regions was found better 
suited than one based only on the number of infarcts to fit the relationships between 
MMSE and MRI lesions.   
The strengths of this study are the large number of elderly patients and the relative 
homogeneity of the cognitive status of the population made of non-demented and 
non-disabled subjects with leukoaraiosis. The limitations are the analysis of cross-
sectional data with the need of confirmation in a prospective aspect, the different 
number of patients for analysis of the 3 composite Z scores due to a different number 
of missing data, the lack of very detailed anatomical analysis and the use of 
compound measures of cognitive performances which might have hampered the 
detection of subtle cognitive effects of infarcts location. Analyzing the effect of lacune 
location was also a challenging task because this effect partly combines with the 
potential influence of the number of lacunes. In the present study, we considered that 
lacune location would be related to cognitive impairment if the coefficients obtained 
for different locations were significantly different in a multiple regression model 
(analysis of covariance). This corresponds to compare a regression model with equal 
coefficients and whatever the location, to a model with separate coefficients for each 
location. In the LADIS sample, the number of patients with lacunes in each location 
was limited. Thus, detecting a differential effect according to location had low power. 
To overcome this difficulty, we pre-processed the data in order to diminish the number 
of parameters estimated and to decrease the variance of parameter estimates. This is 
a potential limitation of the study as well as the difficulty in estimating the exact effect 
of lacune location and that of lacune number. We showed that for MMSE, the model 
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with lacune locations better fitted the data than a model with the number of lacunes 
irrespective of their location. However, the respective impact of number and location 
could not be fully evaluated and would deserve a larger study. In future studies, it will 
also be useful to take into consideration cerebral atrophy, whose impact on cognition 
has been recently recognized in small vessel disease.28 Finally, the findings in this 
population may not be valid at more severe stages of small vessel disease or in 
demented subjects, particularly in presence of large amounts of lacunar infarcts 
and/or severe cerebral atrophy whose effects could exceed that of subcortical location 
of ischemic lesions. 
In conclusion, our study emphasized the impact of WMH on memory, speed and 
motor control, and executive functions. Moreover, it showed that not only the load, but 
also the location of “silent” lacunar infarcts, especially in specific subcortical 
structures, are additional determinants of cognitive impairment in non-disabled elderly 
subjects. Whether the location of lacunar lesions increases the risk of cognitive 
decline and disability in this population will require further investigations and 
prospective studies. 
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Abstract
Background: Investigating associations between the change of white matter 
hyperintensities (WMH) and clinical symptoms over time is crucial for establishing a 
causal relationship. However, the most suitable method for measuring WMH 
progression has not been established yet. We compared reliability and sensitivity of 
cross-sectional and longitudinal visual scales with volumetry for measuring WMH 
progression. 
Methods: Twenty MRI scan pairs (interval two years) were included from the 
Amsterdam center of the LADIS study. Semi-automated volumetry of WMH was 
performed twice by one rater. Three cross-sectional scales (Fazekas scale, Age-
Related-White-Matter-Changes scale, Scheltens scale) and two progression scales 
(Rotterdam Progression scale, Schmidt Progression scale) were scored by four and 
repeated by two raters. 
Results: Mean WMH volume (24.6 ± 27.9 ml at baseline) increased by 4.6 ± 5.1 ml 
(median volume change [range] = 2.7 [-0.6 - 15.7] ml). Measuring volumetric change 
in WMH was reliable (intra-rater: intra-class coefficient = 0.88). All visual scales 
showed significant change of WMH over time, although the sensitivity was highest for 
both of the progression scales. Proportional volumetric change of WMH correlated 
best with the Rotterdam Progression scale (Spearman’s r = 0.80, p < 0.001) and the 
Schmidt Progression scale (Spearman’s r = 0.64, p < 0.01). Although all scales were 
reliable for assessment of WMH cross-sectionally, WMH progression assessment 
using visual scales was less reliable, except for the Rotterdam Progression scale 
which had moderate to good reliability (weighted Cohen’s Kappa = 0.63 [intra-rater], 
0.59 [inter-rater]).  
Conclusion: To determine change in WMH, dedicated progression scales are more 
sensitive and/or reliable and correlate better with volumetric volume change than 
cross-sectional scales.  
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Background 
White matter hyperintensities (WMH) are frequently seen on brain MRI of elderly 
persons.1 Although WMH have been associated with cognitive impairment, gait 
disturbances, depression and vascular risk factors,2-5 clinical-radiological association 
studies have yielded inconsistent results. 
The interest in WMH has gradually shifted from cross-sectional studies, examining 
clinical relations and risk factors, to longitudinal designs to characterize the 
associations between change of WMH and clinical symptoms over time and to 
investigate a causal relationship of these changes.6 Also, the progression of WMH 
has been proposed for use in clinical intervention studies.7 WMH assessment 
methods have been shown to be reliable in a cross-sectional setting,8-10 but their use 
as a tool for measuring WMH progression has not been established yet. To date, few 
reliability studies have evaluated visual rating scales, visual change scales and 
volumetry to detect WMH progression. Scales designed for cross-sectional evaluation 
of WMH have shown not to be reliable for evaluation of WMH in longitudinal studies.10
In contrast, evaluation of dedicated progression scales has shown varying results.11, 12
At the other end of the spectrum, quantitative segmentation has been proposed as a 
reliable and sensitive technique to measure WMH progression.13 Generally speaking, 
however, volumetry is not widely applicable and, as most volumetric methods still 
need user interference, can be time-consuming. 
We therefore compared three conventional visual rating scales and two visual 
progression scales with semi-quantitative volumetry to determine the most reliable 
and sensitive method for measuring progression of WMH over time.  
Methods
Subjects 
Data were drawn from the multicenter, multinational Leukoaraiosis and Disability 
(LADIS) study. The LADIS project studies the role of WMH as an independent 
predictor of the transition to disability in initially non-disabled elderly. The rationale 
and design of the LADIS study have been described elsewhere.14 In short, 639 elderly 
subjects (age [SD] =  74 [5] years; women N [%] = 314 [55]) who had no or only mild 
disability in their instrumental activities of daily living (IADL), and were stratified for 
grade of WMH severity, were followed up for three years. Subjects presented with 
complaints including mild memory loss, minor motor disturbances, minor focal 
cerebrovascular events or non-specific reasons for undergoing a cranial neuroimaging 
study (and had WMH as incidental finding). To be included, subjects had to have: (a) 
an age between 65 and 84, (b) WMH on MRI of any degree, according to the 
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categorization into the three severity classes of the modified Fazekas scale,15 (c) no 
or only mild disability as determined by the IADL scale, (d) presence of a regularly 
contactable informant, (e) agreement to sign an informed consent. Exclusion criteria 
were: (a) likely drop out because of the presence of severe illnesses (cardiac, hepatic, 
or renal failure, cancer or other relevant systemic diseases), (b) severe unrelated 
neurological diseases, (c) leukoencephalopathy of non-vascular origin (immunologic-
demyelinating, metabolic, toxic, infectious, other), (d) severe psychiatric disorders, (e) 
inability to give an informed consent, (f) inability or refusal to undergo cerebral MRI.  
MRI scans 
All subjects underwent brain MRI scanning at baseline. In Amsterdam, additional 
yearly MRI scans were performed. For the current study, we selected consecutive 
MRI scan pairs of 20 subjects of the Amsterdam center that agreed to MRI scanning 
at the two year follow-up evaluation (mean interval of 2.1 ± 0.3 years). As a 
consequence of the baseline stratification by WMH severity according to the modified 
Fazekas scale, subjects with moderate and severe WMH were relatively 
overrepresented, comparable with the total LADIS sample (n = 5; n = 8; n = 7 for mild, 
moderate and severe WMH, respectively). The imaging protocol included axial FLAIR 
images (TE 100 - 140 ms, TR 6000 - 10000 ms, TI 2000 - 2400 ms, slice thickness 5 
mm, interslice gap 0.5 mm, FOV 250 mm, matrix size 256 x 256) which were used for 
assessment of WMH. 
WMH progression measurements 
Semi-automated volumetric measurement of WMH was performed on a Sparc 5 
workstation (SUN, Palo Alto, Calif.) on the axial FLAIR images by one trained and 
blinded rater.16 Lesions were marked and borders were set using local thresholding 
(homedeveloped software Show_Images, version 3.6.1) on each slice. No distinction 
was made between subcortical and periventricular hyperintensities. Areas of 
hyperintensity on T2-weighted images around infarctions and lacunes were 
disregarded. When all lesions were delineated, the program calculated the total 
surface of the outlined area. By multiplying with the interslice distance, total volume of 
WMH was established. Volumetric measurements were done on the baseline and 
follow up scan separately. Typical examples of the volumetric WMH measurements 
showing progression of WMH using are illustrated in figure 1. Baseline volumes were 
subtracted from follow-up volumes to obtain absolute WMH volume change (ǻ
volume). In addition, proportional volume change was calculated as follows: %ǻ
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Figure 1 
FLAIR images of baseline MRI (A1 and B1) and follow-up MRI (A2 and B2) of two subjects (A and B) 
represent typical examples of WMH progression using the volumetric assessment method.  
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volume =  ǻ volume / baseline volume. The volumetric measurement was repeated 
after an interval of four months to determine intra-observer reliability.  
Three cross-sectional visual scales were used: the Fazekas scale,15 the Age-Related-
White-Matter-Changes (ARWMC) scale17 and the Scheltens scale.18 The Fazekas 
scale has a range of 1 – 6. In periventricular regions scores 0 – 3 can be given and in 
the subcortical region scores 1 – 3 can be given for mild, moderate or severe lesions, 
respectively. The ARWMC scale has a range from 0 to 30 where scores 0 – 3 can be 
given in 5 regions, each left and right. The Scheltens rating scale ranges from 0 to 84 
(scores 0 – 6 can be given in 13 subcortical regions and scores 0 – 2 for 3 
periventricular regions). Boundaries of the brain regions on axial slices were defined 
as follows: the division between the frontal and parietal lobes is the central sulcus, or 
at the halfway mark of the brain when the central sulcus is not evident, downwards 
until the splenium becomes apparent. At and below the splenium, the brain is divided 
into the frontal, temporal and occipital lobes. The temporal and occipital lobes are 
divided by two lines at a 90º angle extending from the tips of the occipital horns, or 
stemming from the aqueduct at lower levels. Four raters, all experienced with rating of 
WMH on MRI, determined WMH scores on baseline and follow-up scans in a side-by-
side manner. Change scores (ǻ-scores) were obtained by subtracting the baseline 
scores from the follow-up scores.  
Two dedicated progression scales were used: the Rotterdam Progression scale12 and 
the progression scale used by Schmidt et al.11 The Rotterdam Progression scale 
(range –7 to 7) measures decrease, no change or increase (-1, 0, 1 respectively) of 
WMH for three periventricular regions and four subcortical regions. The Schmidt 
Progression scale measures WMH progression as absent, mild or marked. Mild 
progression is defined as increase in number of WMH lesions of 1 to 4 without 
transition in WMH grade (mild, moderate, severe), as defined in the Fazekas scale. 
When an increase in number of lesions of more than 4 or a transition in WMH grade 
occurred, the WMH progression was defined as ‘marked’. Four raters visually scored 
the progression scales that are by definition scored side-by-side. WMH assessment in 
a side-by-side fashion allowed the raters to match the contrast and intensity levels of 
the baseline and follow-up scan as much as possible. To determine intra-rater 
reliability of the visual rating scales, two raters repeated all scoring of cross-sectional 
and progression scales after an interval of 6 months. 
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Statistical analysis
For analysis of (change in) WMH volumes, the average of the first and second 
measurement was used. For each visual rating scale the average of the four raters 
was used. Sensitivity of volumetric and visual measurements was assessed by 
analyzing the mean change scores with one-sample Student’s t-tests. Standardized 
Response Means (SRM) of the change scores were calculated.19 The SRM provides 
an estimate of change in the measure, standardized relative to the between patient 
variability in change scores and reflects the degree of sensitivity of the measure. It is 
defined as the mean score change divided by the standard deviation of that score 
change. An SRM can be considered large (> 0.80), moderate (0.5 - 0.8) or small (< 
0.5), whereby higher scores reflects higher sensitivity. Relationships between change 
scores of the visual scales and proportional and absolute WMH volume change were 
evaluated by Spearman’s correlation analysis. For intra-observer reliability of (change 
in) WMH volumes, intra-class coefficients (ICC) were calculated. The intra- and inter-
observer agreement of (change in) visual rating scales were assessed by weighted 
Cohen’s Kappa scores. Mean weighted Kappa’s of < 0.20 were considered to reflect 
poor agreement, 0.21 to 0.40 fair agreement, 0.41 to 0.60 moderate agreement, 0.61 
to 0.80 good agreement, and above 0.81 very good agreement.20
Results
At baseline, mean WMH volume of the study sample was 24.6 ± 27.9 ml. After two 
years, WMH volume increased with 4.6 ± 5.1 ml on average (p < 0.001). Median 
volume change (range) was 2.7 (-0.6 – 15.7) ml. WMH volumes for each individual  
Table 1. Sensitivity of measuring WMH progression. 
 Baseline Follow-up WMH 
progression 
SRM
     
Volumetry (ml) 24.6 (27.9) 29.2 (30.5) 4.6 (5.1) **  0.9 
     
Fazekas scale 4.3 (1.4) 4.6 (1.3) 0.3 (0.4) * 0.8 
ARWMC scale 12.3 (5.5) 13.2 (5.2) 0.9 (1.5) * 0.6 
Scheltens scale 22.7 (8.2) 24.1 (8.0) 1.4 (2.0) ** 0.7 
     
Schmidt Progression scale - - 0.9 (0.6) *** 1.5 
Rotterdam Progression scale - - 2.9 (2.9) *** 1.0 
Values are means (SD) of the raters. All analyses are one-sample T-tests. WMH = white matter 
hyperintensities. ARWMC = age-related white matter changes. SRM (standardized response mean) is 
defined as mean score change divided by the standard deviation of that score change.  
* p < 0.05, ** p < 0.01, *** p < 0.001. 
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are represented in figure 2. Table 1 shows mean baseline, follow-up and change in 
WMH volume, and WMH ratings using visual cross-sectional scales and progression 
scales. All visual scales showed significant change of WMH over time. On visual 
inspection, SRM values were higher and sufficiently large (> 0.80) for WMH volume 
and both the progression scales than for cross-sectional rating scales, implying higher 
sensitivity for measuring WMH progression. 
Figure 2 
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Table 2 shows correlation analyses of visual versus proportional and absolute change 
in WMH volume. Change in ARWMC scale, Rotterdam Progression scale and 
Schmidt Progression scale were significantly correlated with proportional change in 
WMH volume. However, the strongest associations were found with the Rotterdam 
Progression scale, followed by the Schmidt Progression scale. When considering 
absolute WMH volume changes, only the association with the Rotterdam Progression 
scale was significant. 
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Table 2. Non-parametric correlations between visual scales and volumetry. 
WMH assessment scale Correlation with %  
ǻ volume 
Correlation with 
ǻ volume 
   
ǻ Fazekas score 0.37 0.21 
ǻ ARWMC score 0.50 * 0.40 
ǻ Scheltens score 0.44 0.43 
Schmidt Progression score 0.64 ** 0.33 
Rotterdam Progression score 0.80 *** 0.58** 
* p < 0.05, ** p < 0.01, *** p < 0.001, WMH = white matter hyperintensities. ARWMC = age-related white 
matter changes. ǻ volume = follow up volume – baseline volume. % ǻ volume = ǻ volume / baseline 
volume.
Reliability analyses of cross-sectional and change of WMH assessment are listed in 
Table 3. Intra-observer reliability and both intra- and inter-observer reliability are 
available for WMH volumetry and visual scales, respectively. Both WMH volumetry 
and visual scales are reliable for cross-sectional assessment of WMH. In addition, for 
measuring progression of WMH over time, volumetry is a reliable method. However, 
reliability of measuring WMH change using cross-sectional visual scales is 
insufficient. Regarding the progression scales, in contrast to the fair reliability of the 
Schmidt Progression scale, the Rotterdam Progression scale had a moderate to good 
reliability.
Discussion
In this study, we compared three cross-sectional visual rating scales and two 
progression scales to standard ROI-based volumetry to determine the most reliable 
and sensitive method for measuring WMH progression in longitudinal studies. In 
addition, we confirmed earlier findings that conventional visual rating scales are 
reliable for measuring WMH in a cross-sectional setting.9, 10 First, we demonstrated 
that all WMH assessment methods showed significant progression of WMH over two 
years in a sample of subjects stratified for WMH grade, although the sensitivity was 
higher for the dedicated progression scales than for the conventional rating scales. 
Second, we found stronger associations of (proportional) WMH volume change with 
both dedicated progression scales than with the cross-sectional scales, implying 
higher validity. Third, the Rotterdam Progression scale had the highest reliability for 
measuring progression of WMH. We therefore conclude that dedicated progression 
scales are more suitable than cross-sectional visual scales for visual assessment of 
WMH progression. Moreover, the choice between the progression scales will be 
dependent on the research question, as the progression scales assess different 
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Table 3. Reliability of measuring WMH progression.  
WMH assessment  Intra-observer 
Inter-
observer 
     
Cross- Volumetry Baseline 0.998  - 
sectional  Follow-up 0.998  - 
Fazekas score Baseline 0.79  0.70  
 Follow-up 0.82  0.72  
ARWMC score Baseline 0.91  0.88  
 Follow-up 0.92  0.86  
Scheltens score Baseline 0.84  0.80  
 Follow-up 0.88  0.82  
    
Change ǻ Volumetry  0.881  - 
ǻ Fazekas score  0.64  0.22  
ǻ ARWMC score  0.47  0.34  
ǻ Scheltens score  0.46  0.33  
 Schmidt Progression score  0.40 0.22  
 Rotterdam Progression score  0.63  0.59  
Values for reliability of the visual scales are mean weighted Kappas, available for n = 2 and n = 4 for intra- 
and inter-observer reliability, respectively. Values for intra-observer reliability of WMH volumetry are intra-
class coefficients, available for n = 1. WMH = white matter hyperintensities. ARWMC = age related white 
matter changes. 
aspects of WMH progression. The Schmidt Progression scale measures the severity 
of WMH change while the Rotterdam Progression scale reflects the absence or 
presence of WMH change.  
An earlier study compared several cross-sectional scales and the Rotterdam 
Progression scale with WMH volumetry.12 The Rotterdam Progression scale was 
found to have a fair to moderate inter-observer reliability and a comparable 
association with WMH volume change. Our study confirms these findings with 
different raters and a different set of subjects. We additionally evaluated the ARWMC 
scale and a second dedicated progression scale of Schmidt et al. We found that the 
Schmidt progression scale seems to have superior sensitivity, a strong correlation 
with proportional WMH volume change but only a fair reliability. This is in agreement 
with an earlier report that found that this scale was only reliable when major 
progression with change in WMH grade was present.11
The insufficient reliability of cross-sectional WMH assessment tools for measuring 
WMH progression, may reflect the fact that those tools require separate 
measurements at baseline and at follow-up. Because WMH progression is calculated 
by subtracting baseline data from the follow-up data, measurement error is included 
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twice. This reduces the reliability of cross-sectional methods.21 By contrast, dedicated 
progression scales provide direct change scores by side-by-side assessment and 
therefore have only one measurement error. On the other hand, scoring in a side-by-
side fashion could be less ideal because of impossibility of blinding of the data.  
Ideally, an automated volumetric method would be preferred to assess change of 
WMH, as it provides the most detailed and objective information. A semi-automated 
volumetric method has been proved to be reliable for measuring WMH progression.13
However, as this method still requires user interference, it is relatively time consuming 
and less widely available. While a fast fully automatic method for measuring WMH 
cross-sectionally is available,22 it has not been examined for its reliability to measure 
WMH change. Moreover, all volumetric methods have been evaluated in single center 
studies, but are more difficult to implement in large longitudinal multi-center studies 
using several MRI scanners. To date we are not aware of a multicenter study that has 
analyzed WMH progression with a volumetric method. Until a volumetric method is 
available, we feel that dedicated progression scales are a reasonable alternative for 
measuring progression of WMH. 
When interpreting the results of this study, one has to realize that a gold standard for 
WMH progression does not exist at the moment. WMH volumetry can not be regarded 
as such, as WMH volumetry is equal to visual scales with respect to  associations with 
clinical measures such as physical performance and cognition.23 Furthermore, the 
sample that was used in this study consisted of consecutive Amsterdam participants 
of the LADIS study, that was stratified for WMH grade, in order to include a wide 
range of WMH. Our study sample is therefore representative of the whole LADIS 
population, but the large WMH volume change that we measured may not be 
representative for the general population.  
In conclusion, to determine change in WMH, dedicated progression scales are more 
sensitive and have higher correlations with WMH volume change than conventional 
cross-sectional scales. The Rotterdam Progression scale is the most reliable visual 
assessment tool and measures presence/ absence of WMH progression, while the 
highly sensitive Schmidt Progression scale reflects severity of WMH progression. 
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Abstract
Objective: We studied the natural course of white matter hyperintensities (WMH) and 
lacunes, the main MRI representatives of small vessel disease (SVD), over time and 
evaluated possible predictors for their development. 
Methods: Baseline and repeat MRI (3-year follow-up) were collected within the multi-
center, multinational LADIS study (n = 396). Baseline WMH were scored on MRI by 
the Fazekas scale and the Scheltens scale. WMH progression was assessed using 
the modified Rotterdam Progression Scale (absence/ presence of progression in 9 
brain regions). Baseline and new lacunes were counted per region. WMH and lacunes 
at baseline and vascular risk factors were evaluated as predictors of WMH 
progression and new lacunes. 
Results: WMH progressed (mean ± SD = 1.9 ± 1.8) mostly in the subcortical white 
matter, where WMH was also most prevalent at baseline. The majority of new 
lacunes, which were found in 19% of the subjects (maximum = 9), also appeared in 
the subcortical white matter, mainly of the frontal lobes, while most baseline lacunes 
were located in the basal ganglia. Baseline WMH and lacunes predicted both WMH 
progression and new lacunes. Furthermore, previous stroke, diabetes and blood 
glucose were risk factors for WMH progression. Male sex, hypertension, systolic 
blood pressure, previous stroke, body mass index, HDL and triglyceride levels were 
risk factors for new lacunes.
Conclusion: WMH and lacunes progressed over time, predominantly in the subcortical 
white matter. Progression was observed especially in subjects with considerable 
WMH and lacunes at baseline. Moreover, the presence of vascular risk factors at 
baseline predicted WMH progression and new lacunes over a three-year period.  
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Background
Cerebral small vessel disease (SVD) is a major cause of vascular cognitive 
impairment and dementia.1 White matter hyperintensities (WMH) and lacunes are 
frequently observed in elderly subjects and are considered to be the main MRI 
representatives of SVD.2, 3
Post-mortem studies have shown that WMH correspond to heterogeneous 
pathological substrates, with varying degrees of demyelination, arteriolosclerosis and 
gliosis, representing incomplete infarction but also tissue degeneration.4, 5 Lacunes 
are small cavities, located in the white matter or subcortical gray matter. They have 
been regarded as small ischaemic infarcts, but several pathogenetic mechanisms 
may exist.6
In cross-sectional studies, both WMH and lacunes have been shown to be associated 
with vascular risk factors, such as hypertension and cardiovascular disease.3, 7-9 WMH 
are clinically important as they are associated with cognitive impairment, gait 
disturbances and depression.10, 11 Although most lacunes appear to be ‘silent’, i.e. not 
accompanied by stroke-like symptoms, they have been associated with subtle 
cognitive dysfunction.3 Furthermore, both types of SVD are associated with an 
increased risk of future stroke.12
The interest in SVD is gradually shifting from cross-sectional studies to longitudinal 
designs. Earlier studies have assessed possible risk factors and clinical 
consequences of WMH progression,11, 13-17 but little has been reported on the 
appearance of new lacunes.18, 19 In this MRI study, we studied the natural course of 
both WMH and lacunes in a sample of initially independently living elderly, stratified 
by WMH grade at baseline, over a three-year period and we investigated which 
baseline variables predicted WMH progression and new lacunes. 
Methods
Patients
Data were collected as part of the multi-center, multinational Leukoaraiosis and 
Disability (LADIS) study. The LADIS study investigates the role of WMH as an 
independent predictor of the transition to disability in initially non-disabled elderly. The 
rationale and design of the LADIS study have been described elsewhere.20 In short, 
639 elderly subjects who had no or only mild disability in their instrumental activities of 
daily living (IADL) were enrolled in a hospital based setting. Among the reasons for 
presentation were mild memory loss, minor motor disturbances, minor focal 
cerebrovascular events, depressive symptoms or non-specific reasons for undergoing 
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a cranial neuroimaging study (WMH as incidental finding). To be included, subjects 
had to have: an age between 65-84; WMH on MRI of any degree21; no or only mild 
disability as determined by the Instrumental Activities of Daily Living Scale22;
presence of a regularly contactable informant; agreement to sign an informed 
consent. Exclusion criteria were: likelihood of dropping out because of the presence of 
severe illnesses e.g. cardiac, hepatic or renal failure, cancer or other relevant 
systemic diseases; severe unrelated neurological diseases; leukoencephalopathy of 
nonvascular origin (immunologic, demyelinating, metabolic, toxic, infectious, other); 
severe psychiatric disorders; inability to give an informed consent; inability or refusal 
to undergo cerebral MRI. Subjects were selected and stratified for WMH severity - 
according to the categorization into three severity classes of the modified Fazekas 
scale.21 Subjects were followed for three years.  
Risk factors 
To assess vascular risk factors at baseline, a structured data questionnaire was used 
together with a review of available records by trained medical personnel. The risk 
factors used in this paper are:8, 20 patient demographics - age (years), sex; medical 
history – history of hypertension (treatment with antihypertensive medications or with 
values  140/90 mmHg, based on measurements taken on several separate 
occasions), history of diabetes mellitus (treatment with antidiabetic medications, or at 
least 8-hour fasting plasma glucose t 7.0 mmol/L or 126 mg/dL), clinical history of 
stroke, atrial fibrillation (based on history and/or available clinical records such as 
ECG), history of myocardial infarction (documented by history, ECG or cardiac 
enzymes), history of hypercholesterolaemia (documented by total cholesterol > 200, 
LDL > 130, HDL < 35 mg/dL, and/or hypertriglyceridemia based on serum triglyceride 
> 200 mg/dL, on at least two occasions), past or present cigarette smoking 
(packyears, defined as packs of cigarettes per day multiplied by years smoked); 
physical examination – systolic and diastolic blood pressure (mmHg), body mass 
index (BMI; weight[kg]/ height[m]2); and laboratory examination (all in mmol/L) – total 
cholesterol, HDL, LDL, triglyceride and glucose. 
MRI examinations 
MRI scanning was performed at baseline (ten centers 1.5 T; one center 0.5 T) and 
repeated after 3 years, using the same protocol. For follow-up evaluation (all 1.5 T), 
new MRI scanners were used in three centers. The MR protocol included the 
following sequences: T1-weighted 3D-MPRAGE (magnetization prepared rapid-
acquisition gradient-echo, scan parameters: coronal or sagittal plane, TE 2 – 7 ms, 
TR 9 – 26 ms, FA 15 - 30º, voxelsize 1 x 1 x 1 - 1.5 mm3), T2-weighted FSE (fast spin  
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echo, scan parameters: axial plane, TE 100 – 130 ms, TR 4000 – 6600 ms, voxelsize 
1 x 1 x 5 mm3, 19 - 31 slices), and FLAIR (fluid-attenuated inversion recovery, scan 
parameters: axial plane, TE 100 – 160 ms, TR 6000 – 10000 ms, TI 2000 – 2400 ms, 
voxelsize 1 x 1 x 5 mm3, 19 - 31 slices).  
Assessment of WMH and lacunes 
Baseline WMH assessment and scoring of lacunes and infarcts were performed 
centrally by a single rater who was blinded to clinical information. The degree of WMH 
severity was rated visually on axial FLAIR images using the modified Fazekas scale 
(WMH grade = mild, moderate, severe)21 and the Scheltens rating scale (range of 0 - 
84),23 in which scores 0 – 6 can be given in 13 subcortical regions (subcortical white 
matter, basal ganglia and infratentorial region) and scores 0 – 2 for three 
periventricular regions. To identify lacunes, we used FLAIR, MPRAGE and T2-
images. The combination of the three scan sequences was used to distinguish 
lacunes from Virchow Robin spaces (VRS) and microbleeds. The intensities of 
lacunes and VRS are similar to cerebrospinal fluid in all scan sequences, but lacunes 
mostly have a hyperintense rim around the cavity on FLAIR-images in contrast to 
VRS. When lacunes present without a hyperintense rim (e.g. in the basal ganglia or 
infratentorial), they can often be distinguished by their size and shape: lacunes are 
defined as cavities 3 – 10 mm and are mostly ovoid/spheroid, while VRS are smaller 
and follow the vessel (seen on coronal/ sagittal MPRAGE). T2-images were used to 
identify lacunes in the basal ganglia and infratentorial regions, as FLAIR-images are 
less sensitive to detect lacunes in these areas and to distinguish lacunes from 
microbleeds, as microbleeds are hypointense on T2. Lacunes were scored in five 
brain regions (frontal, parieto-occipital, temporal, basal ganglia and infratentorial). 
Boundaries of the brain regions on axial slices were defined as follows: the division 
between frontal and parietal lobes is the central sulcus, or at the halfway mark of the 
brain when the central sulcus is not evident. At and below the level of the splenium, 
the brain is divided between frontal, temporal and occipital lobes. Temporal and 
occipital lobes are divided by two lines at a 90º angle extending from the occipital 
horns, or stemming from the aqueduct at lower levels. Eight-teen randomly selected 
scans that were scored twice for the determination of the intrarater reliability (Fazekas 
scale: weighted Cohen’s Kappa = 0.84, Scheltens scale: intra-class correlation 
coefficient [ICC] = 0.92).  
At follow-up, visual rating of WMH progression and new lacunes was performed in a 
side-by-side fashion, blinded to clinical details. WMH progression was rated on FLAIR 
images according to the modified Rotterdam Progression scale,24 in which absence or  
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presence of progression (0 and 1, respectively) was rated in three periventricular 
regions (frontal caps, occipital caps, bands), four subcortical white matter regions 
(frontal, parietal, occipital, temporal), basal ganglia and infratentorial region. New 
lacunes were counted in the same regions. The intra-rater reliability was determined 
on 20 randomly selected scans that were scored twice (WMH progression: weighted 
Cohen’s Kappa = 0.81, number of new lacunes: ICC = 0.84). During the evaluation of 
follow-up MRI scans, a misclassification of 22 MRI scans was corrected in the 
baseline database. This correction does not affect the main results of the baseline 
analysis, but has caused small differences in the numbers of the reported baseline 
data.
Statistical analysis  
Differences between groups were tested with student’s T-tests and Chi-squared tests, 
where appropriate. Possible predictors of SVD progression were assessed with 
logistic regression analyses. The evaluated variables were categorized into: patient 
demographics, medical history (dichotomized into yes/no), physical examination 
(recoded into quintiles), laboratory examination (recoded into quintiles) and baseline 
MRI variables (WMH grade, number of lacunes). Dichotomized WMH progression 
(highest quintile: 0 – 3 vs > 3) and new lacunes (0 vs  1) were the dependent 
variables. First, all analyses were corrected for age, sex and center. Subsequently, all 
baseline variables were entered simultaneously. 
Results
During follow-up, 43 subjects died and 73 subjects dropped out of the study. 
Therefore, at three year follow-up, 523 subjects could be evaluated clinically of which 
43 subjects received a follow-up evaluation with a telephone interview. Thirty subjects 
were not scanned due to refusal and subjects of one center (47 subjects) could not be 
scanned because of lack of funding. Thus, follow-up MRI scans were available for 403 
patients. Seven scans were excluded because of absent FLAIR images (6 scans) or 
inappropriate slice positioning (1 scan). Therefore, 396 scans could be evaluated for 
this study (mean scan interval 3.1 ± 0.3 years). 
A baseline description of the study sample is given in table 1. The subjects that 
received a follow-up MRI were younger, had more years of education, had higher 
MMSE scores and lower ADAS-scores at baseline, had higher diastolic blood 
pressure, lower total cholesterol, LDL, triglyceride and glucose levels than subjects 
who were not scanned at follow-up. Baseline MRI characteristics were comparable 
between the groups with and without follow-up MRI.  
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Table 1. Baseline characteristics of subjects with and without follow-up MRI scans. 
Data are represented as mean ± SD or n (%). SPPB: range 0 – 12, low scores reflect impairment; ADAS: 
modified + delayed recall, range 0 – 80, high scores reflect impairment. *p < 0.05, **p < 0.01, ***p < 0.001 
The relative frequency of the total Rotterdam Progression scores and number of new 
lacunes are shown in figure 1. Over three years, WMH increased with 1.9 ± 1.8 points 
(mean ± SD) on the Rotterdam Progression scale (one-sample T-test: p < 0.001). The 
median (interquartile range) of the Rotterdam Progression score was 2 (0 – 3). A
  With follow-up 
MRI (n = 396)  
Without follow-up 
MRI (n = 243) 
     
Demo- Age (years)  73.6 ± 5.0 74.8 ± 5.0 ** 
graphics Sex (women)  212 (54%)  139 (57%) 
 Education (years)  9.8 ± 4.1 9.2 ± 3.3 * 
Mini-Mental State Examination 27.7 ± 2.3 26.8 ± 2.5 *** Clinical  
Short Physical Performance Battery (SPPB) 9.9 ± 2.1 9.7 ± 2.3 
 Alzheimer Disease Assessment Scale (ADAS) 16 ± 7 18 ± 8 *** 
     
Medical  Hypertension  279 (71%) 166 (69%) 
history Diabetes  52 (13%) 40 (17%) 
 Stroke   124 (31%) 64 (26%) 
 Myocardial infarct   45 (11%) 27 (11%) 
 Hypercholesterolaemia  198 (51%) 117 (50%) 
 Atrial fibrillation  25 (6%) 24 (10%) 
 Smoking (packyears)  13 ± 20 14 ± 22 
     
Systolic blood pressure (mmHg)  150 ± 20 148 ± 21 Physical 
examination Diastolic blood pressure (mmHg)  85 ± 11 82 ± 11 ** 
 Body Mass index (kg/m2)  26 ± 3.9 26 ± 4.6 
     
Total cholesterol (mmol/L)  5.5 ± 1.1 5.8 ± 1.1 ** Laboratory  
examination HDL (mmol/L)  1.5 ± 0.5 1.5 ± 0.5 
 LDL (mmol/L)  3.3 ± 1.0 3.5 ± 1.0 ** 
 Triglycerids (mmol/L)  1.6 ± 0.8 1.8 ± 1.3 * 
 Glucose (mmol/L)  5.7 ± 1.5 6.0 ± 2.0 * 
     
MRI  WMH - Fazekas  Mild 178 (45%) 106 (44%) 
  Moderate 124 (31%) 73 (30%) 
  Severe  94 (24%) 64 (26%) 
 WMH - Scheltens   18.2 ± 8.9 18.4 ± 9.5 
 Lacunes (number) 0 207 (52%) 128 (53%) 
  1 - 3 134 (34%) 83 (34%) 
  > 3 55 (14%) 30 (12%) 
 Cortical infarcts Present 38 (10%) 21 (9%) 
  Absent 358 (90%) 219 (91%) 
Chapter 3.2 
82
Figure 1 
The proportional frequency of total Rotterdam Progression Scores (A) and new lacunes (B) with absolute 
number of subjects are depicted. While subscores could not be given in two subjects due to bilateral 
infarcts, the total number of subjects for WMH progression is 394. 
score of 0, that indicates no change in WMH, was present in 26% of the subjects 
while 74% had a score of one or higher, reflecting WMH progression in one or more 
regions. More specifically, 21% of the subjects showed WMH progression in one 
region and 53% in at least two regions. At follow-up, 81% of the subjects had no new 
lacunes, one new lacune was present in 11% and 8% of the subjects had more than 
one new lacune (maximum = 9). WMH progression was modestly correlated with the 
number of new lacunes (Spearman’s r = 0.15; p < 0.01). These results indicate that 
progression of SVD was present in a considerable proportion of our study sample.  
To investigate the spread of WMH through the brain, we compared the regional 
baseline WMH according to the Scheltens scale (figure 2a) with WMH progression 
(Rotterdam Progression scale, figure 2b). At baseline, half of the total Scheltens-score 
was accounted for by hyperintensities in the subcortical white matter, mainly the 
frontal and parietal lobes. Progression of WMH is also most commonly seen in the 
subcortical white matter (54%), especially the frontal and parietal lobes, followed by 
the periventricular regions (33%). These figures roughly indicate that the regional 
distribution of WMH progression after three years is proportional to the distribution of 
WMH load at baseline. As the difference in the range of the scales may influence the 
results of the distribution, we additionally transformed the Scheltens scale to match 
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the range of the Rotterdam Progression scale (regional scores were dichotomized: 
score 0/1 = 0; score > 1 = 1). Overall, results remained comparable with the original 
scales (data not shown). 
Figure 2 
WMH load at baseline (figure 2a) and WMH progression (figure 2b) are represented in the following brain 
regions: PVL = periventricular, SC = subcortical white matter (WM), BG = basal ganglia, IT = infratentorial, 
T = temporal WM, O = occipital WM, P = parietal WM and F = frontal WM. 
Lacunes at baseline and the occurrence of new lacunes were also compared by brain 
region (figure 3). At baseline, the relative prevalence of lacunes was comparable 
between the basal ganglia (45%) and subcortical white matter (43%). During follow-
up, new lacunes mostly occurred in the subcortical white matter, mainly the frontal 
lobes (41%), while new lacunes were less prevalent in the basal ganglia (28%). In 
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Figure 3 
The distribution of baseline and new lacunes in brain regions (F = frontal, PO = parieto-occipital, T = 
temporal, BG = basal ganglia, IT = infratentorial) are shown in figure 3a and 3b, respectively.
contrast to WMH progression, the regional distribution of lacunes seemed to shift over 
time. An example of a patient who had lacunes in the basal ganglia at baseline and a 
new lacune in the frontal lobe is shown in figure 4. 
To investigate which baseline variables predicted progression of WMH and incidence 
of new lacunes, we performed logistic regression analyses with baseline variables 
corrected for age, sex, and center (table 2). Baseline WMH and lacunes predicted 
both WMH progression (Rotterdam Progression score >3) and new lacunes. 
Moreover, history of diabetes, higher blood glucose, and history of stroke predicted 
WMH progression. The occurrence of new lacunes was predicted by male sex, history 
of hypertension, higher systolic blood pressure, history of stroke, higher BMI, lower 
HDL, and higher triglyceride. When all baseline variables were entered 
simultaneously, baseline WMH remained a significant predictor of WMH progression 
(OR [95%-CI]: 2.8 [1.5 - 5.1]), while significance was lost for the other univariate risk 
factors. In addition, higher age became a significant predictor of WMH progression 
(OR [95%-CI]: 1.1 [1.0 - 1.3]) and higher triglyceride appeared to protect for WMH 
progression (OR [95%-CI]: 0.6 [0.4 - 0.9]). For the appearance of new lacunes, 
baseline WMH and lacunes, systolic blood pressure, and HDL remained significant 
predictors in the multivariate analysis (OR [95%-CI]: 2.1 [1.2 - 3.6]; 1.2 [1.0 - 1.3]; 2.1 
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Figure 4 
Coronal MPRAGE images (A to D) and axial FLAIR images (E and F) of one patient. The baseline MRI (A, 
C, E) shows basal ganglia lacunes (see arrows), while on the follow-up MRI (B, D, F) a new lacune in the 
frontal lobe (arrow head) has appeared.  
[1.4 - 3.3]; 0.5 [0.3 - 0.7], respectively). Also, unexpected associations appeared with 
high diastolic blood pressure (OR [95%CI]: 0.6 [0.4 - 0.9]) and high LDL (OR [95%CI]: 
0.5 [0.3 - 1.0]) protecting for new lacunes. Additional analyses to correct for 
antihypertensive and antihyperlipaemic medication, did not change the results 
essentially.
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Table 2. Baseline predictors of SVD progression.  
Physical and laboratory examination variables are recoded into quintiles. Values are Odds Ratios (95%-
confidence intervals), corrected for age, sex and center. Subscores could not be given for WMH 
progression in two subjects due to bilateral infarcts. *p < 0.05, **p < 0.01, ***p < 0.001 
Discussion 
In this MRI study we report three main findings. First, we found in a large group of 
initially independently living elderly, stratified for a wide range of WMH, that both 
WMH and lacunes progressed over time. Second, WMH progression seems to appear 
mostly in the subcortical white matter, where WMH was also most prevalent at 
baseline. New lacunes also preferentially occurred in the subcortical white matter, 
while baseline lacunes were equally prevalent in the basal ganglia. Third, WMH 
progression and new lacunes were observed especially in subjects with considerable 
WMH and lacunes at baseline. Moreover, history of diabetes, high blood glucose and 
Baseline variable n WMH  
progression
(0 – 3 vs > 3) 
New lacunes
(0 vs > 0) 
     
Patient  Age per year 396 1.1 (1.0 – 1.1) 1.0 (0.9 – 1.0) 
demographics Female sex  396 1.2 (0.7 – 2.0) 0.6 (0.3 – 1.0) * 
     
Medical  Presence of hypertension 395 1.2 (0.6 – 2.1) 2.0 (1.1 – 3.9) * 
history Presence of diabetes  393 2.4 (1.1 – 5.3) * 1.4 (0.7 – 3.0) 
 Presence of previous stroke 396 1.8 (1.0 – 3.3) * 2.7 (1.5 – 4.7) *** 
 Presence of atrial fibrillation 396 0.9 (0.3 – 2.7) 1.1 (0.4 – 3.2) 
 Presence of hypercholesterolaemia 387 0.9 (0.5 – 1.5) 1.0 (0.5 – 1.7) 
 Presence of myocardial infarction 395 0.7 (0.3 – 1.7) 1.5 (0.7 – 3.3) 
 Smoking (packyears) 396 1.0 (1.0 – 1.0) 1.0 (1.0 – 1.0) 
     
Physical  Systolic blood pressure 396 0.9 (0.7 – 1.1) 1.3 (1.1 – 1.6) ** 
examination Diastolic blood pressure 396 1.0 (0.9 – 1.3) 1.1 (0.9 – 1.3) 
 Body mass index  396 1.1 (0.9 – 1.3) 1.3 (1.1 – 1.6) ** 
     
Laboratory Total cholesterol 335 1.0 (0.8 – 1.3) 1.0 (0.8 – 1.2) 
examination HDL 309 1.0 (0.8 – 1.3) 0.6 (0.5 – 0.8) *** 
 LDL 281 1.1 (0.9 – 1.3) 1.0 (0.8 – 1.2) 
 Triglyceride 313 0.9 (0.7 – 1.1) 1.2 (1.0 – 1.5) * 
 Glucose 321 1.3 (1.0 – 1.6) * 1.1 (0.9 – 1.3) 
     
MRI  WMH per Fazekas grade 396 2.5 (1.7 – 3.5) *** 2.4 (1.7 – 3.4) *** 
 Lacunes (number) 396 1.1 (1.0 – 1.2) ** 1.2 (1.1 – 1.3) *** 
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history of stroke predicted WMH progression, while for new lacunes the following risk 
factors were found: male sex, history of hypertension, systolic blood pressure, history 
of stroke, low HDL and high triglyceride levels and high BMI.  
This study is consistent with earlier publications with respect to the finding that WMH 
progress over time, mostly in subject with considerable WMH at baseline.11,13,16,17,25,26
Our results suggest that WMH progression mainly results from an increase of existing 
WMH,17 raising the question when the baseline WMH have occurred, and in what time 
frame. Only two longitudinal studies described progression of lacunes.18,19 We found 
that one out of five subjects had at least one new lacune in three years, which was 
associated with WMH and lacunes at baseline. Our finding of new lacunes in a fairly 
high proportion of subjects may be related to the stratification by WMH severity, which 
resulted in a relative overrepresentation of moderate and severe WMH. The regional 
distribution of lacunes seemed to shift over time as new lacunes occurred mostly in 
the subcortical white matter - especially in the frontal lobes - while at baseline lacunes 
were equally prevalent in the basal ganglia. It is tempting to speculate that basal 
ganglia lacunes could have a different pathogenesis than lacunes in the subcortical 
white matter. Histopathology studies have proposed several pathogenetic 
mechanisms for lacunes, including thromboembolism, arteriolosclerosis, blood brain 
barrier leakage, Wallerian degeneration or collapse of sublethally damaged tissue.6,27
Differences in lacune morphology may also point to the direction of distinct 
pathogenetic mechanisms.28
We found a relation of diabetes, high blood glucose and stroke with WMH 
progression. Earlier studies have suggested various risk factors, including diastolic 
blood pressure, diabetes, smoking, female sex, infarct at baseline and ICAM level as 
risk factors for WMH progression.15,16,25,26,29 In our study, hypertension was not a risk 
factor for WMH progression. We have found diabetes as a risk factor, which is 
consistent with one previous study.25 In the multivariate model, high triglyceride 
unexpectedly appeared to protect against WMH progression. Earlier studies also 
described that vascular risk factors, such as hypercholesterolaemia, hyperlipidemia 
and low BMI, seemed to protect against WMH progression.16, 17 In addition, some risk 
factors found after 3 year follow-up, were lost at longer follow-up periods.13 For the 
appearance of new lacunes, we identified male sex, hypertension, high systolic blood 
pressure, stroke, high BMI, low HDL and high triglyceride levels as risk factors. Again, 
unexpected associations appeared in the multivariate analyses, with high diastolic 
blood pressure and high LDL protecting for new lacunes.  
Chapter 3.2 
88
Strengths of the current study are the large group of subjects and the representation 
of a broad range of WMH, supplying us with the statistical power to find subtle 
associations. While stratification by WMH may hamper the generalizability of the 
results to the general population, the reasons for referral were those commonly 
leading to the discovery of WMH in elderly persons, so the LADIS sample likely 
reflects the patient population with WMH encountered in the everyday clinical 
practice. The high attrition rate could be a limitation of our study because it could have 
led to a survival bias. Although patients without follow-up MRI had less favourable 
values for some baseline risk factors than our study population, the baseline MRI 
variables were comparable. Furthermore, the multi-center design of the study could 
have led to heterogeneity in the study sample. We have therefore corrected our 
analyses for the effect of center. Another potential limitation is the use of visual rating 
scales. Although a fully automated method was preferred over a crude visual method 
in a single center study,30 it has never been used in studies with multiple scanners. 
Automated assessment of WMH progression was difficult to implement in our study, 
and would have led to the exclusion of far more scans. Visual rating scales have 
proven to be reliable for WMH assessment.31 We therefore feel that the Rotterdam 
progression scale was the method of choice in this study. This scale, designed for 
side-by-side assessment of WMH progression, was found to be reliable and 
correlated well with a volumetric method.24 The non-linear results, however, are less 
easily interpretable than absolute volume changes and the side-by-side rating may 
have resulted in an overestimation of WMH progression. We expect that 
computerized methods will be available for future multi-center studies. Furthermore, 
automated methods would provide an objective measure for new lacunes. Although 
the count of new lacunes was reliable, regional differences in reproducibility may exist 
as it is conceivable that new lacunes are harder to reproduce in areas with a higher 
density of lesions. 
In this study, we have investigated the natural course over time of WMH and lacunes, 
two MRI representatives of SVD, and established risk factors for their progression. 
Future studies should be aimed to include other expressions of small vessel disease, 
such as changes in the normal appearing white matter or microbleeds. 
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Abstract
Background: We investigated regional differences in MRI characteristics and risk 
factor profiles of incident lacunes over a three-year period. 
Methods: Baseline and 3-year follow-up MRI were collected within the LADIS study (n 
= 358). Incident lacunes were characterized with respect to brain region, their 
appearance within pre-existent white matter hyperintensities (WMH), surrounding 
WMH size and risk factors. 
Results: 106 incident lacunes were observed in 62 patients (58 subcortical white 
matter (WM), 35 basal ganglia and 13 infratentorial). Incident subcortical WM lacunes 
occurred more often within pre-existing WMH (p = 0.01) and were mostly 
accompanied by new and expanded WMH (p < 0.001), compared to incident basal 
ganglia and infratentorial lacunes. Risk factors for incident subcortical WM lacunes 
were history of hypertension and stroke, whereas atrial fibrillation predicted incident 
basal ganglia/ infratentorial lacunes.  
Conclusion: Differences in relation to WMH and risk factor profiles, may suggest that 
incident lacunes in the subcortical WM have a different pathogenesis than those in the 
basal ganglia and infratentorial region.  
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Background
Lacunes are often defined as subcortical ischaemic infarcts, resulting from an 
occlusion of a small perforating artery and are regarded as an expression of cerebral 
small vessel disease on MRI.1,2 They may cause typical lacunar syndromes but may 
also be clinically ‘silent’.2 Furthermore, they have been associated with subtle 
cognitive dysfunction and a higher risk of future stroke.3 White matter hyperintensities 
(WMH) are another MRI expression of small vessel disease and develop due to 
several mechanisms including incomplete infarction as a consequence of diffuse 
hypoxia.4,5 The pathogenesis of lacunes has not been fully elucidated and it has been 
proposed that distinct lacunar entities exist.6-8 In this longitudinal study, we compared 
incident MRI-defined lacunes between brain regions, with respect to their relationship 
with WMH and risk factor profile.  
Methods
Patients
Data were collected within the multi-center Leukoaraiosis and Disability (LADIS) study 
in which 639 independently living elderly subjects, who were stratified for WMH 
severity, were followed for three years.9 Vascular risk factors were assessed at 
baseline.9 Baseline and three-year follow-up MRI were available for 396 subjects. For 
this study concerning detailed characterization of incident lacunes, 358 subjects were 
available as subjects with 0.5Tesla MRI scans (n = 37) and movement artefacts (n = 
1) were excluded.  
MRI assessment 
Incident lacunes were defined on MRI as newly emerged cavities of Ø 3 – 10 mm with 
signal intensities similar to cerebrospinal fluid in all performed scan sequences (1.5 T: 
T1-weighted 3D-magnetization prepared rapid-acquisition gradient-echo, T2-weighted 
FSE and fluid-attenuated inversion recovery images).10 Incident lacunes were 
characterized with respect to brain region (subcortical white matter (WM), basal 
ganglia or infratentorial region), the emergence within pre-existing WMH at baseline, 
suggesting the development of a cavity within the WMH (yes/ no) and the (change in) 
WMH size surrounding the incident lacune. 
Statistical analyses 
Differences between groups and brain regions were tested using t-tests and Ȥ2-tests. 
Specific risk factors (age, presence of hypertension, diabetes mellitus, stroke and 
smoking [packyears]) of incident lacunes in the different brain regions were assessed 
using logistic regression analyses with presence of incident subcortical WM lacunes 
and presence of incident basal ganglia/infratentorial lacunes as the dependent 
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variables (each compared with subjects without new lacunes in that particular brain 
region, corrected for age, gender and center).  
Results
There were 62 subjects with 106 new lacunes (range 1 – 8). Subjects with new 
lacunes had more severe WMH and lacunes at baseline than subjects without new 
lacunes (severe WMH = 29 [47%] vs 54 [18%]; presence of baseline lacunes = 44 
[72%] vs 123 [41%] for subjects with and without new lacunes [n = 296]). Groups 
were comparable with respect to age, gender and education.  
There were 58 (55%) new lacunes in the subcortical white matter, 35 (33%) in the 
basal ganglia and 13 (12%) in the infratentorial region (Table 1). 47% of the new 
lacunes in the subcortical WM appeared in pre-existing WMH that were visible on the 
baseline scan (Figure 1), compared to only 17% in the basal ganglia and 23% in the 
infratentorial region (p = 0.01).  
Table 1. Characteristics of incident lacunes. 
Values are numbers (%). WM(H) = white matter (hyperintensities) 
When new lacunes appeared outside pre-existing WMH, those located in the 
subcortical WM were often surrounded by development of new significant WMH 
(71%), while most of the incident basal ganglia (86%) and infratentorial lacunes (90%) 
only had a hyperintense rim or no surrounding (new) WMH at all (p < 0.001, Figure 2). 
When new lacunes emerged within pre-existing WMH, the surrounding WMH of 23 
(64%) new lacunes increased in size,  while in ten new lacunes  (28%)  there  was  no 
difference and in three cases (8%) the surrounding WMH decreased in size (no 
regional difference). 
Subcortical 
WM
Basal 
ganglia 
Infraten-
torial
p-value  
(Ȥ2-tests)  
Total 
 58 (55%)  35 (33%)  13 (12%)   106 
Appearance in pre-existent WMH 27 (47%) 6 (17%)  3 (23%) 0.01 36 (34%)  
Surrounding WMH size      
        Outside pre-existent WMH      
                       Significant WMH 22 (71%)  4 (14%) 1 (10%) < 0.001 27 (39%) 
                       No or rim of WMH 9 (29%)  25 (86%) 9 (90%)  43 (61%) 
        In pre-existent WMH      
                       Increase 19 (71%) 3 (50%) 1 (33%) Not significant 23 (64%) 
                       No difference 6 (22%) 2 (33%) 2 (67%)  10 (28%) 
                       Decrease 2 (7%) 1 (17%) 0 (0%)  3 (8%) 
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Figure 1 
FLAIR(A/B) and MPRAGE images(C/D) of a patient with an incident subcortical white matter lacune 
appearing within pre-existent white matter hyperintensities (arrows).  
Risk factors for incident subcortical WM lacunes were history of hypertension and 
stroke (OR [95%-CI] = 5.8 [1.7 – 19.8], p < 0.01 and 4.5 [2.1 – 9.9], p < 0.001), 
whereas age, diabetes, atrial fibrillation and smoking were not predictive (OR [95%-
CI] = 1.0 [0.9 - 1.0]; 1.8 [0.7 – 4.3]; 0.4 [0.0 – 3.2] and 1.0 [1.0 - 1.0]). Atrial fibrillation 
was the only risk factor for incident basal ganglia/ infratentorial lacunes (OR [95%-CI] 
= 3.4 [1.1 – 10.7], p < 0.05), whereas age, history of hypertension, diabetes, stroke 
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and smoking were not significant (OR [95%-CI] = 1.0 [0.9 - 1.1]; 1.5 [0.6 – 3.5]; 1.5 
[0.6 – 3.8]; 1.9 [0.9 –4.1] and 1.0 [1.0 - 1.0]).
Figure 2 
An incident subcortical white matter lacune is surrounded by significant white matter hyperintensities (A1 = 
baseline, A2 = follow-up). An incident infratentorial lacune that is not surrounded by white matter 
hyperintensities is shown in B1 (baseline) and B2 (follow-up). 
Discussion 
WMH develop due to stenosis of multiple vessels and vary from subtle diffuse 
ischemia/hypoxia to incomplete infarction.4 At the other end of the spectrum of small 
vessel disease, lacunes are caused by occlusion of a single deep thalamoperforant, 
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lenticulostriate or pontine paramedian arteriole.1,5 However, a subtype of lacunes has 
been described that is not cavitated yet and may represent an intermediate stage 
between WMH and a fully cavitated lacune.11 We found that incident subcortical WM 
lacunes often developed within pre-existent WMH and were surrounded by significant 
new WMH. In the light of previous studies, we postulate that subcortical WM lacunes 
often develop slowly in an area with already compromised perfusion, i.e. pre-existent 
WMH, due to increasing hypoxia/ischaemia, leading to frank infarction. As the 
subcortical WM is a watershed area, it is more vulnerable to ischemia.5 On the other 
hand, our finding that new lacunes in the basal ganglia and infratentorial region often 
appeared with only few surrounding WMH and in locations that appeared normal at 
baseline, suggests a more acute development. The direct origin from large arteries 
might make these arterioles more prone to acute occlusion. The hypothesis that 
distinct lacunar entities exist with differences in etiology and prognosis has also been 
proposed by clinical studies.7, 8 Alternatively, tissue characteristics may influence the 
survival as the neurons in the deep gray matter may react differently to ischemia than 
glial cells in the subcortical WM. The difference in risk factor profile support our MRI 
findings and suggest that incident lacunes in the subcortical WM may have a different 
pathogenesis than lacunes in the basal ganglia and infratentorial region.  
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Abstract
Background: White matter hyperintensities (WMH), lacunes and microbleeds are 
regarded as typical MRI expressions of cerebral small vessel disease (SVD) and they 
are highly prevalent in the elderly. Clinical associations of SVD are modest and 
inconsistent. By reviewing studies that directly correlated postmortem MRI and 
histopathology, we aimed to elucidate the pathological substrates and underlying 
mechanisms of SVD. 
Summary of review: Postmortem MRI studies have shown that pathological 
heterogeneity exists in WMH. Damage to the fibre network ranges from slight 
loosening to varying degrees of myelin and axonal loss. Glial cell responses include 
astrogliosis, clasmatodendrosis, loss of oligodendrocytes and distinct microglial 
responses. Moreover, lipohyalinosis, arteriosclerosis, vessel wall leakage and venous 
collagenosis are recognized microvascular changes. Suggested pathogenetic 
mechanisms are ischemia/hypoxia, hypoperfusion owing to altered cerebrovascular 
autoregulation, blood-brain barrier leakage, inflammation, degeneration and amyloid 
angiopathy. Few postmortem MRI studies have focused on lacunes and microbleeds. 
Multiple mechanisms are postulated, but many questions concerning their etiology 
remain to be answered. Recently, it has been suggested that SVD features, ‘invisible’ 
on T2-weighted MRI (cortical microinfarcts and changes in the normal appearing 
white matter), also contribute to clinical symptoms. 
Conclusion: Pathological substrates of WMH are heterogeneous in nature and 
severity, which may explain the weak clinical-radiological associations found in SVD. 
The etiology of lacunes and microbleeds, visible on MRI, should be further unraveled. 
Future studies should target the full spectrum of SVD features, and consider 
quantitative MRI techniques, which may be both more sensitive and specific with 
regard to the underlying pathology. 
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Background
Clinical expressions of small vessel disease
On brain MRI of elderly subjects, various expressions of small vessel disease (SVD) 
can often be identified. White matter hyperintensities (WMH), lacunes and 
microbleeds, are regarded as MRI expressions of SVD. In non-demented subjects 
with SVD, the occurrence of clinical symptoms is variable. WMH have been found to 
be modestly strongly associated with subtle cognitive dysfunction (i.e. mental speed 
and executive functions), gait disturbances, depression and urinary incontinence.1-6
Lacunes may cause typical ‘lacunar syndromes’, subtle cognitive dysfunction and are 
a risk factor for future stroke.1,7 Microbleeds are prevalent in the general and hospital 
population, but their clinical role has not yet been fully elucidated. A detrimental effect 
on cognition was found, mainly within the domain of executive functioning.8,9
MRI  expressions of SVD are even more prevalent in patients with Alzheimer’s 
disease (AD).10 In addition to the neuropathological characteristics of AD, i.e. amyloid 
plaques and neurofibrillary tangles in the gray matter, expressions of cerebrovascular 
pathology are also more frequently observed in AD compared to the general elderly 
population.11,12 The impact of cerebrovascular pathology on cognitive decline in AD 
patients remains to be established. For WMH, some studies have suggested a 
synergistic effect on cognitive decline in AD patients,13,14 whereas others did not find a 
role for WMH in AD.15
SVD in the elderly may be of substantial influence on clinical disability and is also 
potentially treatable. Therefore, an increased insight in underlying pathological 
mechanisms of SVD may have important clinical implications.  
MRI appearance in vivo
WMH are commonly defined on T2-weighted MRI scans (including FLAIR). These 
areas can be distinguished as periventricular WMH, as caps and bands, or as WMH 
in the deep white matter. The extent of deep WMH is generally rated as punctate, 
early confluent and confluent.16 Lacunes are identified on MRI as small cavities with a 
diameter of 3mm to 10-15mm, and signal intensities comparable to cerebrospinal fluid 
(CSF). They are located in the white matter (WM) or subcortical gray matter and often 
have a surrounding hyperintense halo. WMH and lacunes are regarded to have an 
ischemic origin, but actually several pathogenetic mechanisms may exist.17-19
Microbleeds are small, round, hypointense foci on gradient-echo T2*-weighted MRI, 
mostly located in the basal ganglia or cortical-subcortical area.20 Recently, it has been 
suggested that certain expressions of SVD, such as cortical microinfarcts and tissue 
changes in the normal appearing white matter (NAWM), not readily detectable on 
conventional MRI, play an important clinical role. A comprehensive overview of SVD 
expressions on MRI is given in Figure 1. 
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Figure 1 
A schematic representation of small vessel disease (SVD) expressions is shown including illustrative 
postmortem MRI and histological sections. SVD expressions that are visible on MRI are illustrated as: a 
pre-frontal coronal FLAIR image and a matching Bodian Silver stained section of white matter 
hyperintensities (WMH); a parietal coronal FLAIR image and a Klüver-Barrera stained section of two 
lacunes (two arrows in the magnification); and a cerebellar axial T2*-image and Haematoxylin Eosin-
stained section of a microbleed (reproduced with permission from Fazekas AJNR 199986). SVD expressions 
that are not readily detected by conventional MRI include: cortical microinfarcts, illustrated by 
microglial/macrophage activation on a HLA-DR stained section; and changes in the normal appearing white 
matter, e.g. astrogliosis (GFAP stained section). Future studies should be directed to assess the whole 
spectrum of SVD, because all expressions may contribute to clinical symptoms in the elderly subject. 
The problem with clinical MRI studies 
Clinical MRI studies have only found inconsistent and modest associations between 
expressions of SVD on MRI and clinical symptoms in demented and non-demented 
elderly. A possible explanation for this problem may be heterogeneity of the 
neuropathological substrates underlying SVD. T2-weighted MRI dichotomizes the  
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white matter as ‘hyperintense’ (WMH) or ‘normal’ (NAWM), whereas the hyperintense 
areas may reflect tissue changes that vary in type and severity. Moreover,  
conventional MRI is not sensitive to changes in the NAWM. It further shows the 
presence of lacunes and microbleeds (size, location and number), but lacks specificity 
for pathological changes. Additionally, pathological changes underlying MRI 
expressions of SVD may differ between patient groups. A small proportion of patients 
suffer from genetic disorders, such as cerebral autosomal dominant arteriopathy with 
subcortical infarcts and leukoencephalopathy (CADASIL) or hereditary cerebral 
amyloid angiopathy (CAA). As these diseases have a distinct etiology, we will only 
focus on SVD observed in typical aging and AD 
To better understand the pathogenetic mechanisms involved in SVD,21,22 postmortem 
MRI scanning and the direct correlation with pathology may be a valuable tool, as it 
bridges the gap between MRI findings and clinical studies. As it has been shown for 
other neurological diseases, such as multiple sclerosis,21,23 postmortem MRI-
histopathology correlation studies may help to solve the weak clinical-radiological 
associations of SVD.  
Aim of the current review
We aimed to highlight the pathological substrates and pathogenesis of WMH and 
other features of SVD, by comprehensively reviewing studies that have directly 
compared postmortem MRI and histopathology by virtue of postmortem scanning. We 
further aimed to define where gaps in knowledge still exist and we provide the 
readership with suggestions for further studies, hopefully leading to the development 
of successful interventions of SVD in demented and non-demented elderly. 
Method (search strategy)
We have systematically searched PubMed for scientific reports correlating 
postmortem MRI and histopathological assessment of WMH, lacunes and 
microbleeds until December 2008. The following search terms were used: 
postmortem, MRI, magnetic resonance, white matter (hyperintensities/lesion[s]), 
lacune, lacunar infarct(ion), microbleed(s). Articles were also identified through 
searches of the authors' own files and by searches of the reference lists. 
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Box: Sensitivity and specificity of postmortem MRI 
Before pathological substrates of SVD by postmortem MRI studies are described, it is 
important to address the reliability of postmortem MRI scanning. All studies that were 
identified by the abovementioned search criteria made use of formalin-fixed brain 
specimens. Fixation duration and time to autopsy may influence the reliability of 
postmortem MRI measurements. It has been shown that tissue fixation decreases 
both T1- and T2-relaxation times in gray and white matter.24,25
Postmortem MRI studies confirmed in vivo studies, stating that WMH are highly 
prevalent (94%) in unselected elderly populations.26 Early descriptive studies claimed 
that postmortem MRI of 0.25T to 1.5T provide images of a quality that is comparable 
to that obtained during life.22,27,28 However, the sensitivity of postmortem MRI 
appeared to be dependent on the size of WMH. Smaller punctate WMH, thought to 
have little clinical impact, could be less readily identified on postmortem MRI.29-31 A 
sensitivity of 95% (87-99%) and specificity of 71% (44-90%) were found for PVL on 
postmortem MRI compared to myelin pallor on Luxol Fast Blue-stained sections. For 
DWMH, the sensitivity was 86% (79-93%) and specificity was 80% (72-88%).30,32
Overall, postmortem MRI may be considered a valuable technique for translating 
pathological findings to the clinical setting. 
White matter hyperintensities (WMH)
Studies that correlated postmortem MRI to histopathology of WMH are summarized in 
Table 1. The first studies were small and descriptive. Subsequent studies specified 
WMH by distinguishing periventricular versus deep WMH and the extent of DWMH. 
Recently, pathogenetic mechanisms of WMH have been investigated using detailed 
molecular characterization.  
Descriptive MRI and histology studies
Using MRI-pathological correlations, a spectrum of histopathological alterations in 
WMH has been described. WMH could be associated with dilated perivascular spaces 
and vascular ectasias, in combination with mild myelin pallor and arteriosclerosis. A 
proportion of WMH reflected more severe pathological changes with additional axonal 
degeneration and gliosis in the subependymal layer.27
Heterogeneous pathological correlations of WMH were reported in several patient 
groups, including patients with AD, cortical infarctions and Binswanger’s 
disease.22,28,33 WMH was demonstrated to reflect partial loss of myelin, axons and 
oligodendroglial cells, astrogliosis, dilatation of perivascular spaces, activated 
macrophages and fibrohyalinotic vessel changes. This range of tissue changes was  
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AD = Alzheimer’s disease, neur (-) controls = non-demented subjects without neurological disease, neur (+) 
controls = non demented patients with neurological disease. FTD = frontotemporal dementia, VaD = 
vascular dementia. HE = Haematoxylin-Eosin, LFB = Luxol Fast Blue, LFB-PAS = Luxol Fast Blue/ periodic 
acid-Schiff, KB = Klüver-Barrera, EvG = Elastic van Gieson, MBP = myelin basic protein, GFAP = glial 
fibrilary acidic protein, HIF = hypoxia inducible factor, IgG = immunoglobulin, PTAH = Phosphotungstic Acid 
Hematoxylin, MMP7 = matrix metalloproteinase 7, ICAM1 = intercellular adhesion molecule, Ngb = 
neuroglobin, NMBR = neuromedin B receptor, VEGFR2 = vascular endothelial growth factor receptor 2, 
Mcm2, PCNA and Ki67 = cell proliferation-related molecules, B7-2, CD40 and CD40-Ligand = immune 
costimulatory molecules, PDGFaR = platelet-derived growth factor a receptor, OPC = oligodendrocyte 
precursor cells, MAP-2 +13 = microtubule-associated protein-2 expressing exon 13, CD31 = vascular 
integrity, hGLUT-5 = human glucose transporter-5, APP = amyloid precursor protein, HLA-DR = human 
leukocyte antigen-DR, P-gp = P-glycoprotein, (D)WMH = (deep) white matter hyperintensities, PVL = 
periventricular white matter hyperintensities, DTI = diffusion tensor imaging, (Q)MRI = (quantitative) 
magnetic resonance imaging, CAA = cerebral amyloid angiopathy, PA = pathology 
suggested to be consistent with incomplete infarcts. Also complete deep white matter 
infarcts were found in WMH with arteriolosclerotic vessel changes.22,33 True infarcts 
were surrounded by swollen reactive astrocytes that stained positively for serum 
proteins, probably due to blood brain barrier leakage.34
Distinct types of WMH
In clinical studies using in vivo MRI, an attempt to improve specificity for WMH was 
made by distinguishing between periventricular WMH (thin line, smooth halo or 
irregular bands/ caps) and WMH in the deep WM (punctate, early confluent and 
confluent WMH).16 Postmortem MRI and histopathology correlation studies have 
described that each type of WMH reflect distinct pathological changes.29,35-38
Mild periventricular WMH presented with discontinuity of the ependyma, mild-
moderate gliosis in the subependymal layer, loosening of the fibre network and myelin 
loss around tortuous venules and dilated perivascular spaces. No arteriolosclerotic 
vessel changes were found.29,39 Irregular PVL corresponded to more severe, partly 
confluent, areas with varying fibre and myelin loss and reactive gliosis. Some 
complete infarcts were seen, in combination with fibrohyalinotic and arteriosclerotic 
vessels.  
Punctate, early confluent and confluent WMH in the deep WM were associated with 
increasing severity of tissue changes. In punctate DWMH, tissue changes were mild 
and confined to the area around dilated perivascular spaces with myelin loss and 
atrophic neuropil around fibrohyalinotic arterioles. In early confluent DWMH, 
perivascular rarefaction of myelin was accompanied by varying degrees of axonal loss 
and astrogliosis. In confluent DWMH, diffuse areas of incomplete parenchymal 
destruction were seen with loss of myelin, axons and oligodendrocytes, astrogliosis, 
spongiosis and focal transitions to complete infarcts.29,32,35-37,40 Examples of 
pathological sections of periventricular and deep WMH, defined on postmortem MRI, 
are given in Figure 2. 
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Figure 2 
Prefrontal coronal FLAIR image (A) of an 88-year-old female Alzheimer’s disease patient. Regions of 
interest represent white matter hyperintensities (WMH) in the periventricular area (green; B1 to E1); WMH 
in the deep white matter (yellow; B2 to E2); and an area of normal appearing white matter (white, B3 to E3). 
Bodian Silver stained sections (B, original magnification 200x) showed lower axonal density in WMH (B1 
and B2) than in NAWM (B3); more microglial activation (C) was observed in WMH (C1 and C2) than in 
NAWM (C3) on HLA-DR immunohistochemical sections (original magnification 200x); WMH also showed 
more myelin loss (D1 and D2) compared to NAWM (D3) in Luxol-Fast-Blue/Cresyl-Violet stained sections 
(original magnification 100x); the severity of astrogliosis (E) (GFAP-immunostained sections, original 
magnification 400x) was not clearly different between WMH and NAWM in this patient. Adapted with 
permission from Gouw, Brain 2008 52.
These studies provide clues that smooth periventricular WMH and punctate WMH are 
mild forms of WMH and may therefore not be clinically relevant/ detectable.40 Irregular 
periventricular WMH and confluent DWMH, however, correspond to more severe 
tissue changes, probably of ischemic origin and are therefore more likely to produce 
clinical symptoms.34-36,40 Of note is the dependence on subject selection: in the 
relatively healthy NUN-study cohort, evidence of ischemia was not found in extensive 
DWMH.39 Alternative pathogenetic mechanisms of DWMH include blood-brain barrier 
leakage with associated edema, altered cerebral blood flow autoregulation, axonal 
depletion from Wallerian degeneration or toxic effects of amyloid on vascular 
permeability in AD patients.41
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Pathogenetic mechanisms of WMH
Recently, several studies further delved into possible pathogenetic mechanisms of 
WMH by quantitative assessment of immunohistochemical stainings. These studies 
include important work on the MRC CFAS cohort, that prospectively collects 
unselected brain specimens from a large community-based cohort. 
First, the role of hypoxia in the pathogenesis of WMH was investigated using specific 
markers for vascular morphology and tissue hypoxia.42 Thicker vessel walls and larger 
perivascular spaces were found in WMH. In DWMH specifically, capillary endothelial 
cells were activated and an increased expression of several hypoxia markers was 
observed. Other studies on characterization of afferent vessels showed arteriolar 
tortuosity and decreased vessel densities in WMH.43,44 These findings supported an 
ischemic pathogenesis of WMH, especially in DWMH.  
Second, blood-brain barrier dysfunction was demonstrated in a certain proportion of 
WMH.34,45 This was shown by the presence of swollen, eosinophilic, GFAP-positive 
astrocytes in both DWMH and PVL.46 These clasmatodendritic astrocytes stained 
positively for serum fibrinogen implying leakage of the blood-brain barrier.47
Furthermore, vascular integrity (CD31) and P-glycoprotein, an important constituent of 
the blood-brain barrier, were decreased in WMH.48 Venous collagenosis resulting in 
venous insufficiency and consequently ischemic stress may cause blood-brain barrier 
dysfunction.44,46
Third, the role of microglial cells in the pathogenesis of WMH was investigated.49
Microglial cells in the PVL show a greater tendency to immune activation than DWMH, 
shown by the expression of MHC class II. DWMH contained microglial cells with an 
amoeboid morphology, which are less immune activated but likely involved in the 
phagocytosis of myelin breakdown products.  
These findings have pointed out that WMH are related to various underlying 
pathological profiles and biological responses and are summarized in Figure 3.18 The 
cohort, however, consists of a heterogeneous community-based group of subjects, 
including healthy elderly, AD patients and subjects with neurological disorders. In light 
of this variability, the pathogenesis of WMH may differ in distinct patient groups.45
Heterogeneity of WMH between patient groups
Few studies have investigated whether pathological substrates of WMH differ 
between patient groups. In line with MRI studies, multiple vascular pathologies were 
more common in brain specimens of demented than of non-demented individuals.10-
12,50 These studies emphasize the importance of mixed pathologies in the 
development of clinical dementia.  
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Figure 3 
Schematic overview of the heterogeneous pathogenetic mechanisms and pathological substrates of white 
matter hyperintensities. Heterogeneity of the pathogenesis/ pathological changes is probably also involved 
in other MRI expressions of small vessel disease, such as lacunes and microbleeds. These gaps in current 
knowledge will hopefully be clarified in future studies. 
Although WMH was found to be more extensive in AD patients than in controls, the 
nature of pathological correlates, including vascular morphological changes and 
ischemic factors, was comparable between these groups.42,50,51 The severity of tissue 
changes, however, differed with more severe loss of myelinated axons, ependyma 
denudation, gliosis and thicker adventitia of the deep white matter arteries in AD 
patients.50,51 A recent study found that increased microglial activation in WMH was 
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specific for AD patients.52 The histopathological nature of WMH was comparable in 
AD and vascular dementia (VaD).53 The globally comparable pathology suggest that 
WMH associated with aging, AD and VaD do not have a distinct pathogenesis, but are 
part of a pathological continuum.42
A specific pathology possibly linking SVD and AD is cerebral amyloid angiopathy 
(CAA).54,55 CAA is characterized by amyloid deposition in the smooth muscle cells of 
cortical, subcortical, and leptomeningeal small arteries and arterioles.37,56 Besides 
causing vessel wall rupture, CAA can induce focal ischemic lesions via amyloid beta 
(Aȕ) mediated luminal narrowing. Patients with CAA can present with intracerebral 
hemorrhage, transient neurologic events or cognitive decline.56 In a cohort of CAA 
patients, WMH severity was associated with the severity of CAA (number of 
intracerebral hemorrhages on MRI).54 A possible explanation for this association is 
that vascular amyloid deposition causes a more global vascular dysfunction, including 
the vasculature in the WM.54 In AD, however, the role of CAA in the development of 
WMH is controversial. Some studies have found weak correlations between WMH 
and CAA in AD,57,58 or only a relationship between CAA and DWMH,42 whereas other 
studies failed to do so.12,33,34,50
Postmortem quantitative MRI: more specific for SVD-related pathology than T2-
weighted MRI?
Heterogeneity in pathological substrates of WMH may explain (part of) the weak 
clinico-radiological associations reported so far. To be able to draw more clinically 
relevant conclusions, additional pathology-specific tools are needed in vivo. Recently, 
quantitative MRI techniques (QMRI) have been suggested to be more specific for 
underlying pathology.30,32,53 Magnetization Transfer Imaging (MTI) and Diffusion 
Tensor Imaging (DTI) have enabled a distinction between WMH and NAWM in 
demented patients and healthy elderly.41,59 Other QMRI techniques that quantify 
tissue characteristics are T1- and T2-relaxation time mapping. Pathological correlates 
of abnormal QMRI parameters in SVD can be unraveled by correlational postmortem 
MRI and histopathology studies, and can subsequently be translated to the in vivo 
situation. When using postmortem QMRI, it needs to be taken into account that both 
time to autopsy and fixation duration have an effect on T1- and T2-relaxation times 
and diffusivity measures.60,61
Although several postmortem studies using QMRI have been performed in patients 
with multiple sclerosis and other neurological diseases,62-64 postmortem QMRI studies 
in (demented) elderly are still scarce. The feasibility of quantifying WMH using 
postmortem DTI was shown in two small studies.65,66 DTI quantifies the diffusivity of 
water molecules with respect to extent and spatial directionality (fractional 
anisotropy).67 DTI measures in WMH corresponded to the degree of myelin loss, but 
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the area of diffusivity changes was more extensive than the hyperintense areas on 
conventional MRI.65,66 Pathological correlates of fractional anisotropy (FA) in DTI and 
T1-relaxation time were established in a recent study of AD patients and controls. 
Axonal loss was the only independent predictor for FA, whereas T1-relaxation time 
was independently predicted by axonal loss, myelin loss and microglial activation.52
These few studies reveal that QMRI techniques are promising to assess tissue 
damage in vivo, because they reflect the severity of heterogeneous pathological 
substrates and reveal tissue changes in areas that appear normal on conventional 
MRI (NAWM).  
Other expressions of SVD
Lacunes
In pathological terms a ‘lacune’ correspond to small (lacunar) infarcts, dilated 
perivascular spaces or old, small hemorrhages.68,69 However, the term ‘lacune’ is 
generally used for a lacunar infarct. They can be detected on MRI as focal CSF filled 
cavities, often surrounded by a hyperintense rim on FLAIR images. Lacunes are 
typically located in the areas supplied by the deep thalamoperforant, lenticulostriate, 
or pontine paramedian arterioles, i.e. basal ganglia, thalamus, internal capsule, pons 
and centrum semiovale.70,71
The few postmortem MRI studies that have focused on lacunes are largely descriptive 
(summarized in Table 2). On histological examination, lacunes correspond to irregular 
cavitations with scattered fat-laden macrophages, that can be accompanied by 
surrounding reactive gliosis and myelin and axonal loss.28,69,72,73 With increasing age 
of the lacune, macrophages diminish and the gliosis becomes fibrillary.73 A subtype of 
lacunes has been described that is not cavitated yet, but shows selective neuronal 
loss with relative preservation of glial elements.74
Several postmortem MRI studies have compared lacunes with dilated perivascular 
spaces (also called ‘Virchow-Robin spaces’) as their similar signal intensity on MRI 
hindered their distinction.27,35,37 Clinically, however, it is important to make the 
distinction, as perivascular spaces are considered to be asymptomatic. Postmortem 
MRI correlation studies found that lacunes are commonly larger (> 3 mm) than dilated 
perivascular spaces and can be accompanied by perifocal signal changes.75,76 Focal 
cavities in the anterior perforated substance and the lower part of the basal ganglia / 
putamen have been found to be perivascular spaces rather than lacunes.77-79
The most frequently reported cause of lacunes is acute arteriolar occlusion by 
arteriosclerosis/thrombosis, but the existence of non-cavitated lacunes and the 
relationship with WMH, suggest that there may be other pathogenetic mechanisms 
with a more gradual development.17,68,74,80 Moreover, clinical MRI studies have
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hypothesized that multiple pathogenetic mechanisms may exist.81-83 Possible 
alternatives include thrombo-embolism, general and ongoing hypoxia or tissue 
damage by extravasated toxic serum proteins due to blood-brain barrier leakage.80,84
Future postmortem MRI studies with pathological correlation are warranted to 
investigate these possible mechanisms. 
Microbleeds
Clinical MRI studies have recognized small foci of signal loss on gradient-echo T2*-
MRI sequences as microbleeds,20,85 i.e. accumulation of hemosiderin after small 
vessel leakage, but scepticism remains about the origin of these MRI lesions. 
Pathological descriptions of gradient-echo MRI hypointensities may solve this 
controversy.  
So far, only few studies have used direct postmortem MRI-pathological correlation to 
investigate these MRI-hypointensities (see Table 3).86-88 On gross pathology, they 
appeared as brown spots and, histologically, they corresponded to focal 
accumulations of hemosiderin-containing macrophages in the perivascular space. 
They were occasionally surrounded by gliosis and incomplete ischemia, indicative of 
old hemorrhages.86,87,89 Various arteriolar changes could be found near the 
hemosiderin deposits, including fibrohyalinotic vessel changes, arteriosclerosis or 
amyloid deposition in the vessel walls.86,90 MRI studies have suggested an ischemic 
pathogenesis for microbleeds,85,90 but microbleeds have also been linked to lobar 
hemorrhages in CAA.87 The number and location of microbleeds may be suggestive 
of underlying pathogenesis, but the relationship has not been consistently found yet.91
Gaining more pathological specificity is important because microbleeds are not only a 
predictor of future lobar intracerebral hemorrhage, but are also independently 
associated with cognitive decline.9,92
MRI-‘invisible’ expressions of SVD
There is accumulating evidence that there are also pathological changes that are 
‘invisible’ to conventional MRI. In addition to the so-called NAWM, SVD may involve 
the cortex and can then be pathologically identified as microinfarcts. 
Cortical microinfarcts are tiny lesions, beyond the resolution of current MRI scanners. 
They are attributed to ischemia, consisting of complete or incomplete cavitation with 
myelin pallor and neuronal loss, surrounded by glial cells and/or macrophages.93
Cystic microinfarcts tend to be larger (up to 5 mm) than non-cystic microinfarcts (0.05 
- 0.4 mm).93,94 Several population-based prospective autopsy studies have shown that 
cortical microinfarcts are major determinants of dementia.93-95 Microinfarcts also have 
an independent influence on cognitive decline in non-demented elderly individuals 
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with little or moderate AD pathology.96,97 Moreover, microinfarcts are associated with 
CAA in patients with VaD.93
There is accumulating evidence that the areas that appear normal on postmortem 
MRI (NAWM) can also reflect pathological changes. A proportion of NAWM 
corresponded to mild tissue changes with a slightly lower myelin density, activated 
endothelium, a looser but intact axonal network and normal glial density.26,32
Furthermore, it has been shown that the density of small afferent vessels is not only 
decreased in WMH, but extend into the NAWM and cortex.43
These findings suggest that SVD is a widespread disease and has various 
expressions throughout the brain of which only some aspects are visible on 
conventional MRI. As illustrated in Figure 1, MRI-‘invisible’ pathologies, including 
cortical microinfacts and tissue changes in the NAWM, also contribute to the clinical-
radiological association in SVD. This means that MRI-visible lesions constitute only 
part of the puzzle.  
Considerations for future research 
We have reviewed the pathological correlates and pathogenic mechanisms of MRI 
expressions of SVD. The available literature suggests that several explanations exist 
for the weak clinical-pathological associations. Firstly, pathological substrates of SVD 
expressions on MRI, such as WMH, lacunes and microbleeds, are heterogeneous in 
nature and differ in severity. Secondly, conventional T2-weighted MRI (including 
FLAIR), which is most commonly used in radiological practice, is insufficiently 
sensitive to detect all the abnormalities related to SVD and generates insufficiently 
specific information regarding the various tissue changes. Therefore, the full spectrum 
of SVD expressions (both ‘visible’ and ‘non-visible’ on conventional T2-based MRI) 
should be considered in order to reliably explain and predict clinical disability in the 
elderly patient.1,96,97  Novel QMRI techniques are more ‘pathology-specific’ than 
conventional MRI and may therefore be valuable tools for future studies on the clinical 
impact of SVD.
In contrast with WMH, postmortem MRI-pathology correlation studies of lacunes and 
microbleeds have been scarce, and many issues still remain to be elucidated. 
Pathological correlation studies are warranted to investigate the hypothesis proffered 
by clinical MRI studies, stating that lacunes and microbleeds also have multiple 
etiologies and solve the controversy concerning microbleeds. For lacunes, the 
suggested pathogenesis includes acute thromboembolism, continuing moderate 
ischemia with eventual focal tissue loss or inflammation. Basal ganglia and thalamic 
lacunes are associated with cognitive decline, whereas lacunes in the subcortical 
white matter are mostly asymptomatic, implying a role for location of lacunes on 
cognitive dysfunction.19 For microbleeds, MRI characterization of the location and 
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number may give directions towards a pathogenesis of arteriosclerosis or CAA and 
give clues to the underlying disorder (AD or CAA).91 These distinct pathogenesis may 
explain why some of these MRI lesions lead to clinical symptoms, such as 
ischemic/hemorrhagic strokes or cognitive decline, whereas others remain 
asymptomatic.81,82,92
Spectrum of SVD
So far, clinical MRI studies have often focused on separate aspects of SVD and found 
only weak associations with clinical symptoms. However, not only WMH, but also 
lacunes and microbleeds have an effect on clinical symptoms such as cognitive 
decline.1,8 Furthermore, MRI-‘invisible’ lesions, i.e. microinfarcts and tissue changes in 
the NAWM, are clinically relevant, independent of MRI-‘visible’ SVD.96 We suggest 
that future studies assess the full spectrum of SVD expressions on MRI (Figure 1). 
Considering a wider array of disease aspects will more accurately reflect the actual 
extent and character of tissue changes related to SVD, and is therefore expected to 
be a better predictor for the clinical disability in the elderly patient.96,97 It was shown 
that separate SVD expressions predicted 6 – 11% of the relationship with cognitive 
decline, whereas the combination of SVD expressions together explained 22%.98 This 
value is comparable to the relationship between Braak stage and cognitive decline, 
which implies that the combined assessment of SVD is a valid predictor for cognitive 
decline in the elderly. Of course, SVD should still be assessed together with other 
(degenerative) brain changes, e.g. AD pathology, CAA or cortical Lewy bodies, as 
they may modulate each others’ specific contributions to cognitive decline.95,99,100
More specifically, vascular changes may have an interactive effect on the 
degenerative changes involved in AD. This is in line with pathological studies showing 
that the relationships between pathology and MRI findings (hippocampal, cortical 
atrophy and SVD) in aging and dementia are complex.101 Even hippocampal atrophy 
on postmortem MRI, the main MRI characteristic of AD, was not specific for AD 
pathology, but also correlated with other pathological substrates (argyrophilic grain 
disease, hippocampal sclerosis etc).102
Pathology-specific MRI techniques
Novel QMRI techniques, such as DTI, MTI, T1- and T2 relaxation time measurements 
have two advantages over conventional MRI. First, QMRI reflects the severity of 
underlying pathological substrates. Second, it may better reveal clinically relevant 
tissue changes in the WM that appears normal on conventional MRI.65,66 They are 
therefore more sensitive to the full range of SVD expressions. With several QMRI 
abnormalities having been confirmed histopathologically, these techniques are now 
also promising as more pathology-specific tools for future in vivo studies. It should be 
Chapter 4.1 
122
noted that, even though study logistics will be more complex, the use of fresh brain 
tissue in exploratory post mortem MRI studies is preferred above the use of fixed 
specimens, as formalin fixation influences tissue characteristics. Unlike tissue 
changes in the NAWM, QMRI techniques have not been investigated to visualize 
cortical microinfarcts. The future use of high resolution MRI, using 7 Tesla MRI 
scanners, may achieve in vivo assessment of these lesions, which are probably 
beyond the resolution of 1.5 or 3 Tesla MRI. 
Conclusion
Postmortem MRI studies have convincingly shown that SVD is pathologically greatly 
heterogeneous. Several different aspects of SVD were addressed, among which 
abnormalities that are either ‘visible’ or ‘invisible’ on conventional MRI. In order to 
better explain and predict the clinical impact of SVD in elderly subjects, future studies 
should take into account all aspects of SVD and brain aging instead of focusing on 
separate expressions of SVD only. The use of more pathology-specific, quantitative 
MRI techniques is essential in achieving this goal.  
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Abstract
Background: White matter hyperintensities (WMH) are frequently seen on T2-
weighted magnetic resonance imaging (MRI) scans of elderly subjects with and 
without Alzheimer’s disease (AD). WMH are only weakly and inconsistently 
associated with cognitive decline, which may be explained by heterogeneity of the 
underlying neuropathological substrates. The use of quantitative MRI could increase 
specificity for these neuropathological changes. We assessed whether postmortem 
quantitative MRI is able to reflect differences in neuropathological correlates of WMH 
in tissue samples obtained postmortem from AD patients and from non-demented 
elderly.
Methods: Thirty-three formalin-fixed, coronal brain slices from 11 AD patients (mean 
age: 83 ± 10 yrs, 8 females) and 15 slices from 7 non-demented controls (mean age: 
78 ± 10 yrs, 4 females) with WMH were scanned at 1.5T using qualitative (FLAIR) and 
quantitative MRI (diffusion tensor imaging [DTI] including estimation of apparent 
diffusion coefficient [ADC] and fractional anisotropy [FA], and T1 relaxation time 
mapping based on flip-angle array). A total of 104 regions of interest were defined on 
FLAIR images in WMH and normal appearing white matter (NAWM). 
Neuropathological examination included (semi-)quantitative assessment of axonal 
density (Bodian), myelin density (LFB), astrogliosis (GFAP), and microglial activation 
(HLA-DR). Patient groups (AD versus controls) and tissue types (WMH versus 
NAWM) were compared with respect to QMRI and neuropathological measures.  
Results: Overall, AD patients had significantly lower FA (p < 0.01) and higher T1 
values than controls (p = 0.04). WMH showed lower FA (p < 0.01) and higher T1 
values (p < 0.001) than NAWM in both patient groups. A significant interaction 
between patient group and tissue type was found for the T1 measurements, indicating 
that the difference in T1 relaxation time between NAWM and WMH was larger in AD 
patients than in non-demented controls. All neuropathological measures showed 
differences between WMH and NAWM, although the difference in microglial activation 
was specific for AD. Multivariate regression models revealed that in AD, axonal 
density was an independent determinant of FA, whereas T1 was independently 
determined by axonal and myelin density and microglial activation.  
Conclusion: Quantitative MRI techniques reveal differences in WMH between AD and 
non-demented elderly, and are able to reflect the severity of the neuropathological 
changes involved.  
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Introduction
White matter hyperintensities (WMH) form an important expression of small vessel 
disease on MRI and are observed in a significant proportion of demented and non-
demented elderly subjects.1 WMH have been distinguished by location into 
periventricular WMH, which are directly adjacent to the lateral ventricles, and deep 
WMH, which are located in the subcortical white matter (WM). Furthermore, the 
severity of deep WMH is generally scored into punctate, early confluent and confluent 
WMH.2 In healthy elderly, WMH are mostly regarded as a normal aging phenomenon, 
but especially confluent WMH have been associated with loss of specific cognitive 
functions, such as psychomotor speed.3 However, the associations are only weak and 
inconsistently found across MRI studies.4-6
MRI studies have shown that WMH are prevalent in patients with Alzheimer’s disease 
(AD).7,8 Although AD is considered to be a mainly cortical dementia with senile 
plaques and neurofibrillary tangles in the gray matter of the brain,9 cerebrovascular 
pathology often co-exists in brains of AD patients.10,11 The clinical significance of 
WMH in AD patients is insufficiently known. Some authors reported that WMH have 
an additive effect on cognitive decline in dementia, whereas others could not confirm 
this association.12-14
A possible explanation for the inconsistent and weak associations between WMH and 
clinical symptoms in demented and non-demented elderly would be heterogeneity of 
the neuropathological substrates underlying WMH.7 Although with the 
abovementioned classification system an attempt was made to specify WMH on T2-
weighted images, these MRI sequences are generally not sufficiently specific for the 
demonstration of underlying pathological changes in the composition of the brain. It is 
well conceivable that the high signal intensity on T2-based images (e.g. FLAIR) 
actually reflects a spectrum of neuropathological substrates or tissue damage with 
varying severity. Whether this is the case for AD patients and non-demented subjects 
with WMH, can be investigated by postmortem MRI scanning and direct matching of 
the MRI hyperintensities to pathological stainings.15 Previous postmortem MRI – 
pathology correlation studies in AD or in non-demented elderly showed that the 
pathological correlates of WMH include myelin and axonal loss, astrogliosis, reduction 
of oligodendrocytes, mild microglial activation and dilated perivascular spaces to 
variable degrees providing support for the notion of heterogeneity in WMH 
pathology.16-18 Recent studies provided detailed immunohistochemical 
characterization of different expressions of WMH including associations with specific 
hypoxia markers, altered fluid dynamics or discontinuity of the ependymal lining.19-21
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From a clinical standpoint, investigations with sufficient pathological specificity are 
needed in vivo to be able to assess the clinical impact of WMH. In vivo studies using 
more advanced quantitative MRI techniques (QMRI), such as diffusion tensor imaging 
(DTI) and T1 relaxation time measurements, claim that these techniques are more 
specific to the presence of structural brain damage than the current gold standard for 
the detection of WMH (conventional T2-weighted MRI).22-24 DTI quantifies the extent 
of diffusivity of water molecules as well as tissue anisotropy, which is the spatial 
restriction of water movements in certain directions.25 Normal WM, for example, is 
highly anisotropic because diffusion is more readily directed along the long axis of 
fiber bundles whereas the perpendicular movement of water molecules is relatively 
restricted.23,26 T1-mapping that determines tissue-specific T1 relaxation times, may 
reflect pathological processes related to intraparenchymal changes in water content 
such as edema, widening of the extracellular space, subtle blood-brain barrier 
leakage or glial proliferation.27 These in vivo QMRI techniques are promising to further 
improve understanding of WMH in aging. However, the neuropathological substrates 
that define changes in QMRI parameters in WMH are still unknown.19,28
In this study, we therefore investigated whether post mortem QMRI reflects 
heterogeneity in basic neuropathological hallmarks of WMH, i.e. whether QMRI shows 
differences between WMH of AD patients and of non-demented controls. Also, we 
aimed to identify which of these neuropathological substrates most strongly 
determines the possible changes in QMRI parameters of white matter. 
Methods
Patients
Eleven consecutive brain specimens of patients older than 70 years with a clinical 
diagnosis of AD were prospectively selected from the Netherlands Brain Bank (NBB). 
Controls were selected from the VU University Medical Center (i.e. hospitalized 
patients at the VU University Medical Center who died during the admission). Controls 
were defined as non-demented subjects according to clinical records. Patients and 
controls were only included when extensive periventricular WMH and/or (beginning) 
confluent areas of deep WMH were present on postmortem MRI.2 Subjects were 
excluded if they had a history of resuscitation and if they had suffered from a 
neurological disease other than AD or small cerebral infarcts outside the selected 
tissue samples, as revealed by clinical, neuroradiological or neuropathological 
evaluation. General pathological assessment was performed according to the 
dementia protocol of the NBB. The clinical diagnosis of AD was pathologically 
confirmed using the Braak criteria and Consortium to Establish a Registry for 
Alzheimer’s Disease (CERAD) criteria,9,29 whereas control subjects had to have a 
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Braak stage scoring for neurofibrillary tangles < 2. All subjects were excluded when 
pathological evidence of other types of dementia was present. After rapid autopsy (all 
within 24h, except for one subject) and at least four weeks of fixation in 10% formalin 
(mean fixation time ± SD: 10 ± 4 weeks) one hemisphere was cut into 10 mm-thick 
coronal brain slices using a 10mm-deep cutting panel to improve precision. Two to 
four slices per subject (were selected for MRI scanning including one pre-frontal slice 
(first slice cranial of frontal horns of the lateral ventricle), one frontal slice (at the level 
of the hippocampus, caudate and lenticular nuclei) and one parietal slice (at the level 
of the cella media). The study was approved by the institutional ethics review board, 
and all patients approved of the use of their brain tissue for research and review of 
their medical history by signing an informed consent prior to their death. Patients’ 
characteristics are listed in Table 1. 
Table 1. Patient characteristics
Case  Age 
(yr)
Gender 
(M/F)
Postmortem 
delay (h:min)
Cause of death Nr slices  
(left/right)
AD  1 93 F 6:45 Cerebral infarction 3 (0 / 3) 
 2 88 F 4:35 Cachexia and dehydration 3 (1 / 2) 
 3 72 M 5:25 Dehydration 2 (0 / 2) 
 4 73 M 6:15 Sudden death 3 (0 / 3) 
 5 77 F 3:05 Dehydration, mamma carcinoma 2 (0 / 2) 
 6 99 F 5:10 Dehydration 3 (0 / 3) 
 7 75 F 15:00 Cardiac arrest 4 (0 / 4) 
 8 86 F 5:55 Cachexia and dehydration 4 (0 / 4) 
 9 70 M 4:50 Pneumonia 2 (0 / 2) 
 10 90 F 5:35 Colon carcinoma, dehydration 3 (0 / 3) 
 11 86 F 5:05 Pneumonia 4 (0 / 4) 
       
Control  1 98 M 10:46  Unknown 2 (0 / 2) 
 2 76 F < 24h Myocardial infarction 2 (2 / 0) 
 3 71 F < 24h Ruptured abdominal aorta 3 (1 / 2) 
 4 83 F 3:20 Euthanasia 1 (1 / 0) 
 5 70 M < 24h Myocardial infarction 3 (0 / 3) 
 6 79 F < 24h Bronchopneumonia 1 (0 / 1) 
 7 71 M < 24h Myocardial infarction 3 (2 / 1) 
AD = Alzheimer’s Disease. 
Postmortem MRI protocol 
Postmortem MRI scanning was performed using a 1.5 Tesla MRI scanner (Vision, 
Siemens AG, Erlangen, Germany). The brain slices were separately placed in a 
purpose-built perspex multi-slice holder that exactly fits into the head-coil of the MRI 
system. The MRI protocol that was optimized for fixed brain slices included: 
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Qualitative MRI sequences:  
1. Dual-echo T2-weighted spin-echo (T2SE) images - TR/ TE/ NEX: 2755 ms/ 45 ms 
and 90 ms/ 2; field of view: 80 x 128 mm; matrix size: 160 x 256; slice thickness: 3 
mm; acquisition time: 7 min 25 sec. 
2. 3D fluid-attenuated inversion recovery (3D-FLAIR) images - TR/ TE/ TI/ NEX: 6500 
ms/ 120 ms/ 2200 ms/ 1; 8 partitions per slab; partition thickness: 1.25 mm; field of 
view: 125 x 200 mm; matrix size: 160 x 256; acquisition time: 7 min 54 sec.  
Quantitative MRI sequences:   
1. T1 relaxation time measurements: 3D fast low-angle shot (FLASH), TR/ TE/ NEX: 
15 ms/ 4 ms/ 4; partition thickness: 3 mm; field of view: 80 x 128 mm; matrix size: 
80 x 128, with flip angles of  2°, 5°, 10°, 15°, 20°, and 25° respectively. The T1 
relaxation times (T1) was then calculated for each pixel through a nonlinear least-
squares fit 30.
2. DTI: diffusion-weighted single shot STEAM sequence, TR/ TE/ NEX: 6000 ms/ 65 
ms/ 8; slice thickness: 8 mm; field of view: 80 x 128 mm; matrix size: 40 x 64; flip 
angle: 11°. Diffusion encoding gradients were applied in six noncollinear directions: 
(0, 1, 1), (0, 1, -1), (1, 0, 1), (1, 0, -1), (1, 1, 0), and (1, -1, 0), given in the gradient 
coordinate system (x, y, z), using a b-value of 750 s/mm2.31 For each slice, one 
image without use of a diffusion gradient (b = 0) was also acquired. Pixelwise maps 
of the apparent diffusion coefficient (ADC) and fractional anisotopy (FA) maps were 
calculated. ADC reflects the magnitude of water diffusivity, whereas the FA 
indicates spatial directionality of water diffusivity. DTI measurements had to be 
excluded in seven brain slices due to image artifacts and were therefore available 
for 41 brain slices. 
Definition of WMH and selection of regions of interest (ROIs)  
The scans and quantitative maps were displayed on a Sun workstation (Sun 
Microsystems, Mountainview, CA, USA) using an in-house developed image viewer 
(Show_Images) for analyses. Rectangular regions of interest (ROIs) were defined on 
3D-FLAIR images in a consensus meeting of two experienced raters. The ROIs 
(mean size: 9.7 ± 3.0 mm2 and minimum size: 4.9 mm2) were drawn within areas of 
WMH and normal appearing white matter (NAWM). Care was taken not to include the 
borders of the area of WMH or NAWM in the ROIs to avoid miscategorization. WMH 
included extensive periventricular WMH and (beginning) confluent areas of deep 
WMH, according to the widely used Fazekas scale.2 Rimlike periventricular WMH or 
small punctate deep WMH were not included, because it is more difficult to match 
these small areas exactly with (immuno)histochemical stainings.16 NAWM was 
defined as white matter that showed no visually appreciable signal intensity increase 
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on T2-weighted or 3D-FLAIR images. Only scans of brain slices with at least one 
WMH ROI were included for analyses. Forty-five ROIs in WMH and 30 ROIs in 
NAWM were defined in 33 brain slices of AD patients; 16 WMH and 13 NAWM ROIs 
were defined in 15 sliced of controls (totalling 104 ROIs). 
Neuropathology and matching procedure 
As part of routine pathological description of each brain specimen, Braak staging was 
performed for confirmation of the clinical diagnosis of AD and controls.9 Furthermore, 
evaluation of the agonal state was performed on haematoxylin-eosin (HE) stainings 
by assessment of red (hypoxic) neurons and cortical pericellular edema in the frontal, 
temporal and occipital lobes (graded as absent/ mild/ moderate/ severe). Hemispheric 
brain slices were paraffin-embedded and subsequently cut until halfway to reveal the 
center of the imaged plane on which the ROIs were defined. This way, the brain slices 
could be reliably matched to the MR images. Serial 8 ȝm thick sections were then cut, 
mounted onto glass slides and stained with HE, Luxol Fast Blue/ Cresyl Violet (LFB) 
and Bodian silver to assess general tissue morphology, myelin density, and axonal 
density, respectively. Standard immunohistochemical stainings were performed on 
adjacent sections, which were mounted on poly-L-lysine-coated glass slides for 
microglial activation with HLA-DR antibodies and for astrogliosis with antibodies 
directed against glial fibrillary acidic protein (GFAP). Endogenous peroxidase activity 
was blocked by incubating the sections in methanol with 0.3% H2O2 for 30 min. The 
sections were rinsed for 30 min with 0.01M phosphate-buffered saline (PBS; pH 7.4). 
HLA-DR staining, sections were pretreated by heating in a microwave oven (750W) at 
100°C for 10 min in a citrate buffer (0.01M, pH 6.0), cooling down to room 
temperature and rinsing with PBS. Primary antibodies (HLA-DR, clone LN3: mouse 
antibody, dilution 1:50, gift from Dr. J.H. Hilgers, Department of Obstetrics and 
Gynaecology, VUmc); GFAP: rabbit polyclonal antibody, dilution 1:2000, gift from 
dr. Hilgers) were diluted in PBS containing 1% bovine serum albumin and were 
incubated overnight at 4°C. Primary antibodies were omitted for negative controls. 
After rinsing, immunolabeling with primary antibodies was detected with the EnVision-
HRP complex (DakoCytomation, Glostrup, Denmark). Sections were lightly 
counterstained with haematoxylin and mounted with Depex (BDH, Poole, UK). 
The FLAIR images, on which the ROIs were defined, were carefully matched to the 
corresponding QMRI maps and to the hemispheric tissue sections. The WMH and 
NAWM ROIs were then copied onto the corresponding areas in the QMRI maps and 
tissue sections by visual inspection using cortical anatomy and WM abnormalities as 
landmarks.15 A representative matching of postmortem MRI to histopathology is 
illustrated in Figure 1. 
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Figure 1 
Prefrontal brain slice of an 88-year-old female Alzheimer’s Disease patient (case 2 in Table 1). Regions of 
interest (ROIs) were defined on the FLAIR image (A) and copied onto the quantitative MRI maps: T1-map 
(B), Fractional Anisotropy-map (C); and Apparent Diffusion Coefficient-map (D) 
and  histochemically stained whole hemispheric sections including Bodian Silver (E) and Luxol-Fast-
Blue/Cresyl-Violet (F) stained sections after careful matching, using cortical anatomy as 
landmarks.  Microscopic sections of the ROIs are illustrated in G to J. The green ROIs represent white 
matter hyperintensities (WMH) in the periventricular area (G1 to J1). The yellow ROIs  are  located in WMH 
in the deep white matter (G2 to J2). The white ROIs are drawn in an area of normal appearing white matter 
(NAWM, G3 to J3). Bodian Silver stained sections (G, original magnification 200x) showed lower axonal 
density in WMH (G1 and G2) than in NAWM (G3); more microglial activation (H) was observed in WMH (H1 
and H2) than in NAWM (H3) on  HLA-DR immunohistochemical sections (original magnification 200x); 
WMH also showed more myelin loss (I1 and I2) compared to NAWM (I3) in Luxol-Fast-Blue/Cresyl-Violet 
stained sections (original magnification 100x); the difference in severity of astrogliosis (J) between WMH 
and NAWM (GFAP-immunostained sections, original magnification 400x), varied between patients: in this 
patient, the degree of astogliosis was roughly comparable between tissue types, but at a group level, 
astrogliosis was more severe in WMH than in NAWM.  
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All measurements were performed within the ROIs and were assessed blinded to 
clinical, pathological and MRI information. Myelin and axonal densities were quantified 
by assessing light transmittance of digital images of the LFB and Bodian Silver 
stainings (TmLFB and TmBodian, respectively), using the software programme ImageJ 
version 1.37 (freely downloadable from rsb.info.nih.gov). Images were converted into 
8-bit gray scale images and the mean light transmittance within the ROIs was 
measured (arbitrary units, ranging from 0 to 255). High values (increased light 
transmittance) correspond to low staining intensity. Severity of microglial activation 
was scored on HLA-DR stained sections using templates (Figure 2A): (0) no increase 
of microglia, only perivascular macrophages are stained; (1) mild microglial activation: 
slight increase of activated microglial cells; (2) moderate increase of activated 
microglial cells; (3) severe microglial activation with severe increase of activated 
microglial cells. Furthermore, the most predominant microglial phenotype was 
assessed: predominantly microglial cells or predominantly macrophages.32 Severity of 
Figure 2 
Templates illustrate the semi-quantitative assessment of microglial activation (A) and astrogliosis (B).   
A score of 0 – 3 could be given for the severity of microglial activation assessed on HLA-DR 
immunostained sections (A): (0) no increase of microglia; (1) mild microglial activation with a slight increase 
of microglial cells; (2) moderate increase of microglial cells; and (3) severe microglial activation with 
significant increase of microglial cells. Severity of astrogliosis (B) was assessed on GFAP-immunostained 
sections according to the following semi-quantitative score (range 0 – 3): (0) normal tissue with normal cell 
bodies and visible ramifications and low staining of glial processes; (1) mild reactive astrogliosis with slight 
enlargement of cell bodies and slightly increased staining of glial processes; (2) moderate reactive 
astrogliosis: significant enlargement of cell bodies, ramifications of glial processes are not visible due to 
increased staining; (3) severe reactive astrogliosis with a gemistocytic appearance of cell bodies and dense 
staining of glial processes.  
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astrogliosis was assessed using templates on the GFAP-immunostained sections 
according to the following semiquantitative score (range 0 – 3, see Figure 2B): (0) 
normal: normal cell bodies with visible ramifications and low staining of glial 
processes; (1) mild reactive astrogliosis: slight enlargement of cell bodies and slightly 
increased staining of glial processes; (2) moderate reactive astrogliosis: significant 
enlargement of cell bodies, ramifications of glial processes not visible due to 
increased staining; (3) severe reactive astrogliosis: gemistocytic appearance of cell 
bodies and dense staining of glial processes.  
Statistical Analysis 
Data analysis was performed by using SPSS version 12.0.1 for Windows (SPSS, Inc., 
Chicago, Ill., USA). Patient demographics were compared between groups using 
Student’s t-tests and Chi-squared tests, where appropriate. Neuropathological and 
quantitative MRI measures were compared between patient groups (AD and non-
demented controls) and tissue types (WMH and NAWM). Quantitative variables of the 
QMRI (T1, FA, and ADC) and neuropathological (TmBodian and TmLFB) measures were 
compared using linear mixed model analyses, accounting for the nested design where 
several brain slices were selected from each subject and one or more ROIs were 
drawn on each brain slice. For these analyses, the quantitative neuropathological and 
MRI measures were entered as the dependent variables, while the patient groups (AD 
versus controls) and tissue types (WMH versus NAWM) were the independent 
variables, and variables for both patient and slice were entered as repeated measures. 
Semiquantitative neuropathological scorings (HLA-DR scores and GFAP scores) were 
evaluated between groups (NAWM controls, WMH controls, NAWM AD patients, and 
WMH AD patients) using Kruskal-Wallis tests and post-hoc Mann-Whitney U-tests. To 
illustrate relationships between neuropathological measures mutually and with QMRI 
variables, univariate associations were assessed using Pearson’s correlation 
coefficients. Subsequently, to assess which neuropathological measures determined 
the QMRI parameters in AD patients, linear mixed model analyses were used. The 
QMRI parameters were the dependent variables (T1, FA and ADC) and the 
neuropathological measures (TmLFB, TmBodian, HLA-DR score and GFAP-score,) the 
independent variables, whereas variables for both patient and slice were entered as 
repeated measures. Standardized ßs are reported. First, all analyses were performed 
for each neuropathological measure separately, corrected for age, gender and fixation 
time. Subsequently, a stepwise backward model was performed, in which first all 
neuropathological measures and covariates (age, gender, fixation time) were entered, 
and the neuropathological measures with the highest p-value were subsequently 
excluded until only significant predictors remained in the model.  
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Results
Cases 
Thirty-three formalin-fixed, coronal hemispheric brain slices from eleven AD patients 
(mean age: 83 ± 10 yrs, eight females, mean Braak stage: 5, postmortem delay 
(h:min): 6:09 ± 3:05) and fifteen hemispheric slices from seven controls (mean age: 
78 ± 10 yrs, four females, mean Braak stage: 1, postmortem delay: <24 h) were 
selected. The groups were age- and gender-matched. At slice level, the fixation time 
for T1 relaxation time measurements and neuropathological measures were 
comparable (fixation time [months]: 2.6 ± 1.2 for controls versus 2.3 ± 0.9 for AD 
patients). The fixation time for DTI scanning, however, was slightly longer in brain 
slices of control subjects than AD patients, because some slices were rescanned due 
to initial imaging artifacts (fixation time [months]: 4.4 ± 0.4 for controls versus 3.1 ± 1.1 
for AD patients, p< 0.001).  
Quantitative MR imaging 
To differentiate tissue characteristics of WMH and NAWM between AD patients and 
controls, the results of the QMRI parameters are listed per patient group and tissue 
type in Table 2 and illustrated as boxplots in figure 3. Linear mixed models showed 
main effects for patient group, as AD patients had higher T1 (p = 0.04) and lower FA 
values (p < 0.01) than controls in both tissue groups together. In addition, there were 
main effects for tissue type as WMH showed higher T1 (p < 0.001) and lower FA 
values (p < 0.01) than NAWM. A significant interaction between patient group and 
tissue type was found for the T1 relaxation time measurements (p = 0.04), indicating 
that the difference in T1 relaxation time between NAWM and WMH was larger in AD 
patients than in controls. For FA, there was no interaction between patient group and 
tissue type. No differences between patient groups or tissue types were found for 
ADC.
Neuropathology 
Group differences of the neuropathological characteristics are given in Table 2 and 
are illustrated as bargraphs and boxplots in Figure 4. Linear mixed models showed 
main effects for tissue type, as more axonal loss (TmBodian) and myelin loss (TmLFB)
were found in WMH compared to NAWM of both patient groups together. However, 
for axonal loss (TmBodian) and myelin loss (TmLFB), there was no main effect for patient 
group and there were no significant interaction terms. Higher values of GFAP-scores 
were observed in WMH compared to NAWM of both patient groups together, 
indicating more astrogliosis. No differences between AD subjects and controls and no 
significant interaction between patient group and tissue type exist for severity of 
astrogliosis. AD patients showed more severe microglial activation than controls, as  
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Boxplots of quantitative MRI measures are shown by patient group and tissue type: normal appearing white 
matter (NAWM) of controls, white matter hyperintensities (WMH) of controls, NAWM of Alzheimer’s disease 
(AD) patients and WMH of AD patients. Group characteristics of the (A) fractional anisotropy (FA), (B) 
apparent diffusion coefficient (ADC) and (C) T1 relaxation time are depicted.  
Figure 3 
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Figure 4 
Neuropathological characteristics are depicted by patient group and tissue type: normal appearing white 
matter (NAWM) of controls, white matter hyperintensities (WMH) of controls, NAWM of Alzheimer’s disease 
(AD) patients and WMH of AD patients. Axonal loss (A) and myelin loss (B), represented by light 
transmittance of Bodian Silver stained sections (TmBodian) and Luxol Fast Blue-Cresyl Violet stained sections 
(TmLFB), are illustrated as boxplots and microglial activation (C) and astrogliosis (D) are depicted as 
bargraphs with error bars.  
represented by higher HLA-DR scores. Moreover, more microglial activation (HLA-DR 
scores) was observed in the WMH than in the NAWM of AD patients, whereas this 
effect was not found in controls. Furthermore, a higher proportion of macrophages as 
the most predominant HLA-DR positive cell type was found in AD subjects compared 
to controls (N [%]: 31 [43%] for AD vs 1 [4%] for controls, p<0.001). Moreover, more 
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macrophages were present in the WMH than in the NAWM of the AD group (N [%]: 24 
[55%] in WMH vs 7 [25%] in NAWM, p = 0.014), whereas the proportion of 
macrophages was comparable in both tissue types of controls. As expected, axonal 
loss (TmBodian) and myelin loss (TmLFB) were partially interrelated (Pearson’s r = 0.46, 
p<0.001). Furthermore, severity of astrogliosis (GFAP-scores) correlated with axonal 
and myelin loss (Pearson’s r = 0.25, p = 0.047 for astrogliosis ~ myelin loss; r = 0.26, 
p = 0.039 for astrogliosis ~ axonal loss), whereas microglial activation (HLA-DR 
score) was not correlated with any other histopathological measure (data not shown). 
QMRI – pathology correlations
Relationships of QMRI parameters with neuropathological measures in AD patients 
are illustrated as scatterplots in Figure 5. The scatterplots illustrate that WMH and 
NAWM do not have separate distributions, but partly overlap, implying a gradual 
difference between these tissue types.  
To assess which neuropathological measures were the strongest determinants of the 
QMRI parameters in AD patients, linear mixed models were built (Table 3). When 
Table 3. Neuropathological determinants of QMRI parameters  
Model 1 Model 2 
T1 TmBodian 0.72 *** 0.47 *** 
 TmLFB 0.55 *** 0.29 ** 
 GFAP-score 0.32 **  
 HLA-DR score 0.37 ** 0.35 *** 
    
FA TmBodian -0.62 *** -0.62 *** 
 TmLFB -0.51 ***  
 GFAP-score -0.41 ***  
 HLA-DR score -0.12  
    
ADC TmBodian 0.13  
 TmLFB 0.002  
 GFAP-score -0.08  
 HLA-DR score -0.18  
Values are standardized ßs, estimated with linear mixed models. The dependent variables were T1 (T1 
relaxation time), FA (fractional anisotropy) and ADC (apparent diffusion coefficient) and the 
neuropathological measures were the independent variables.  
Model 1: each neuropathological measure was separately entered, adjusted for age, gender and fixation 
time.
Model 2: stepwise backward model: first the covariates (age, gender and fixation time) were entered. 
Subsequently the neuropathological measures were included in a stepwise backward manner.  
* p<0.05; ** p0.01; *** p0.001. TmBodian = light transmittance Bodian staining, inversely related to axonal 
density; TmLFB = light transmittance LFB staining, inversely related to myelin density. 
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Relationships between quantitative MRI parameters (T1-relaxation time [ms; first column], FA [second 
column], and ADC [ȝm2/s; third column]) and neuropathological measures (TmBodian [higher values 
represent more axonal loss; first row], TmLFB [higher values represent more myelin loss; second row], 
GFAP-score [astrogliosis; third row], and HLA-DR score [microglial activation; fourth row]) are illustrated in 
scatterplots. The coloured dots correspond to white matter hyperintensies (WMH), whereas the open dots 
represent normal appearing white matter (NAWM). Univariate associations are assessed using Pearson’s 
correlation coefficient. The scatterplots show that WMH and NAWM have partly overlapping distributions, 
implying a gradual difference between these tissue types.  
Figure 5 
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neuropathological measures were entered separately, adjusted for age, gender and 
fixation time, axonal loss (TmBodian), myelin loss (TmLFB) and astrogliosis (GFAP-score) 
were determinants of FA. In the stepwise analysis, however, the only independent 
determinant of FA was axonal loss (TmBodian). All neuropathological measures were 
associated with T1 in the first model. The stepwise model revealed that axonal loss 
(TmBodian), myelin loss (TmLFB) and microglial activation (HLA-DR score) were 
independent determinants of T1 relaxation time, whereas the astrogliosis (GFAP-
score) lost statistical significance. There were no associations between any of the 
neuropathological measures and ADC.  
Discussion  
We found that QMRI techniques reveal differences between WMH of AD patients and 
WMH of controls and reflect the severity of underlying neuropathological changes.  
QMRI increases specificity for neuropathological changes within WMH 
We hypothesized that the inconsistent and weak relationships between the presence 
and severity of WMH on conventional T2-weighted MRI and clinical symptoms in both 
demented and non-demented elderly subjects may be explained by heterogeneity in 
the neuropathological substrates of WMH. Several postmortem MRI studies have 
demonstrated that pathological substrates of WMH are heterogeneous. Punctate 
WMH corresponded to mild perivascular tissue damage around lipohyalinotic 
arterioles with large perivascular spaces, atrophic neuropil and slight axonal loss.16
Confluent areas of WMH, however, reflect severe incomplete ischemic damage with 
extensive axonal and myelin loss, reactive astrogliosis and lipohyalinotic arterioles, 
partly developing towards complete infarctions.17 More recently, detailed 
immunohistochemical characterization of WMH in a large prospective 
neuropathological study (MRC CFAS) has contributed substantially to our 
understanding of the pathology and pathogenetic mechanisms of WMH, and has yet 
again confirmed the heterogeneous nature of WMH histopathology. Differences in 
microglial responses and the expression of hypoxia-related markers suggest that in 
the development of a proportion of WMH a hypoxic environment is involved, whereas 
other WMH are related more to immune activation resulting from disintegration of the 
ependyma or blood-brain barrier dysfunction.20, 21
In this study, we focused on QMRI techniques in an attempt to increase MRI 
specificity for WMH. It has been reasoned, though not verified, that QMRI 
measurements reflect histopathological changes in aging and dementia.28 Only one 
previous postmortem DTI study in demented subjects demonstrated that DTI is 
feasible in the postmortem setting and correlated with myelin loss using one 
conventional myelin stain in two AD patients.33 In the current study, we demonstrated 
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that, in AD, FA reflects the extent of astrogliosis and of myelin and axonal loss, and 
that the strongest predictor of the FA is axonal loss, whereas the relationships with 
myelin loss and astrogliosis are largely determined by their correlation with axonal 
density. T1 relaxation times independently reflected microglial activation, axonal loss 
and myelin loss. The FA was therefore more specific than T1 relaxation time 
measurements for the severity of axonal loss, whereas T1 relaxation time reflected a 
larger array of pathology. 
QMRI. demonstrates that WMH tissue change is more severe in AD. 
Our data confirm the in vivo literature claiming that QMRI techniques show differences 
between WMH and NAWM.22,34 We further showed that AD patients had lower FA 
values and longer T1 relaxation times than controls. Additionally, we have found that 
QMRI parameters show differences between WMH of AD patients and WMH of 
controls as the difference in T1 relaxation time between WMH and NAWM was larger 
in AD patients than in controls. The T1 relaxation time difference between patient 
groups may be a reflection of the difference in microglia/macrophage activation, as we 
also found that WMH in AD patients had more severe microglial activation than 
NAWM, whereas in controls no difference was found. These findings are consistent 
with our correlation data showing that the degree of microglial activation was an 
independent predictor of T1 relaxation time. It is known that microglial activation plays 
a crucial role in AD as microglial cells become overactivated when they are engaged 
in the clearance of amyloid-ß.35 Alternatively, amyloid-ß may directly recruit and 
activate microglial cells as suggested by studies of congophilic angiopathy.36
Microglial activation may subsequently lead to neuronal loss and to damage in the 
microvasculature.35 We postulate that the T1 relaxation time prolongation in WMH of 
AD may be an expression of a diffuse inflammatory reaction due to microglial 
activation and accompanying increase of interstitial fluid due to blood-brain barrier 
leakage and vascular damage.27 More extensive immunohistochemical stainings for 
inflammatory markers and leakage of blood-brain barrier proteins such as fibrinogen 
or collagen should be performed to further investigate this hypothesis.37 One previous 
study of the MRC CFAS could not confirm the difference in microglial activation 
between demented and subjects when using CD68-stainings.21 The use of different 
antibodies for microglial staining could explain this difference.35 An alternative 
explanation is the difference in study design. Our case-control design may reflect two 
ends of a spectrum and is therefore more likely to demonstrate actual differences, 
whereas the MRC CFAS reflects an epidemiologically based community sample. One 
could argue that several other factors such as agonal state or concomitant disease 
could also play a role, though our brain specimens were carefully controlled for other 
dementias and Braak stage. Moreover, comparable results were yielded when all 
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analyses were repeated with and without subjects with a severe grade of hypoxic 
neurons (3 AD subjects and 1 control subject; data not shown), which renders it highly 
likely that our findings are truly disease-specific tissue changes. Other 
neuropathological differences in WMH such as extensive denudation of the ventricular 
ependyma, gliosis and more severe axonal loss in AD patients as compared to 
controls were also reported.18 On the other hand, a recent study using markers for 
hypoxic injury concluded that WMH in demented and non-demented subjects are 
comparable and form part of a pathological continuum common to the aged brain.21 In 
our study using basic measures for neuropathology, we found differences in 
inflammatory responses and in QMRI parameters that reflect underlying tissue 
changes between AD patients and controls.  
Periventricular versus deep WMH 
Previous literature reported that PVL and DWMH areas differ with respect to several 
pathological measures.17,21,32 We have performed comparison of QMRI and 
neuropathological measures between DWMH and PVL in our study (data not shown), 
but we did not find consistent differences and therefore pooled them into ‘WMH’ for 
further analyses. An explanation for the fact that we did not find differences between 
PVL and DWMH may lie in our definition of WMH. We only included WMH when 
significant PVL and/or (beginning) confluent DWMH were present. Whereas rimlike 
PVL or smooth halos and DWMH have been found to have different pathological 
correlates, we are probably comparing irregular large PVL with confluent DWMH, that 
have been described to be pathologically comparable.17
Normal appearing white matter 
We have predominantly focused on changes that are visible on T2-weighted MRI, but 
it may be possible that pathological changes in the NAWM, i.e. WM that appears 
normal on MRI, also contribute to the clinical correlates of WMH.19,38 Although our 
study could not adequately assess pathological and QMRI characteristics of NAWM, 
as this would have necessitated inclusion of WM from non-diseased control brains, 
our data suggest that a fundamental segregation between WMH and NAWM could not 
be made on the basis of histopathology and QMRI data. We postulate that a 
dichotomization of the white matter into WMH and NAWM may be arbitrary and even 
inappropriate, as our correlation data between QMRI and histopathological measures 
suggest that a continuum may exist from neuropathologically normal to abnormal 
white matter. These changes could therefore also partly explain the weakness of the 
clinico-radiological correlation. Our findings should be reproduced or confirmed in 
studies that also include NAWM of non-lesional brains as this tissue may be 
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pathologically different from NAWM of lesional brains and could therefore be separate 
from the suggested continuum in pathological changes.  
Methodological considerations and recommendations for future study 
In our study, the ADC was not correlated to any of the neuropathological measures 
and was not able to reveal differences between patient groups or tissue types. 
Possibly, the use of formalin-fixed brain specimens influenced the ADC, as death and 
fixation changes the cellular structure by dehydration, change in temperature, failure 
of energy dependent ion transport, lactate acidosis, and formation of cross links. It 
has been shown that diffusivity, which largely depends on the free mobility of water 
molecules, decreases after death and declines further with longer fixation times.39,40
On the contrary, FA was found not to be influenced by formalin fixation.39 Formalin 
fixation also shortens relaxation times, and postmortem MRI values are therefore not 
directly comparable to in vivo MRI values. However, translation to clinically relevant 
values could still be achieved using formalin fixed material.39 As it has been described 
that relaxation times stabilize after 3 – 4 weeks of fixation,40 each brain specimen in 
this study was fixed for at least 4 weeks to minimize the variability of fixation effects 
within the study group. Additionally, linear mixed model analyses were used to correct 
for any remaining effects of fixation time. Furthermore, postmortem delay until tissue 
fixation could be an other factor that causes structural damage due to autolysis and 
influences the brain’s diffusion properties.41 Future analyses should therefore consider 
sampling fresh, unfixed tissue with a short postmortem delay when studying 
postmortem MRI characteristics of ageing and dementia. In addition, as the resolution 
of our FA and ADC maps were lower than the FLAIR and T1, which may have 
rendered it more difficult to match the ROIs with the stained sections. To avoid 
possible misclassification, we used FLAIR images with higher resolution for the 
definition of the ROIs and copied the ROIs to the QMRI-maps. We further took care to 
have at least a rim of WMH around each WMH ROI and to draw NAWM ROIs in areas 
at a distance of signal hyperintensities.  
Understanding the clinical impact of WMH
DTI and T1 relaxation time measurements were shown to be more specific than 
conventional T2-weighted MRI, as these techniques revealed differences between 
WMH of demented and WMH of non-demented subjects, and reflected the severity of 
the underlying neuropathological changes. Our findings should be reproduced in the 
in vivo setting, in order to determine the clinical correlates of WMH changes 
measured with QMRI in demented and non-demented subjects.22,38 Hence, these 
studies should lead to a better understanding of the clinical impact of WMH in 
demented and non-demented elderly.  
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The general objective of this thesis was to explore possible ways to improve the weak 
clinical-radiological associations of SVD in order to increase understanding of SVD 
features. When features of SVD can be determined with more specificity, it will 
eventually be possible to predict the clinical impact of SVD in an elderly individual. In 
this chapter, the main findings of the studies presented in this thesis are summarized 
and discussed. Finally, some recommendations for future research will be presented. 
Part 1. Clinical impact of SVD in cross-sectional MRI studies 
As many studies on clinical impact of SVD on MRI have used a cross-sectional 
design, we first aimed to increase specificity on cross-sectional assessment of SVD. 
The various used visual rating scales and volumetric methods for WMH may differ in 
specificity leading to inconsistencies between studies.1,2 It has been shown that visual 
rating scales correlate well with WMH volume, but, from a clinical point of view, it is 
necessary to investigate their validity, i.e. associations with clinical measures. 
Furthermore, as an independent contribution of lacunes on cognitive consequences 
has inconsistently been found, it may be possible that the location of strategic lacunes 
plays a modifying role in the association.3-5 In the first two studies of this thesis 
(chapter 2), which were performed on baseline data of the LADIS-study, we 
investigated the effect of the complexity of WMH assessment and possible strategic 
locations of lacunes on clinical consequences.  
Chapter 2.1
The first study compared a simple visual rating scale (Fazekas scale),6 a detailed 
visual rating scale (Scheltens scale)7 and semi-automated volumetric assessment of 
WMH8 in relation to gait and balance disturbances and general cognitive function. We 
found that associations between the extent of WMH and the clinical variables were 
significant and comparable across methods of WMH measurement, also after 
adjustment for possible confounders. In congruence with previous studies, the 
correlations were only of modest strength.9,10 This study shows, that simple and 
complex measures of WMH have equal validity with respect to these clinical 
parameters and that the weak clinical-radiological associations could not be improved 
by using more detailed methods of WMH assessment. We suggest that a simple 
visual rating scale for WMH is sufficiently informative in clinical practice. For research 
settings, it is conceivable that volumetric methods remain desirable, as these methods 
are more precise than visual rating scales.8,11
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We then investigated whether the location of lacunes in distinct subcortical structures 
has an independent influence on cognitive performance. Lacunes were counted in the 
following 5 areas: lobar white matter, putamen/ pallidum, thalamus, internal/ external 
capsule, infratentorial areas. General cognitive performance (MMSE and modified 
Alzheimer Diseases Assessment Scale) and specific cognitive domains (memory, 
executive functions, speed and motor control) were assessed. Our results show that 
the presence of lacunes in the thalamus was independently associated with lower 
MMSE and worse performance on speed and motor control and executive functions. 
The presence of lacunes in putamen/ pallidum was associated with worse memory 
and speed/ motor control performance. Results were adjusted for several possible 
confounders including WMH severity. It is concluded that, in non-disabled elderly 
subjects with WMH, the location of lacunes within subcortical grey matter is a 
determinant of cognitive impairment, independent of WMH severity. These findings 
extend on previous studies that have identified the thalamus as a strategic location for 
memory and executive functions.5,12
From these cross-sectional MRI studies, we can conclude that the impact of lacunes 
can be more specifically predicted, when some strategic locations are taken into 
consideration. However, more detailed assessment of SVD on cross-sectional T2-
weighted MRI did not lead to sufficiently improved specificity, as correlations with the 
investigated clinical symptoms remained of modest strength. 
Part 2: Longitudinal studies of SVD 
From the studies of part 1 can be concluded, that the possibilities to specify SVD in 
cross-sectional MRI studies are limited, because they do not provide information on 
temporal relationships and causality. Several longitudinal studies reporting WMH 
change over time have been published, but longitudinal data on the appearance of 
new lacunes are scarce and risk factors are unknown.13-15 In chapter 3, we therefore 
set out to perform longitudinal MRI studies, using baseline and follow-up MRI data 
from the LADIS-study, in order to evaluate the natural course of SVD over time in 
initially non-disabled elderly subjects. We further aimed to characterize the risk factors 
for progression or occurrence of SVD. These temporal relationships may provide 
more insight in the pathogenesis of SVD.  
Chapter 3.1
We first determined the most reliable and sensitive method for measuring progression 
of WMH over time. WMH change was scored by four experienced raters using three 
conventional visual rating scales (Fazekas scale,6 Age-Related-White-Matter-
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Changes scale,16 Scheltens scale;7 scored on baseline and follow-up scan) and two 
dedicated visual progression scales (Rotterdam progression scale17 and Schmidt 
progression scale18). The visual rating scales were compared with volumetric 
assessment (baseline and follow-up measurement). Change scores for the cross-
sectional visual rating scales and volumetry were calculated by subtracting follow-up 
scores from baseline scores. We found that all visual scales showed significant 
change of WMH over time, but the sensitivity was highest for both of the progression 
scales. Volumetric change of WMH correlated best with the Rotterdam Progression 
scale. Although all scales were reliable for assessment of WMH cross-sectionally, 
WMH progression assessment using visual scales was less reliable, except for the 
Rotterdam Progression scale which had moderate to good reliability. In conclusion, to 
determine change in WMH, dedicated progression scales, especially the Rotterdam 
Progression scale, are more sensitive and have higher correlations with WMH volume 
change than conventional cross-sectional scales. 
Chapter 3.2
We then evaluated SVD progression over three years follow-up in the LADIS-study 
using the Rotterdam Progression scale for WMH progression and counts for new 
lacunes. We described their natural course, regional distribution at baseline and 
follow-up and risk factors for progression over time. Results showed that both WMH 
and lacunes progress over time, mostly in subjects who have WMH or lacunes at 
baseline. Our findings extend on previous studies, because we found that not only 
WMH but also lacunes progress over time, especially in subjects with SVD at 
baseline.14,19 Previous cross-sectional studies suggested that mainly the group of 
subjects with severe WMH experience clinical effects.20 We found that SVD also 
progressed in subjects with moderate WMH. This finding may have clinical 
consequences, as the moderate WMH group could eventually progress to severe 
WMH and consequently develop clinical symptoms in the following years. Possible 
intervention or prevention of risk factors should therefore be directed at both patients 
with moderate and severe WMH. We further found that previous stroke, diabetes and 
blood glucose independently predicted WMH progression. Risk factors for the 
occurrence of new lacunes were male gender, hypertension, systolic blood pressure, 
previous stroke, body mass index, HDL and triglyceride levels. Previous studies, 
however, described various other risk factors for WMH progression and showed that 
relationships between baseline predictors and WMH change are complex.18, 21, 22 The 
vascular risk factors, that we found as predictors for the progression of SVD, support 
previous studies that arteriolosclerosis and ischemia play a role in their 
pathogenesis.23 In this study, we further described that WMH progressed mostly in the 
subcortical white matter (WM), where WMH were also most prevalent at baseline. The 
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comparable regional distribution at baseline and follow-up suggests that the change 
was mainly due to increase of existing WMH. The majority of new lacunes appeared 
in the subcortical WM, whereas baseline lacunes were equally prevalent in the basal 
ganglia. The regional distribution of lacunes seemed to shift over time, leading to the 
hypothesis that basal ganglia lacunes have a different pathogenesis than subcortical 
WM lacunes.  
Chapter 3.3
We therefore investigated regional differences in MRI characteristics and risk factor 
profiles of incident lacunes to provide more insight in the pathogenesis of lacunes. 
Incident lacunes were characterized with respect to: 1) brain region (subcortical WM, 
basal ganglia or infratentorial region), 2) the emergence within pre-existing WMH at 
baseline, suggesting the development of a cavity within the WMH (yes/no), 3) the 
(change in) WMH size surrounding the incident lacune and 4) specific risk factors. 
Results show that incident lacunes in the subcortical WM occurred more often within 
pre-existing WMH and were mostly accompanied by new and expanded WMH, 
compared to incident basal ganglia and infratentorial lacunes. Risk factors for incident 
subcortical WM lacunes were history of hypertension and stroke, whereas atrial 
fibrillation predicted incident basal ganglia/ infratentorial lacunes. This study shows 
that there are differences in risk factor profiles and relationship with WMH between 
subcortical and basal ganglia/ infratentorial lacunes. We postulate that subcortical 
WM lacunes develop slowly in an area with already compromised perfusion, i.e. pre-
existent WMH, due to increasing hypoxia/ischemia, leading to frank infarction. In 
contrast, the pathogenesis of lacunes in the basal ganglia and infratentorial region 
may involve a more acute occlusion of a single arteriole. 
In conclusion, these studies show that WMH and lacunes progress over time, 
especially in subjects with SVD and vascular risk factors at baseline. The 
pathogenesis of SVD may involve multiple processes and may differ between features 
of SVD and between brain regions.  
Part 3: Heterogeneity in underlying pathology of SVD 
Several attempts to increase specificity on cross-sectional T2-weighted imaging, such 
as the use of more precise assessments, have not been sufficiently successful. 
Longitudinal MRI studies are informative for investigating the course of SVD over 
time. They suggest that vascular risk factors play a role and that the pathogenesis of 
SVD is heterogeneous and complex.24,25 Still, MRI remains an indirect reflection of the 
true underlying pathological changes and is not able to show the types and severity of 
tissue changes involved. As illustrated in the figure, the only way to unravel the 
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underlying pathological changes of SVD on MRI, is by direct comparison of MRI 
findings with histopathology in the postmortem setting.26,27 Postmortem MRI and 
histopathology correlations bridge the discrepancies between MRI and clinical 
measures, thereby potentially improving the understanding of the impact of SVD on 
MRI.
Figure. Postmortem MRI – pathology correlations have an important function of bridging the discrepancies 
between MRI and clinical symptoms.  
Recently, attempts are being made to improve specificity of in vivo MRI scanning by 
novel quantitative MRI (QMRI) techniques.28,29 The pathological substrates of QMRI in 
SVD, however, are still unknown. When the pathological correlates are unraveled, 
tissue changes in SVD may be translated into in vivo MRI scanning. In this thesis, we 
evaluated pathological correlates of two QMRI techniques: diffusion tensor imaging 
(DTI) and T1-relaxation time mapping. DTI quantifies the diffusivity of water molecules 
with respect to extent and spatial directionality (tissue anisotropy).30 In normal WM, 
that contains many fibre bundles, water molecules diffuse more readily along the long 
axis of the fibres than perpendicular to them. Tissue-specific T1 relaxation times may 
reflect pathological processes related to intraparenchymal changes in water content. 
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Chapter 4.1
We first reviewed studies that correlated postmortem MRI and histopathology, in order 
to elucidate the pathological substrates of the whole range of SVD features. Most of 
the studies that were reviewed, were only small and descriptive. Recently, a few 
larger population based studies attempted to unravel the pathogenesis of WMH.23,31,32
These studies provide valuable data and improve understanding of SVD. Relatively 
many postmortem studies have shown that heterogeneity exist in pathological 
substrates underlying WMH: 1) damage to the fibre network range from slight 
loosening to varying degrees of myelin and axonal loss; 2) glial cell responses include 
astrogliosis, clasmatodendrosis, loss of oligodendrocytes and several kinds of 
microglial responses; and 3) lipohyalinosis, arteriosclerosis, leakage of the vessel 
walls and venous collagenosis are recognized microvascular changes. Suggested 
pathogenetic mechanisms are ischemia/ hypoxia, general hypoperfusion due to 
dysfunction of blood flow autoregulation, blood-brain barrier leakage and 
clasmatodendritic astrogliosis due to serum protein uptake, inflammatory responses, 
degeneration and congophilic amyloid angiopathy. In contrast, relatively few 
postmortem MRI studies have been published with regard to lacunes and 
microbleeds. Many questions about their etiology therefore remain to be answered. 
Recently, clinico-pathological studies have suggested that SVD features, ‘invisible’ on 
T2-weighted MRI (i.e. cortical micro-infarcts and changes in the normal appearing 
WM), also contribute to clinical symptoms.  
Chapter 4.2
We then investigated whether postmortem QMRI and pathological measures show 
differences between WMH of Alzheimer’s Disease (AD) patients and of non-demented 
controls. We further aimed to investigate whether QMRI reflects underlying 
pathological substrates of WMH. Brain slices of AD patients and non-demented age-
matched controls were selected and scanned using postmortem MRI. Regions of 
interest were defined on FLAIR images in WMH and NAWM. Patient groups (AD 
versus controls) and tissue types (WMH versus NAWM) were compared using QMRI 
techniques (DTI, T1-relaxation time mapping) and neuropathological assessment 
(axonal density, myelin density, astrogliosis and microglial activation). We first 
confirmed earlier studies that QMRI and neuropathological assessment distinguishes 
WMH from normal appearing WM.28,33 Results further indicated that QMRI reveals 
differences in WMH between AD and non-demented elderly, with respect to more 
microglial activation in WMH of AD patients than in WMH of controls. This patient 
difference was also reflected by a higher mean T1-relaxation time in WMH of AD 
patients, specifically. QMRI reflected the severity of the neuropathological changes 
involved: axonal density was an independent determinant of DTI (fractional 
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anisotropy), whereas T1-relaxation time was independently determined by axonal and 
myelin density and microglial activation. Moreover, our correlation data between 
QMRI and neuropathology suggested that a continuum exist from neuropathologically 
normal to abnormal white matter. We therefore postulate that a clear distinction 
between WMH and NAWM is arbitrary and can not be made on the basis of 
neuropathology and QMRI data.  
Overall, the postmortem MRI studies showed that an explanation for the weak clinical-
radiological associations needs to be sought in the underlying pathology of SVD: 
pathological substrates of SVD expressions are heterogeneous in nature and differ in 
severity. QMRI revealed differences between WMH of demented and WMH of non-
demented subjects, and reflected the severity of the underlying neuropathological 
changes. Moreover, tissue changes that are ‘invisible’ on MRI probably also 
contribute to the clinical impact of SVD. 
Methodological considerations 
Study population 
The LADIS-study benefits from the large group of subjects and the broad range of 
WMH that is represented. This cohort was stratified for WMH severity and therefore 
consists of relatively many subjects with severe WMH. Unlike most (population based) 
studies, this design provided statistical power to find subtle associations with clinical 
parameters and specific characteristics of SVD on MRI. Because of the longitudinal 
design with repeated MRI scans, we were also able to investigate the change of SVD 
over time. However, the stratification by WMH may hamper the generalizability of the 
results to the general population as the sample represents an elderly patient 
population with WMH, seen in clinical practice, rather than a random population based 
sample. 
Another potential limitation may be the multi-center design of the study. The 
recruitment of subjects in several centers with different MRI scanners could have led 
to clinical heterogeneity in the study sample. Moreover, although imaging guidelines 
were distributed among all centers and repeated MRI scans were performed using the 
same scan protocol, heterogeneity of MRI scans between centers was considerable. 
Our statistical analyses were therefore corrected for the effect of center.  
Longitudinal design 
The longitudinal design of the LADIS-study with repeated MRI scans at baseline and 
at three-year follow-up, enabled us to investigate the natural course of SVD over time. 
However, there are also disadvantages of longitudinal studies. The attrition rate for 
follow-up MRI scanning was rather high, which could be a limitation of our study 
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because it could have led to a survival bias. Although patients without follow-up MRI 
had less favourable values for some baseline risk factors than our study population, 
the baseline MRI variables were comparable. The multi-center design made it also 
more difficult to implement automated methods for measuring WMH progression. 
Although WMH volumetry was reliable cross-sectionally, assessment of change in 
WMH volume involved the subtraction of baseline data from the follow-up data, 
thereby including the measurement error twice. The dedicated progression scales 
turned out to be more suitable for this sample than volumetric measurements of WMH 
change, possibly because they provide direct change scores by side-by-side 
assessment. On the other hand, scoring in a side-by-side fashion could be less ideal 
because of impossibility of blinding of the data. 
Postmortem MRI studies 
Methodological issues of our postmortem MRI study include: the use of formalin fixed 
brain specimens and the relatively basic neuropathological assessment. In this study, 
we only found pathological correlations with fractional anisotropy (FA, spatial 
directionality of water diffusion), but not with apparent diffusion coefficient (ADC, 
extent of water diffusivity). This may explained by the fact that death and formalin 
fixation causes a substantial decrease in ADC, leading to the lack of correlations, 
whereas the FA is less dependent on these factors.34 For post-mortem QMRI 
scanning, the use of fresh brain tissue would be recommended. This design, however, 
is challenging as it warrants a team of investigators to be on call for 24 hours a day 
and the availability of an MRI scanner at any time a death occurs.26 Furthermore, we 
performed relatively basic neuropathological assessment (only four relatively common 
neuropathological stainings), because we chose to focus on the correlations with 
QMRI measures. We were not able to draw specific conclusions on pathogenetic 
mechanisms of WMH, because it would warrant extensive and detailed correlations 
with a larger battery of specific (immuno-) histochemical stainings.  
Implications and future research 
Radiology, pathology and clinical impact 
Chapters 2 and 3 of this thesis focused on the relationships between radiology and 
clinical symptoms, whereas chapter 4 dealt with the correlation between radiology and 
pathology. However, as illustrated in the figure, radiology, pathology and clinical 
impact are interrelated and the current focus in research should aim to integrate all 
three fields to be able to obtain the full picture of SVD. Moreover, longitudinal studies 
are important to investigate temporal relationships and therefore, causality. A way to 
achieve this is to follow a large group of subjects with neuropsychological testing,  
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physical examinations and MRI scans (including QMRI) and to eventually combine 
these longitudinal data with postmortem assessment (with MRI scanning and 
pathological evaluation). Although this design is challenging, such studies are 
currently being performed in the general population and in a cohort of nuns.35, 36
These studies will increase our knowledge of SVD in the elderly population. On the 
other hand, population based studies may lack statistical power because of their 
heterogeneity and may therefore be less suitable to investigate specific differences 
between patient groups. Studies with a case-control design using well characterized 
subjects are warranted for the elucidation of pathophysiological mechanisms. 
The whole spectrum of the aging brain 
Furthermore, it has been shown that not only WMH and lacunes, but also 
microbleeds, cortical microinfarcts and changes in the NAWM are clinically 
relevant.37,38 However, most studies focused on associations with SVD features 
separately. Considering the whole range of SVD features together may better predict 
the clinical consequences. Other (degenerative) brain changes, such as AD 
pathology, congophilic amyloid angiopathy or cortical Lewy bodies, may also have an 
additive effect on cognitive decline.39,40 These complex relationships of pathological 
changes suggest that all aspects in the aging brain should be taken into account, in 
order to understand the influence of SVD on the clinical consequences of an elderly 
subject.  
In vivo ‘pathology-specific’ tools 
Finally, we showed that novel QMRI techniques (DTI and T1-relaxation time mapping) 
are correlated to distinct pathological substrates. QMRI, therefore, has potential to 
bridge the gap between MRI and pathology and may be regarded as ‘pathology-
specific’ tools in vivo, when intervention is still possible. The advantages of novel 
quantitative MRI techniques over conventional MRI are twofold: 1) they reflect the 
severity of underlying pathological changes (in diffuse changes such as WMH), and 2) 
they show tissue changes in areas that appear normal on conventional MRI (NAWM). 
Studies should be directed to establish the relationship between QMRI parameters 
and clinical symptoms. In this thesis, we only investigated the pathological correlates 
of DTI and T1-relaxation time mapping, but other QMRI techniques are available, 
such as Magnetization Transfer Imaging, T2-relaxation time mapping and Magnetic 
Resonance Spectroscopy. These other techniques may have additional value in the 
specificity for pathological changes and a combination in QMRI techniques may 
contribute to predict the clinical symptoms in the individual subject.  
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Conclusions 
The following conclusions can be drawn from the studies presented in this thesis:  
1. WMH severity is associated with gait and balance disorder and cognitive 
dysfunction. As simple and more complex methods yield equal correlations with 
clinical measures, a simple visual rating scale for white matter hyperintensities is 
sufficiently informative for clinical practice.  
2. The location of lacunes within subcortical grey matter is a determinant of cognitive 
impairment, independent of WMH severity. The impact of lacunes on cognitive 
dysfunction can therefore be more specifically predicted, when strategic locations are 
taken into consideration.  
3. Non-disabled elderly with small vessel disease and vascular risk factors at baseline 
are at risk for progression of WMH and lacunes over time. 
4. Differences in risk factor profiles and relationship with WMH exist between 
subcortical and basal ganglia/ infratentorial lacunes. The pathogenesis of lacunes 
may therefore involve multiple processes and differ between brain regions.  
5. Pathological substrates underlying SVD expressions are heterogeneous in nature 
and severity. Besides MRI-‘visible’ SVD, there are also pathological changes that are 
‘invisible’ to conventional T2-weighted MRI. These findings may explain the weak 
clinical-radiological associations of SVD. 
6. QMRI reveals differences between WMH of Alzheimer’s disease patients and of 
non-demented subjects, and reflects (the severity of) the underlying neuropathological 
changes. QMRI can therefore be regarded as ‘pathology-specific’ tools in vivo. 
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Schade aan de kleine hersenvaten op MRI-scans: 
Klinische impact en onderliggende pathologie 
Schade aan kleine hersenvaten, ‘small vessel disease’ 
Bij ouderen worden op MRI scans van de hersenen vaak leeftijds-gerelateerde 
veranderingen gezien, onder andere als gevolg van schade aan de kleine 
hersenvaten. Schade aan kleine hersenvaten wordt in het Engels “small vessel 
disease” genoemd, oftewel SVD. De belangrijkste uitingen van SVD zijn 
wittestofafwijkingen (WSA), lacunaire infarcten en microbloedingen. WSA worden 
gedefiniëerd op T2-gewogen MRI scans (o.a. FLAIR opnames) en worden 
onderverdeeld in periventriculaire en diepe subcorticale WSA. De ernst van 
subcorticale WSA worden over het algemeen aangegeven als punctiform (mild), 
beginnend confluerend (matig) en confluerend (ernstig).1 Lacunes zijn te zien als 
holtes in de witte stof of in de diepe grijze stof. Ze hebben dezelfde signaalintensiteit 
als liquor op alle MRI sequenties en vaak een hyperintense rand op T2-gewogen 
beelden.2,3 Microbloedingen, tenslotte, zijn te zien als kleine, ronde, hypointense 
lesies op gradient-echo T2*-gewogen scans.4
SVD is niet alleen geassocieerd met een hogere leeftijd, maar ook met risicofactoren 
voor hart- en vaatziekten, zoals hypertensie, diabetes, beroerte en roken.5-7 In grote 
klinische studies is aangetoond dat SVD kan leiden tot cognitieve veranderingen, 
loopstoornissen, depressie en urine incontinentie.8-10 Per individu is het optreden van 
symptomen echter moeilijk te voorspellen: het is niet duidelijk waarom SVD in 
sommige personen leidt tot symptomen, terwijl andere personen asymptomatisch 
blijven.11-14 Bij patiënten met de ziekte van Alzheimer komt SVD zelfs nog vaker voor 
dan bij de rest van de bevolking.15 De rol die SVD speelt bij het cognitief verval bij 
deze patiënten is echter nog onbekend.16-18 Aangezien SVD zeer vaak voorkomt en 
kan leiden tot invaliderende symptomen, die potentieel behandelbaar of te voorkomen 
zijn, is het zeer belangrijk ons begrip van deze hersenveranderingen te vergroten.  
In dit proefschrift worden daarom manieren gezocht om de relatie tussen klinische 
uitingen en MRI-uitingen van SVD te verbeteren. Het doel van dit onderzoek is het 
kunnen voorspellen van de klinische impact van SVD per individu. In dit hoofdstuk 
worden de belangrijkste bevindingen van het proefschrift samengevat.  
Deel 1. Klinische impact van SVD in cross-sectionele MRI-studies 
Aangezien veel klinische MRI-studies een cross-sectionele opzet hebben, hebben wij 
ook eerst geprobeerd de specificiteit van SVD te vergroten in cross-sectionele studies 
(hoofdstuk 2). We hebben hiervoor baseline data van de LADIS-studie gebruikt. De 
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LADIS-studie is een samenwerkingsverband van elf Europese centra en heeft als 
doel de impact van WSA op het verlies van zelfredzaamheid bij niet-demente ouderen 
te onderzoeken. Hiervoor zijn 639 proefpersonen jaarlijks gevolgd gedurende een 
periode van drie jaar en kregen zij een MRI-scan op baseline en na drie jaar follow-
up.
In hoofdstuk 2.1 hebben we verschillende methoden om WSA te meten met elkaar 
vergeleken in relatie tot loop/balans- en cognitieve stoornissen. De geteste methoden 
zijn een eenvoudige visuele schaal (Fazekas’ schaal),1 een gedetailleerde visuele 
schaal (Scheltens’ schaal)19 en een volumetrische meting van WSA.20 De resultaten 
tonen aan dat de gevonden associaties tussen WSA en de klinische symptomen 
significant maar vergelijkbaar zijn tussen de verschillende meetmethoden. Zoals 
eerdere studies reeds beschreven, zijn de gevonden correlatie slechts 
bescheiden.14,21 Hieruit blijkt dat eenvoudige en complexe meetmethoden voor WSA 
even ‘valide’ zijn, en dat de zwakke associaties tussen klinische symptomen en MRI 
uitingen van WSA dus niet verbeterd kunnen worden door het gebruik van meer 
exacte meetmethoden.  
In hoofdstuk 2.2 hebben we onderzocht of de locatie van lacunaire infarcten invloed 
heeft op het cognitief functioneren. Lacunes zijn geteld in de volgende 5 gebieden: 
lobaire witte stof, putamen/ globus pallidus, thalamus, capsula interna/externa, 
infratentorieel. We hebben algemene cognitieve maten en specifieke cognitieve 
domeinen onderzocht in relatie tot bovengenoemde gebieden. De resultaten van deze 
studie laten zien dat thalamus lacunes geassocieerd zijn met een lagere MMSE-score 
en met slechtere motorische controle en executieve functies, onafhankelijk van de 
ernst van WSA. Lacunes in het putamen/ globus pallidus zijn geassocieerd met een 
slechter geheugen en een slechtere motorische controle. De locatie van lacunes blijkt 
dus een rol te spelen bij cognitieve functiestoornissen, onafhankelijk van de ernst van 
WSA.22,23
Uit deze cross-sectionele MRI studies kunnen we concluderen dat de impact van 
lacunes beter kan worden voorspeld als een aantal strategische locaties worden 
bepaald. Echter, meer gedetailleerde methoden om WSA te meten op T2-gewogen 
MRI scans leveren geen verbetering op van de associaties met klinische maten. 
Deel 2: SVD in longitudinale studies 
Uit deel 1 van dit proefschrift blijkt dat de mogelijkheden om SVD te specificeren in 
cross-sectionele studies beperkt zijn, mede omdat deze studies geen informatie 
geven over beloop in de tijd en causaliteit. In hoofdstuk 3 hebben we daarom het 
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natuurlijk beloop van SVD beschreven in een follow-up periode van 3 jaar en de 
risicofactoren van SVD-progressie onderzocht. Hiervoor hebben we baseline en 
follow-up MRI data van de LADIS gebruikt.  
Eerst hebben we de meest geschikte methode bepaald om WSA progressie in de tijd 
te meten (hoofdstuk 3.1). Hiervoor hebben vier ervaren onderzoekers verandering 
van WSA in de tijd gescored met behulp van drie conventionele visuele schalen1,19,24
en twee speciaal ontworpen visuele progressie schalen (Rotterdam progressie 
schaal25 en Schmidt progressie schaal26). De visuele schalen zijn vergeleken met 
volumetrische metingen van WSA. De speciaal ontworpen progressie schalen, vooral 
de Rotterdam progressie schaal blijken sensitiever en betrouwbaarder te zijn om 
WSA progressie te meten dan de conventionele schalen. De Rotterdam progressie 
schaal correleert ook het beste met de verandering in WSA volume.  
In hoofdstuk 3.2 hebben we de Rotterdam progressie schaal gebruikt om de WSA 
progressie in de drie jaar follow-up van de LADIS-studie te evaluëren. Daarnaast zijn 
de nieuw ontstane lacunes geteld. We hebben het natuurlijke beloop, de regionale 
distributie en de risicofactoren voor progressie van SVD in de tijd beschreven. Het 
blijkt dat niet alleen WSA, maar ook het aantal lacunes toenemen in de tijd, met name 
in proefpersonen die reeds SVD hadden op baseline. Verder zijn een doorgemaakte 
beroerte, diabetes en een hogere bloedglucosewaarde onafhankelijke risicofactoren 
van WSA progressie. Risicofactoren voor het ontstaan van nieuwe lacunes zijn het 
mannelijke geslacht, hypertensie, een doorgemaakte beroerte, een hogere 
systolische bloeddruk, een hogere body mass index en hogere HDL en triglyceride 
waarden. De gevonden vasculaire risicofactoren suggereren dat arteriolosclerose en 
ischemie een rol spelen in de pathogenese van SVD. Daarnaast lijkt het erop dat 
progressie van WSA met name het gevolg is van toename van bestaande WSA. De 
regionale distributie van lacunes daarentegen, lijkt zich te verplaatsen in de tijd, wat 
leidt tot de hypothese dat lacunes in de basale kernen een andere pathogenese 
hebben dan lacunes in de subcorticale witte stof.  
In hoofdstuk 3.3  hebben we daarom de regionale verschillen in risicofactoren en de 
relatie met WSA van nieuwe lacunes onderzocht om meer inzicht te verkrijgen in hun 
pathogenese. Voor elke nieuw ontstane lacune hebben we de volgende 
eigenschappen bepaald: 1) hersengebied; 2) het ontstaan binnen een gebied van 
WSA op baseline; 3) de grootte van omringende WSA en 4) het risicofactorprofiel. De 
resultaten tonen aan dat nieuwe lacunes in de subcorticale witte stof vaker ontstaan 
in WSA die reeds aanwezig waren op baseline en dat deze veelal omringd worden 
door nieuwe en toegenomen WSA, vergeleken met nieuwe basale kernen en 
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infratentoriële lacunes. Risicofactoren voor nieuwe lacunes in de subcorticale witte 
stof zijn hypertensie en eerdere beroerte. Boezemfibrilleren is een voorspeller voor 
nieuwe basale kernen/ infratentoriele lacunes. Deze studie toont aan dat er 
verschillen zijn in risicofactorprofiel en in de relatie met WSA tussen subcorticale en 
basale kernen/ infratentoriele lacunes. We denken dat lacunes in de subcorticale witte 
stof zich langzaam ontwikkelen in reeds door hypoxie beschadigd weefsel (te zien als 
WSA). Door toenemende hypoxie/ischemie leidt dit uiteindelijk tot infarcering. Het 
ontstaan van basale kernen/ infratentoriële lacunes lijkt meer acuut door occlusie van 
een enkele arteriole.  
De longitudinale studies in hoofdstuk 3 tonen aan dat WSA en lacunes toenemen in 
de tijd, met name in patienten met SVD en vasculaire risicofactoren op baseline. 
Daarnaast kunnen we concluderen dat bij de pathogenese van SVD waarschijnlijk 
meerdere mechanismen zijn betrokken. 
Deel 3: De onderliggende pathologie van SVD 
Uit het eerste deel van dit proefschrift blijkt dat de pogingen om SVD in cross-
sectionele T2-gewogen MRI-studies te specificeren onvoldoende succesvol zijn. De 
longitudinale MRI-studies tonen aan dat vasculaire risicofactoren een rol spelen bij 
SVD progressie en dat er bij de pathogenese van SVD meerdere mechanismen een 
rol spelen.27,28 MRI blijft echter een indirecte afspiegeling van de daadwerkelijke 
onderliggende pathologie. Met conventionele T2-gewogen MRI is het niet mogelijk om 
de verschillende typen en ernst van weefselveranderingen aan te tonen. Door het 
direct matchen van MRI bevindingen met pathologische kleuringen in de postmortem 
setting, kunnen de pathologische veranderingen van SVD op MRI wel aangetoond 
worden.29,30 Door correlaties tussen postmortem MRI en pathologische kleuringen 
worden de discrepanties tussen MRI en kliniek overbrugd. Postmortem MRI studies 
kunnen zo het begrip van MRI aspecten van SVD vergroten. Recente studies hebben 
ook getracht om de specificiteit van in vivo MRI scans te verbeteren met behulp van 
nieuwe kwantitatieve MRI technieken.31,32 Het pathologische substraat van 
kwantitatieve MRI parameters in SVD is echter nog onbekend. Wanneer bekend is 
welke pathologische veranderingen worden weergegeven door deze kwantitatieve 
MRI methoden, kunnen deze vertaald worden naar in vivo MRI scans. In dit 
proefschrift hebben we de pathologische correlaten van twee kwantitatieve MRI 
technieken onderzocht: diffusie tensor imaging (DTI) en T1-relaxatietijd metingen. DTI 
is een techniek, die de mate en de richting van diffusie van watermoleculen meet.33 In 
normale witte stof verloopt de diffusie van watermoleculen gemakkelijker met de 
vezelbanen mee, dan loodrecht op de vezelbanen; deze wordt anisotropie genoemd. 
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T1-relaxatie tijd metingen geven waarschijnlijk pathologische processen weer, die 
invloed hebben op de hoeveelheid water in het hersenweefsel. 
Eerst geven we in hoofdstuk 4.1 een samenvatting van eerdere publicaties, die 
postmortem MRI en pathologie direct aan elkaar hebben gecorreleerd. Deze studies 
beschrijven dat heterogeniteit bestaat in de onderliggende pathologie van WSA: 1) 
schade aan het vezelnetwerk, variërend van een iets losser netwerk tot ernstig 
myeline- en axonen verlies; 2) reacties van gliacellen, waaronder astrogliose, 
clasmatodendrose, verlies van oligodendrocyten en microglia activatie; en 3) 
microvasculaire veranderingen, zoals lipohyalinose, arteriosclerose, vaatwandlekkage 
en veneuze  collagenose. De pathogenetische mechanismen, die worden 
beschreven, zijn ischemie/hypoxie, algehele hypoperfusie door autodysregulatie van 
de bloeddoorstroming, lekkage van de bloed-hersenbarriere en clasmatodendrose 
door opname van serum eiwitten, onstekingsreacties, degeneratie en congofiele 
amyloid angiopathie.34-36 Er is echter nog weinig bekend over de pathologische 
correlaten en pathogenese van lacunes en microbloedingen. Postmortem MRI studies 
kunnen nog veel bijdragen om de etiologie van deze uitingen van SVD te verhelderen. 
Naast deze MRI uitingen van SVD, worden ook corticale microinfarcten en 
weefselveranderingen in de normaal ogende witte stof beschreven, die ‘onzichtbaar’ 
zijn op T2-gewogen MRI scans. Uit klinische-pathologische studies blijkt dat deze 
veranderingen ook een rol spelen bij het ontstaan van klinische symptomen bij SVD. 
De gevonden heterogeniteit in onderliggende weefselveranderingen is waarschijnlijk 
de verklaring voor de zwakke klinische-radiologische associaties bij SVD.  
In hoofdstuk 4.2 hebben we het onderliggende pathologische substraat van twee 
kwantitatieve MRI technieken (DTI en T1-relaxatietijd metingen) onderzocht. 
Daarnaast hebben we onderzocht of we met postmortem kwantitatieve MRI en 
pathologische kleuringen verschillen vinden tussen WSA van Alzheimer patiënten en 
van niet-demente controles. We hebben hiervoor gefixeerde hersenplakken van 
Alzheimer patiënten en niet-demente controles postmortem gescand. Daarna zijn 
pathologische kleuringen gedaan voor axonendichtheid, myelinedichtheid, astrogliose 
en microglia activatie. De resultaten tonen aan dat er pathologische verschillen zijn in 
WSA van Alzheimer patiënten en van niet-demente ouderen, aangezien WSA in 
Alzheimer patiënten meer microglia activatie vertoont. Dit verschil wordt ook 
weergegeven door een hogere gemiddelde T1-relaxatietijd in WSA van Alzheimer 
patiënten. In tegenstelling tot conventionele T2-gewogen MRI, kan met kwantitatieve 
MRI de ernst van de betrokken pathologische veranderingen worden aangetoond: DTI 
(fractionele anisotropie) wordt bepaald door axonen verlies, terwijl de T1-relaxatietijd 
wordt bepaald door axonen/ myeline verlies en microglia activatie. Tot slot denken we 
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dat het onderscheid tussen WSA en normaal ogende witte stof niet zinvol is, omdat er 
een pathologisch continuüm bestaat tussen normale en abnormale witte stof.   
We kunnen uit deze post-mortem MRI studies concluderen, dat de zwakke klinische-
radiologische correlaties o.a. worden veroorzaakt door de onderliggende pathologie 
van SVD: deze is heterogeen van aard en varieert in ernst. Kwantitatieve MRI laten 
verschillen zien in WSA tussen Alzheimer patiënten en niet-demente ouderen en zijn 
specifiek voor onderliggende weefselveranderingen. Verder zijn er ook SVD uitingen 
die niet op T2-gewogen MRI scans gezien kunnen worden, maar wel klinische impact 
kunnen hebben.  
Conclusies
We kunnen het volgende concluderen uit de studies in dit proefschrift:
1. De mate van WSA is geassocieerd met loop/balans- en cognitieve stoornissen. 
Omdat eenvoudige en complexere methoden van WSA metingen vergelijkbare 
correlaties opleveren met klinische maten, is een eenvoudige scoringsmethode 
afdoende voor de klinische praktijk. 
2. De locatie van lacunes in de subcorticale grijze stof bepaalt mede het bestaan 
van cognitieve stoornissen, onafhankelijk van de ernst van WSA. Om de impact 
van lacunes op cognitieve dysfunctie te voorspellen, moet rekening gehouden 
worden met bepaalde strategische locaties.  
3. Ouderen met SVD en vasculaire risicofactoren op baseline lopen risico op 
progressie van WSA en lacunes in de tijd.  
4. Er bestaan verschillen in risicofactorprofiel en de relatie met WSA tussen lacunes 
in de subcorticale witte stof en lacunes in de basale kernen/ infratentoriele regio. 
Er zijn mogelijk meerdere mechanismen betrokken bij het ontstaan van lacunes.  
5. De onderliggende pathologie van SVD uitingen is heterogeen van aard en 
varieert in ernst. Naast MRI-‘zichtbare’ SVD uitingen, bestaan er ook 
pathologische veranderingen die ‘onzichtbaar’ zijn op conventionele T2-gewogen 
MRI. Heterogeniteit in onderliggende pathologie verklaart de zwakke klinische-
radiologische associatie bij SVD. 
6. Kwantitatieve MRI maakt onderscheid tussen WSA van demente en niet-demente 
ouderen en geeft de (ernst van) onderliggende pathologische veranderingen 
weer. Kwantitatieve MRI kan daarom worden gezien als ‘pathologie-specifieke’ 
methoden in vivo.
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promovenda, bedankt voor je bijdrage aan de postmortem projecten. Miriam Cornella, 
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